BioMedLib Search Engine
[ goto HOMEPAGE ]
Find more relevant answers, faster!
Skip to content
Advanced Search
Search History
MeSH Query
Page Format
Query is expanded
Login
Skip to content
Export Citations
Search Results
RSS
Email
Articles' Details
Start new query
Reset All
Refine your query
(more in Advanced-Search):
Search all of MEDLINE
Focus on the recent 5 years
Focus on the current year
Focus on the last 30 days
More choices ...
Focus on articles with free fulltexts
More choices ...
Do simple 'keyword' search (no query expansion)
[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click
here to
RESET
all values
Click
here to
GO BACK
without resetting any value
Advanced Search
Submit one or more of the following items, and they will be searched along with your query in the search box above.
Any submit button will submit all of the items you have changed.
+
Publication-Date
Published in the last:
30 days
60 days
90 days
6 months
12 months
this year
2 years
3 years
5 years
10 years
Or published in the following date range: From (yyyy/mm/dd - month and day are optional)
to ('to' is optional)
+
Full Text
Retrieve articles with hyperlinks to:
full text (either free or subscription)
free full text
subscription full text
no full text link
+
Sort-Order
Sort the retrieved articles by:
relevance
publication date
+
Language
And with languages:
English
French
German
Italian
Japanese
Russian
Spanish
More languages:
Afrikaans
Albanian
Amharic
Arabic
Armenian
Azerbaijani
Bengali
Bosnian
Bulgarian
Catalan
Chinese
Czech
Danish
Dutch
Esperanto
Estonian
Finnish
Georgian
Scottish Gaelic
Greek, Modern
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Kinyarwanda
Korean
Latin
Latvian
Lithuanian
Macedonian
Malayalam
Maori
Malay
Multiple languages
Norwegian
Persian
Polish
Portuguese
Pushto
Romanian
Sanskrit
Serbian
Croatian
Slovak
Slovenian
Swedish
Thai
Turkish
Ukrainian
Undetermined
Urdu
Vietnamese
Welsh
+
Publication-Type
And with publication types:
Clinical Trial
Editorial
Letter
Meta-Analysis
Practice Guideline
Randomized Controlled Trial
Review
More publication types:
Addresses
Bibliography
Biography
Case Reports
Classical Article
Clinical Conference
Clinical Trial, Phase I
Clinical Trial, Phase II
Clinical Trial, Phase III
Clinical Trial, Phase IV
Comment
Comparative Study
Congresses
Consensus Development Conference
Consensus Development Conference, NIH
Controlled Clinical Trial
Corrected and Republished Article
Dictionary
Directory
Duplicate Publication
English Abstract
Evaluation Studies
Festschrift
Government Publications
Guideline
Historical Article
Interactive Tutorial
Interview
Introductory Journal Article
In Vitro
Journal Article
Lectures
Legal Cases
Legislation
Multicenter Study
News
Newspaper Article
Overall
Patient Education Handout
Periodical Index
Portraits
Published Erratum
Retracted Publication
Research Support, N.I.H., Extramural
Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, U.S. Gov't, P.H.S.
Retraction of Publication
Scientific Integrity Review
Technical Report
Twin Study
Validation Studies
+
Species
And for:
Humans
Animals
+
Gender
And for:
Male
Female
+
Age
And for these age groups:
Newborn: birth to 1 month
Infant: 1 to 23 months
Preschool child: 2 to 5 years
Child: 6 to 12 years
Adolescent: 13 to 18 years
Adult: 19 to 44 years
Middle aged: 45 to 64 years
Aged: 65+ years
80 and over: 80+ years
+
Title
And for this query matching the titles:
+
Transliterated-Title
And for this query matching the title in original language:
+
Abstract
And for this query matching the abstratcs:
+
Major-Mesh
And for this query matching the MeSH-Major terms:
+
Mesh
And for this query matching any MeSH terms:
+
Journal
And for one or more of these journal abbreviated names:
OR
OR
(see
title abbreviations
)
+
Volume
And with journal volume number:
+
Issue
And with journal issue number:
+
Page
And with page number:
+
ISSN
And with ISSN:
+
Publication-Place
And with journal's country of publication:
+
Author
And for...
all these author names:
AND
AND
(see
help
)
one or more of these author names:
OR
OR
but not having any of these unwanted author names:
NOT
NOT
+
Affiliation
And with affiliation to:
+
Has-Abstract
Find MEDLINE records with the abstract status:
has abstract
does not have abstract
include both record types
include both record types but rank higher the records having abstract (the default BML behavior)
+
PMID
Show me only articles for these PMIDs (PubMed IDs):
+
Semantic-Type
And with semantic types:
A. Entity
A1. Physical Object
A1.1. Organism
A1.1.1. Archaeon
A1.1.2. Bacterium
A1.1.3. Eukaryote
A1.1.3.1. Animal
A1.1.3.1.1. Vertebrate
A1.1.3.1.1.1. Amphibian
A1.1.3.1.1.2. Bird
A1.1.3.1.1.3. Fish
A1.1.3.1.1.4. Mammal
A1.1.3.1.1.4.1. Human
A1.1.3.1.1.5. Reptile
A1.1.3.2. Fungus
A1.1.3.3. Plant
A1.1.4. Virus
A1.2. Anatomical Structure
A1.2.1. Embryonic Structure
A1.2.2. Anatomical Abnormality
A1.2.2.1. Congenital Abnormality
A1.2.2.2. Acquired Abnormality
A1.2.3. Fully Formed Anatomical Structure
A1.2.3.1. Body Part, Organ, or Organ Component
A1.2.3.2. Tissue
A1.2.3.3. Cell
A1.2.3.4. Cell Component
A1.2.3.5. Gene or Genome
A1.3. Manufactured Object
A1.3.1. Medical Device
A1.3.1.1. Drug Delivery Device
A1.3.2. Research Device
A1.3.3. Clinical Drug
A1.4. Substance
A1.4.1. Chemical
A1.4.1.1. Chemical Viewed Functionally
A1.4.1.1.1. Pharmacologic Substance
A1.4.1.1.1.1. Antibiotic
A1.4.1.1.2. Biomedical or Dental Material
A1.4.1.1.3. Biologically Active Substance
A1.4.1.1.3.1. Neuroreactive Substance or Biogenic Amine
A1.4.1.1.3.2. Hormone
A1.4.1.1.3.3. Enzyme
A1.4.1.1.3.4. Vitamin
A1.4.1.1.3.5. Immunologic Factor
A1.4.1.1.3.6. Receptor
A1.4.1.1.4. Indicator, Reagent, or Diagnostic Aid
A1.4.1.1.5. Hazardous or Poisonous Substance
A1.4.1.2. Chemical Viewed Structurally
A1.4.1.2.1. Organic Chemical
A1.4.1.2.1.5. Nucleic Acid, Nucleoside, or Nucleotide
A1.4.1.2.1.6. Organophosphorus Compound
A1.4.1.2.1.7. Amino Acid, Peptide, or Protein
A1.4.1.2.1.8. Carbohydrate
A1.4.1.2.1.9. Lipid
A1.4.1.2.1.9.1. Steroid
A1.4.1.2.1.9.2. Eicosanoid
A1.4.1.2.2. Inorganic Chemical
A1.4.1.2.3. Element, Ion, or Isotope
A1.4.2. Body Substance
A1.4.3. Food
A2. Conceptual Entity
A2.1. Idea or Concept
A2.1.1. Temporal Concept
A2.1.2. Qualitative Concept
A2.1.3. Quantitative Concept
A2.1.4. Functional Concept
A2.1.4.1. Body System
A2.1.5. Spatial Concept
A2.1.5.1. Body Space or Junction
A2.1.5.2. Body Location or Region
A2.1.5.3. Molecular Sequence
A2.1.5.3.1. Nucleotide Sequence
A2.1.5.3.2. Amino Acid Sequence
A2.1.5.3.3. Carbohydrate Sequence
A2.1.5.4. Geographic Area
A2.2. Finding
A2.2.1. Laboratory or Test Result
A2.2.2. Sign or Symptom
A2.3. Organism Attribute
A2.3.1. Clinical Attribute
A2.4. Intellectual Product
A2.4.1. Classification
A2.4.2. Regulation or Law
A2.5. Language
A2.6. Occupation or Discipline
A2.6.1. Biomedical Occupation or Discipline
A2.7. Organization
A2.7.1. Health Care Related Organization
A2.7.2. Professional Society
A2.7.3. Self-help or Relief Organization
A2.8. Group Attribute
A2.9. Group
A2.9.1. Professional or Occupational Group
A2.9.2. Population Group
A2.9.3. Family Group
A2.9.4. Age Group
A2.9.5. Patient or Disabled Group
B. Event
B1. Activity
B1.1. Behavior
B1.1.1. Social Behavior
B1.1.2. Individual Behavior
B1.2. Daily or Recreational Activity
B1.3. Occupational Activity
B1.3.1. Health Care Activity
B1.3.1.1. Laboratory Procedure
B1.3.1.2. Diagnostic Procedure
B1.3.1.3. Therapeutic or Preventive Procedure
B1.3.2. Research Activity
B1.3.2.1. Molecular Biology Research Technique
B1.3.3. Governmental or Regulatory Activity
B1.3.4. Educational Activity
B1.4. Machine Activity
B2. Phenomenon or Process
B2.1. Human-caused Phenomenon or Process
B2.1.1. Environmental Effect of Humans
B2.2. Natural Phenomenon or Process
B2.2.1. Biologic Function
B2.2.1.1. Physiologic Function
B2.2.1.1.1. Organism Function
B2.2.1.1.1.1. Mental Process
B2.2.1.1.2. Organ or Tissue Function
B2.2.1.1.3. Cell Function
B2.2.1.1.4. Molecular Function
B2.2.1.1.4.1. Genetic Function
B2.2.1.2. Pathologic Function
B2.2.1.2.1. Disease or Syndrome
B2.2.1.2.1.1. Mental or Behavioral Dysfunction
B2.2.1.2.1.2. Neoplastic Process
B2.2.1.2.2. Cell or Molecular Dysfunction
B2.2.1.2.3. Experimental Model of Disease
B2.3. Injury or Poisoning
Page Format
Any submit button will submit all of the items you have changed.
[theme]
Use this page design theme:
original
twenty ten
[shown]
Results per page:
5
10
20
50
100
200
500
[expand/collapse]
show these sections expanded by default:
Advanced search
MeSH query
Search history
Page format
Query expansion
Articles details
Export citations
Email
[text size]
use this font size for text:
25%
50%
75%
100%
125%
150%
200%
or enter your choice of font size:
[page width]
use this page width (relative to the default initial value):
25%
50%
75%
100%
125%
150%
200%
or enter your choice of page width:
[highlight color]
use this color to highlight query words in the articles:
red
green
blue
black
purple
yellow
orange
navy
olive
maroon
none
[query history]
maximum number of queries shown in the history section:
[annotate]
Annotate these parts of each article:
title
abstract
both
none
Reset all values
Find best MeSH terms for
Search History
1
anal melanoma 2005:2010[pubdate] *count=100
351 results
Searchbox
Export
PDF
RSS
Email
Delete
Email this search result to the following email address:
[X] Close
Expand the query
'
anal melanoma
' expanded to all its synonyms;
details
Email the results to the following email address:
Export the checked citations in RIS format (RIS format is used by RefWorks, Endnote, among others).
Items 1 to 100 of about 351
1.
Kang JH, Katayama Y, Han A, Shigaki S, Oishi J, Kawamura K, Toita R, Han XM, Mori T, Niidome T:
Mass-tag technology responding to intracellular signals as a novel assay system for the diagnosis of tumor.
J Am Soc Mass Spectrom
; 2007 Jan;18(1):106-12
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Mass-tag technology responding to intracellular signals as a novel assay system for
the diagnosis
of tumor.
A novel mass spectrometry-based assay system for determining protein kinase activity employing mass-tagged substrate peptide probes was used for
the diagnosis
of tumors.
The phosphorylation ratio for the reaction of the H-type peptide probe with the tumor tissue lysate (B16
melanoma
) was more than three times higher than that of the D type peptide probe with the normal skin tissue lysate.
These results show that the novel assay system for detecting protein kinase activity using mass-tag technology can be a simple and useful means to profile protein kinase activity for cell or tissue lysate samples, and can be applied to
the diagnosis
of tumors.
[MeSH-major]
Melanoma
, Experimental /
diagnosis
. Peptides / chemistry. Protein Kinases / analysis. Skin Neoplasms /
diagnosis
. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization / methods
MedlinePlus Health Information.
consumer health - Skin Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Am Soc Mass Spectrom. 2005 Apr;16(4):482-90
[
15792717.001
]
[Cites]
Crit Rev Oncog. 1994;5(5):429-50
[
8519807.001
]
[Cites]
Curr Opin Cell Biol. 1997 Apr;9(2):161-7
[
9069266.001
]
[Cites]
Biochem J. 1992 Apr 1;283 ( Pt 1):159-64
[
1567363.001
]
[Cites]
Endocr Relat Cancer. 2003 Sep;10(3):389-96
[
14503915.001
]
[Cites]
Anal Biochem. 2005 May 1;340(1):165-70
[
15802142.001
]
[Cites]
Anal Chem. 2005 Jul 1;77(13):3979-85
[
15987100.001
]
[Cites]
Bioorg Med Chem Lett. 2004 Feb 23;14(4):847-50
[
15012979.001
]
[Cites]
Biochem J. 2002 Sep 15;366(Pt 3):977-81
[
12119045.001
]
[Cites]
Biochim Biophys Acta. 2004 Mar 11;1697(1-2):39-51
[
15023349.001
]
[Cites]
J Am Soc Mass Spectrom. 2005 Jun;16(6):940-7
[
15907708.001
]
[Cites]
Anal Chem. 2005 Dec 15;77(24):7845-51
[
16351129.001
]
[Cites]
Cancer Metastasis Rev. 2005 Jun;24(2):287-300
[
15986138.001
]
[Cites]
Biochem J. 1993 Sep 1;294 ( Pt 2):335-7
[
8373348.001
]
[Cites]
Melanoma Res. 2004 Apr;14(2):85-9
[
15057036.001
]
[Cites]
Biomacromolecules. 2002 Sep-Oct;3(5):905-9
[
12217034.001
]
[Cites]
Curr Opin Cell Biol. 1990 Apr;2(2):192-7
[
2194521.001
]
[Cites]
J Control Release. 2006 Jan 10;110(2):431-6
[
16309776.001
]
[Cites]
Biochem J. 1993 Apr 15;291 ( Pt 2):329-43
[
8484714.001
]
[Cites]
J Am Soc Mass Spectrom. 2005 Dec;16(12):2027-38
[
16253516.001
]
(PMID = 17046276.001).
[ISSN]
1044-0305
[Journal-full-title]
Journal of the American Society for Mass Spectrometry
[ISO-abbreviation]
J. Am. Soc. Mass Spectrom.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Enzyme Inhibitors; 0 / Indoles; 0 / Maleimides; 0 / Peptides; 125313-65-7 / Ro 31-7549; EC 2.7.- / Protein Kinases; EC 2.7.11.13 / Protein Kinase C
2.
Kabuyama Y, Litman ES, Templeton PD, Metzner SI, Witze ES, Argast GM, Langer SJ, Polvinen K, Shellman Y, Chan D, Shabb JB, Fitzpatrick JE, Resing KA, Sousa MC, Ahn NG:
A mediator of Rho-dependent invasion moonlights as a methionine salvage enzyme.
Mol Cell Proteomics
; 2009 Oct;8(10):2308-20
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
RhoA controls changes in cell morphology and invasion associated with
cancer
phenotypes.
Cell lines derived from
melanoma
tumors at varying stages revealed that RhoA is selectively activated in cells of metastatic origin.
MedlinePlus Health Information.
consumer health - Melanoma
.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
(L)-Methionine
.
SciCrunch.
HGNC: Data: Gene Annotation
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Anal Chem. 1996 Mar 1;68(5):850-8
[
8779443.001
]
[Cites]
Annu Rev Cell Dev Biol. 2005;21:247-69
[
16212495.001
]
[Cites]
Mol Pharmacol. 1997 Nov;52(5):903-11
[
9351982.001
]
[Cites]
Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3726-30
[
9520434.001
]
[Cites]
Mol Carcinog. 1998 Nov;23(3):132-43
[
9833774.001
]
[Cites]
J Cell Sci. 2001 Oct;114(Pt 20):3583-90
[
11707510.001
]
[Cites]
J Invest Dermatol. 2006 Apr;126(4):862-8
[
16470169.001
]
[Cites]
Nat Cell Biol. 1999 Jul;1(3):136-43
[
10559899.001
]
[Cites]
J Neurobiol. 2000 Aug;44(2):126-44
[
10934317.001
]
[Cites]
Nature. 2000 Aug 3;406(6795):532-5
[
10952316.001
]
[Cites]
Methods Enzymol. 2000;325:264-72
[
11036609.001
]
[Cites]
Oncogene. 2001 Apr 19;20(17):2112-21
[
11360195.001
]
[Cites]
Nature. 2001 May 24;411(6836):494-8
[
11373684.001
]
[Cites]
Nat Cell Biol. 2001 Aug;3(8):723-9
[
11483957.001
]
[Cites]
Nat Cell Biol. 2002 Apr;4(4):E97-100
[
11944043.001
]
[Cites]
Crit Rev Oncol Hematol. 2002 Oct;44(1):1-15
[
12398996.001
]
[Cites]
Proc Natl Acad Sci U S A. 2003 Jan 7;100(1):183-8
[
12518064.001
]
[Cites]
Nat Rev Cancer. 2002 Feb;2(2):133-42
[
12635176.001
]
[Cites]
Lab Invest. 2003 Jun;83(6):861-70
[
12808121.001
]
[Cites]
Nat Cell Biol. 2003 Aug;5(8):711-9
[
12844144.001
]
[Cites]
Curr Opin Cell Biol. 2003 Oct;15(5):583-9
[
14519393.001
]
[Cites]
Science. 2003 Oct 10;302(5643):286-90
[
14551435.001
]
[Cites]
J Biochem. 2003 Sep;134(3):309-13
[
14561714.001
]
[Cites]
Biochemistry. 2004 Jan 13;43(1):9-18
[
14705926.001
]
[Cites]
Nat Cell Biol. 2004 Feb;6(2):154-61
[
14743221.001
]
[Cites]
J Biol Chem. 2004 Feb 13;279(7):6196-203
[
14645234.001
]
[Cites]
Clin Cancer Res. 2004 Feb 1;10(3):1192-200
[
14871999.001
]
[Cites]
Trends Plant Sci. 2004 May;9(5):221-8
[
15130547.001
]
[Cites]
BMC Microbiol. 2004 Mar 4;4:9
[
15102328.001
]
[Cites]
Methods Mol Biol. 2004;284:37-49
[
15173607.001
]
[Cites]
J Biol Chem. 2004 Aug 27;279(35):37087-94
[
15215245.001
]
[Cites]
Oncogene. 2004 Oct 18;23(48):7928-46
[
15489911.001
]
[Cites]
J Natl Cancer Inst. 1973 Nov;51(5):1417-23
[
4357758.001
]
[Cites]
In Vitro. 1979 May;15(5):342-50
[
478563.001
]
[Cites]
J Biol Chem. 1983 Jun 10;258(11):6717-20
[
6853500.001
]
[Cites]
J Natl Cancer Inst. 1985 Feb;74(2):283-9
[
3856042.001
]
[Cites]
J Biol Chem. 1988 Jul 15;263(20):9598-606
[
2838472.001
]
[Cites]
Oncogene. 1995 Mar 2;10(5):827-33
[
7898924.001
]
[Cites]
J Virol. 1995 Jun;69(6):3920-3
[
7745747.001
]
[Cites]
Cancer Res. 1996 Mar 1;56(5):1083-90
[
8640765.001
]
[Cites]
Melanoma Res. 1997 Aug;7 Suppl 2:S35-42
[
9578415.001
]
[Cites]
Mol Cancer Ther. 2006 May;5(5):1136-44
[
16731745.001
]
[Cites]
Mol Cell Proteomics. 2006 Aug;5(8):1359-67
[
16644720.001
]
[Cites]
J Biol Chem. 2007 Jul 20;282(29):21477-86
[
17548352.001
]
[Cites]
Protein Sci. 2008 Jan;17(1):126-35
[
18156470.001
]
[Cites]
Cell. 2008 Oct 31;135(3):510-23
[
18984162.001
]
[Cites]
J Cell Biochem. 2009 Feb 1;106(2):210-9
[
19097084.001
]
[Cites]
Science. 1996 Jul 12;273(5272):245-8
[
8662509.001
]
(PMID = 19620624.001).
[ISSN]
1535-9484
[Journal-full-title]
Molecular & cellular proteomics : MCP
[ISO-abbreviation]
Mol. Cell Proteomics
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / P50 CA058187; United States / NCI NIH HHS / CA / F32 CA105796; United States / NCI NIH HHS / CA / R01-CA126240; United States / NIGMS NIH HHS / GM / T32 GM008759; United States / NCI NIH HHS / CA / R01-CA118972; United States / NIGMS NIH HHS / GM / T32-GM008759; United States / NCI NIH HHS / CA / R01 CA118972; United States / NCI NIH HHS / CA / P50-CA058187; United States / NCI NIH HHS / CA / F32 CA112847; United States / NCI NIH HHS / CA / F32-CA112847; United States / NIAID NIH HHS / AI / R01-AI060841; United States / NCI NIH HHS / CA / F32-CA105796; United States / NCI NIH HHS / CA / R01 CA126240; United States / NIAID NIH HHS / AI / R01 AI060841
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural
[Publication-country]
United States
[Chemical-registry-number]
7LP2MPO46S / S-Adenosylmethionine; AE28F7PNPL / Methionine; EC 3.6.5.2 / rhoA GTP-Binding Protein; EC 5.3.1.- / Aldose-Ketose Isomerases; EC 5.3.1.23 / MRDI protein, human
[Other-IDs]
NLM/ PMC2758758
3.
Usaj M, Trontelj K, Miklavcic D, Kanduser M:
Cell-cell electrofusion: optimization of electric field amplitude and hypotonic treatment for mouse melanoma (B16-F1) and Chinese Hamster ovary (CHO) cells.
J Membr Biol
; 2010 Jul;236(1):107-16
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Cell-cell electrofusion: optimization of electric field amplitude and hypotonic treatment for mouse
melanoma
(B16-F1) and Chinese Hamster ovary (CHO) cells.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Anal Biochem. 2002 Mar 15;302(2):213-9
[
11878799.001
]
[Cites]
J Immunol Methods. 1987 Jun 26;100(1-2):5-40
[
3298441.001
]
[Cites]
Biochemistry. 1995 Jul 11;34(27):8520-32
[
7612594.001
]
[Cites]
Bioelectrochemistry. 2004 Jun;63(1-2):327-32
[
15110297.001
]
[Cites]
J Immunol Methods. 2008 Jul 31;336(2):142-51
[
18514220.001
]
[Cites]
Plant Physiol. 1988 Jun;87(2):389-94
[
16666152.001
]
[Cites]
Nat Rev Mol Cell Biol. 2008 Jul;9(7):543-56
[
18496517.001
]
[Cites]
Proc Natl Acad Sci U S A. 1986 Oct;83(19):7132-6
[
3463955.001
]
[Cites]
Radiol Oncol. 2010 Mar;44(1):34-41
[
22933889.001
]
[Cites]
Hybridoma. 1988 Oct;7(5):505-18
[
3198135.001
]
[Cites]
Cancer Immunol Immunother. 1994 Nov;39(5):342-5
[
7987867.001
]
[Cites]
Am J Physiol Cell Physiol. 2007 Jul;293(1):C390-400
[
17537804.001
]
[Cites]
IEEE Trans Biomed Eng. 2009 May;56(5):1491-501
[
19203876.001
]
[Cites]
Biophys J. 1999 Apr;76(4):2090-8
[
10096904.001
]
[Cites]
Biochem Biophys Res Commun. 2006 Aug 4;346(3):829-39
[
16780801.001
]
[Cites]
Cancer Immun. 2002 Nov 07;2:15
[
12747760.001
]
[Cites]
Anal Biochem. 1986 Nov 15;159(1):109-13
[
3812988.001
]
[Cites]
Nature. 1976 Jul 1;262(5563):52-4
[
180426.001
]
[Cites]
J Membr Biol. 2005 Aug;206(3):187-201
[
16456714.001
]
[Cites]
Methods Mol Biol. 1995;48:355-63
[
8528407.001
]
[Cites]
Biochim Biophys Acta. 1982 Nov 30;694(3):227-77
[
6758848.001
]
[Cites]
J Membr Biol. 1993 Feb;132(1):27-40
[
8459447.001
]
[Cites]
Exp Cell Res. 1984 Feb;150(2):477-82
[
6692859.001
]
[Cites]
J Membr Biol. 2009 May;229(1):11-8
[
19418087.001
]
[Cites]
J Cell Sci. 1991 Nov;100 ( Pt 3):431-42
[
1808197.001
]
[Cites]
Bioelectrochemistry. 2008 Nov;74(1):124-9
[
18667367.001
]
[Cites]
Biochem Biophys Res Commun. 2004 Feb 13;314(3):717-23
[
14741694.001
]
[Cites]
Biophys J. 1998 Jun;74(6):3015-22
[
9635756.001
]
[Cites]
Biochim Biophys Acta. 2000 Mar 17;1500(3):265-79
[
10699368.001
]
[Cites]
Biochem Biophys Res Commun. 1986 Oct 15;140(1):258-66
[
3778446.001
]
[Cites]
Biophys J. 1991 May;59(5):1074-84
[
1868154.001
]
[Cites]
Biochim Biophys Acta. 2008 Feb;1778(2):483-90
[
17996722.001
]
[Cites]
FEBS Lett. 1985 Mar 25;182(2):278-80
[
3979550.001
]
[Cites]
Biophys J. 1994 Oct;67(4):1574-81
[
7819489.001
]
[Cites]
Biochim Biophys Acta. 2000 Dec 15;1524(2-3):118-30
[
11113558.001
]
[Cites]
Methods Enzymol. 1993;220:174-96
[
8350753.001
]
[Cites]
Anticancer Res. 2009 Aug;29(8):3125-30
[
19661325.001
]
[Cites]
Biochim Biophys Acta. 1986 Jun 13;858(1):206-16
[
3707962.001
]
[Cites]
J Immunol Methods. 1990 Nov 6;134(1):35-42
[
2172386.001
]
[Cites]
Eur J Biochem. 1989 Jan 15;179(1):109-15
[
2645133.001
]
[Cites]
Science. 1982 Apr 30;216(4545):537-8
[
7071601.001
]
[Cites]
Biochemistry. 1990 May 15;29(19):4561-7
[
2372540.001
]
[Cites]
Biochim Biophys Acta. 1989 Jun 6;981(2):295-302
[
2567186.001
]
[Cites]
Biochim Biophys Acta. 1990 May 16;1034(2):125-31
[
2354188.001
]
[Cites]
Biochim Biophys Acta. 1984 Sep 5;775(3):446-8
[
6466684.001
]
[Cites]
J Membr Biol. 1985;85(3):269-80
[
3897548.001
]
[Cites]
J Cell Biol. 1986 Apr;102(4):1358-62
[
3958050.001
]
[Cites]
AAPS PharmSci. 2002;4(4):E21
[
12645993.001
]
[Cites]
Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2715-8
[
10688917.001
]
[Cites]
Biochim Biophys Acta. 1989 Jul 24;983(1):42-50
[
2758049.001
]
[Cites]
Mol Biotechnol. 2009 Oct;43(2):167-76
[
19562526.001
]
[Cites]
Eur Biophys J. 2006 Feb;35(3):196-204
[
16215750.001
]
[Cites]
Bioelectrochemistry. 2004 Apr;62(1):73-82
[
14990328.001
]
[Cites]
J Immunol. 1979 Jun;122(6):2498-504
[
312871.001
]
[Cites]
Biophys J. 1998 Apr;74(4):1889-98
[
9545050.001
]
[Cites]
Biochim Biophys Acta. 1989 Nov 3;985(3):334-8
[
2804114.001
]
[Cites]
Otolaryngol Head Neck Surg. 2005 May;132(5):755-64
[
15886631.001
]
[Cites]
Clin Immunol. 2002 Jul;104(1):14-20
[
12139943.001
]
[Cites]
Biophys J. 1992 Mar;61(3):810-5
[
1504251.001
]
[Cites]
Cancer Immunol Immunother. 2002 Sep;51(7):367-75
[
12192536.001
]
[Cites]
Mol Biotechnol. 2009 Mar;41(3):286-95
[
19016008.001
]
[Cites]
FEBS Lett. 2007 May 22;581(11):2181-93
[
17395182.001
]
[Cites]
Technol Cancer Res Treat. 2007 Feb;6(1):37-48
[
17241099.001
]
[Cites]
Biochim Biophys Acta. 1993 Nov 7;1152(2):207-18
[
8218321.001
]
[Cites]
J Med Microbiol. 2007 Jun;56(Pt 6):733-7
[
17510256.001
]
(PMID = 20628737.001).
[ISSN]
1432-1424
[Journal-full-title]
The Journal of membrane biology
[ISO-abbreviation]
J. Membr. Biol.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
Advertisement
4.
Ito T, Koyama Y, Otsuka M:
Analysis of the surface structure of DNA/polycation/hyaluronic acid ternary complex by Raman microscopy.
J Pharm Biomed Anal
; 2010 Jan 5;51(1):268-72
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[MeSH-minor]
Animals. Cell Line, Tumor. Freeze Drying. Gene Expression Regulation. Hyaluronic Acid / chemistry.
Melanoma
, Experimental. Mice. Plasmids. Polyethyleneimine / chemistry
Hazardous Substances Data Bank.
HYALURONIC ACID
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19692196.001).
[ISSN]
1873-264X
[Journal-full-title]
Journal of pharmaceutical and biomedical analysis
[ISO-abbreviation]
J Pharm Biomed Anal
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
9002-98-6 / Polyethyleneimine; 9004-61-9 / Hyaluronic Acid; 9007-49-2 / DNA
5.
Kakutani K, Doita M, Nishida K, Miyamoto H, Kurosaka M:
Radiculopathy due to malignant melanoma in the sacrum with unknown primary site.
Eur Spine J
; 2008 Sep;17 Suppl 2:S271-4
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Radiculopathy due to
malignant
melanoma
in the sacrum with unknown primary site.
Melanoma
is an interesting tumor, showing the appearance of metastasis without any trace of its primary lesion.
To report a very rare case
of malignant
melanoma
in the sacrum with unknown primary origin.
The pathological
diagnosis
was
malignant
melanoma
.
No obvious primary
malignant
melanoma
was detected on the skin surface, on the oral or
anal
mucosa, or in the fundus oculi.
However the patient died nine months after initial
diagnosis
.
Malignant
melanoma
in the sacrum with an unknown primary site, showing S1 radiculopathy is reported for the first time.
The
melanoma
could have been a metastatic tumor of the sacrum, although the primary site was not detected.
The incidence of primary
melanoma
is increasing faster than any other
cancer
.
Thus treatment of patients with spinal metastasis of
melanoma
is an important challenge for orthopedic surgeons.
[MeSH-major]
Melanoma
/ secondary. Neoplasms, Unknown Primary / pathology. Radiculopathy / etiology. Radiculopathy / pathology. Sacrum / pathology. Spinal Neoplasms / secondary
MedlinePlus Health Information.
consumer health - Melanoma
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Melanoma Res. 2000 Feb;10(1):78-80
[
10711643.001
]
[Cites]
Cancer. 1997 May 1;79(9):1816-21
[
9129001.001
]
[Cites]
Cancer. 1970 Oct;26(4):816-20
[
5506606.001
]
[Cites]
Oncology. 1972;26(2):265-70
[
5049921.001
]
[Cites]
Cancer. 1972 Dec;30(6):1469-72
[
4641758.001
]
[Cites]
Br J Surg. 1977 Nov;64(11):805-8
[
588977.001
]
[Cites]
JAMA. 1979 Jan 26;241(4):381-3
[
758556.001
]
[Cites]
Br Med J. 1979 Jun 9;1(6177):1530-3
[
466103.001
]
[Cites]
Ann Surg. 1980 Jan;191(1):98-104
[
7352784.001
]
[Cites]
Clin Orthop Relat Res. 1982 Sep;(169):95-102
[
7105592.001
]
[Cites]
CA Cancer J Clin. 1991 Jul-Aug;41(4):201-26
[
2049635.001
]
[Cites]
Cancer. 1991 Dec 15;68(12):2579-81
[
1933805.001
]
[Cites]
Spine (Phila Pa 1976). 1995 Oct 1;20(19):2141-6
[
8588172.001
]
[Cites]
Arch Phys Med Rehabil. 1996 Mar;77(3):307-9
[
8600878.001
]
[Cites]
Br J Surg. 1967 Jul;54(7):651-8
[
6026989.001
]
(PMID = 18075762.001).
[ISSN]
1432-0932
[Journal-full-title]
European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society
[ISO-abbreviation]
Eur Spine J
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Germany
[Other-IDs]
NLM/ PMC2525896
6.
Krafft C, Kirsch M, Beleites C, Schackert G, Salzer R:
Methodology for fiber-optic Raman mapping and FTIR imaging of metastases in mouse brains.
Anal Bioanal Chem
; 2007 Oct;389(4):1133-42
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Brain metastases
of malignant
melanomas were induced by injecting tumor cells into the carotid artery of mice.
Possible reasons why metastatic cells
of malignant
melanomas were not identified in FTIR images are discussed.
[MeSH-minor]
Animals. Automatic Data Processing. Brain / pathology. Cell Line, Tumor. Cluster Analysis. Female. Humans.
Melanoma
/ pathology. Mice. Mice, Nude. Neoplasm Transplantation. Optical Fibers. Spectroscopy, Fourier Transform Infrared / methods. Transplantation, Heterologous
MedlinePlus Health Information.
consumer health - Brain Tumors
.
MedlinePlus Health Information.
consumer health - Diagnostic Imaging
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17639353.001).
[ISSN]
1618-2642
[Journal-full-title]
Analytical and bioanalytical chemistry
[ISO-abbreviation]
Anal Bioanal Chem
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Germany
7.
Huang ZM, Li HZ, Xiao H, Ji ZG:
[Melanoma adrenal metastasis: report of 3 cases and literature review].
Zhonghua Yi Xue Za Zhi
; 2010 Apr 27;90(16):1123-5
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[
Melanoma
adrenal metastasis: report of 3 cases and literature review].
OBJECTIVE: To investigate the clinical
diagnosis
, treatment and prognosis of
melanoma
adrenal metastasis.
METHODS: A total of 48 cases
of malignant
melanoma
from 1985 to 2007 were reviewed.
And three cases of
melanoma
adrenal metastasis were analyzed.
Two cases had a history of cutaneous
melanoma
and another one suffered previously from
anal melanoma
.
The other two cases underwent complete resection of
melanoma
metastasis.
When contralateral adrenal metastasis of
melanoma
was found 6 months later, left adrenalectomy laparoscopically was performed.
CONCLUSION:
Melanoma
metastasis to adrenal gland is rare and it generally has a poor prognosis.
Patients with adrenal metastases from
melanoma
, either isolated or with a limited number of additional metastases, may achieve a survival benefit from surgical resection if all visible lesions are removed.
[MeSH-major]
Adrenal Gland Neoplasms / secondary.
Melanoma
/ pathology. Skin Neoplasms / pathology
MedlinePlus Health Information.
consumer health - Adrenal Gland Cancer
.
MedlinePlus Health Information.
consumer health - Melanoma
.
MedlinePlus Health Information.
consumer health - Skin Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20646432.001).
[ISSN]
0376-2491
[Journal-full-title]
Zhonghua yi xue za zhi
[ISO-abbreviation]
Zhonghua Yi Xue Za Zhi
[Language]
chi
[Publication-type]
Case Reports; English Abstract; Journal Article; Review
[Publication-country]
China
[Number-of-references]
8
8.
Xu Y, Theobald V, Sung C, DePalma K, Atwater L, Seiger K, Perricone MA, Richards SM:
Validation of a HLA-A2 tetramer flow cytometric method, IFNgamma real time RT-PCR, and IFNgamma ELISPOT for detection of immunologic response to gp100 and MelanA/MART-1 in melanoma patients.
J Transl Med
; 2008;6:61
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Validation of a HLA-A2 tetramer flow cytometric method, IFNgamma real time RT-PCR, and IFNgamma ELISPOT for detection of immunologic response to gp100 and MelanA/MART-1 in
melanoma
patients.
BACKGROUND: HLA-A2 tetramer flow cytometry, IFNgamma real time RT-PCR and IFNgamma ELISPOT assays are commonly used as surrogate immunological endpoints for
cancer
immunotherapy.
HLA-A2 (A*0201) tetramer assay specific for gp100209(210M) and MART-126-35(27L), IFNgamma real time RT-PCR and ELISPOT methods were validated using tumor infiltrating lymphocyte cell lines (TIL) isolated from HLA-A2
melanoma
patients.
A positive IFNgamma response (by RT-PCR and ELISPOT) to gp100 was demonstrated in PBMC from 3
melanoma
patients.
These methods can be applied not only to
cancer
vaccines but to other therapeutic proteins as part of immunogenicity and safety analyses.
[MeSH-major]
Antigens, Neoplasm / immunology. Enzyme-Linked Immunosorbent Assay / methods. Flow Cytometry / methods. HLA-A2 Antigen / immunology. Interferon-gamma / genetics.
Melanoma
/ immunology. Membrane Glycoproteins / immunology. Neoplasm Proteins / immunology. Reverse Transcriptase Polymerase Chain Reaction / methods
[MeSH-minor]
Calibration. Cell Line, Tumor. Humans. MART-1 Antigen. Reference Standards. Reproducibility of Results. Sensitivity and Specificity. gp100
Melanoma
Antigen
MedlinePlus Health Information.
consumer health - Melanoma
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Immunol. 1999 Dec 1;163(11):6292-300
[
10570323.001
]
[Cites]
J Clin Invest. 2005 Jul;115(7):1903-12
[
15937544.001
]
[Cites]
J Pharm Biomed Anal. 2000 Jan;21(6):1249-73
[
10708409.001
]
[Cites]
J Immunol. 2000 Aug 15;165(4):2287-96
[
10925318.001
]
[Cites]
J Natl Cancer Inst. 2000 Aug 16;92(16):1336-44
[
10944556.001
]
[Cites]
Cancer Chemother Pharmacol. 2000;46 Suppl:S62-6
[
10950150.001
]
[Cites]
J Immunol. 2000 Dec 1;165(11):6644-52
[
11086110.001
]
[Cites]
Scand J Immunol. 2000 Dec;52(6):544-9
[
11119258.001
]
[Cites]
Int J Cancer. 2002 Mar 20;98(3):376-88
[
11920589.001
]
[Cites]
Clin Cancer Res. 2002 Apr;8(4):1021-32
[
11948109.001
]
[Cites]
J Immunother. 2002 Mar-Apr;25(2):97-138
[
12074049.001
]
[Cites]
Clin Cancer Res. 2003 Feb;9(2):641-9
[
12576430.001
]
[Cites]
Clin Cancer Res. 2003 Apr;9(4):1301-12
[
12684398.001
]
[Cites]
Cancer Immunol Immunother. 2004 Aug;53(8):715-22
[
14997347.001
]
[Cites]
J Immunother. 2004 Jul-Aug;27(4):298-308
[
15235391.001
]
[Cites]
J Immunol Methods. 2004 Aug;291(1-2):175-83
[
15345315.001
]
[Cites]
J Immunol. 1999 Feb 15;162(4):2227-34
[
9973498.001
]
[Cites]
J Exp Med. 1999 Sep 6;190(5):651-67
[
10477550.001
]
[Cites]
J Exp Med. 1999 Sep 6;190(5):705-15
[
10477554.001
]
[Cites]
J Clin Oncol. 2005 Feb 1;23(4):741-50
[
15613700.001
]
[Cites]
Methods Mol Biol. 2005;302:51-86
[
15937345.001
]
[Cites]
Clin Diagn Lab Immunol. 2000 Mar;7(2):145-54
[
10702485.001
]
(PMID = 18945350.001).
[ISSN]
1479-5876
[Journal-full-title]
Journal of translational medicine
[ISO-abbreviation]
J Transl Med
[Language]
eng
[Publication-type]
Evaluation Studies; Journal Article
[Publication-country]
England
[Chemical-registry-number]
0 / Antigens, Neoplasm; 0 / HLA-A2 Antigen; 0 / MART-1 Antigen; 0 / MLANA protein, human; 0 / Membrane Glycoproteins; 0 / Neoplasm Proteins; 0 / PMEL protein, human; 0 / gp100 Melanoma Antigen; 82115-62-6 / Interferon-gamma
[Other-IDs]
NLM/ PMC2605437
9.
Parra RS, Almeida AL, Badiale GB, Moraes MM, Rocha JJ, Féres O:
Melanoma of the anal canal.
Clinics (Sao Paulo)
; 2010;65(10):1063-5
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Melanoma
of the
anal
canal.
[MeSH-major]
Anus
Neoplasms / pathology.
Melanoma
/ secondary
MedlinePlus Health Information.
consumer health - Anal Cancer
.
MedlinePlus Health Information.
consumer health - Melanoma
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Chir Ital. 2003 Jul-Aug;55(4):575-80
[
12938606.001
]
[Cites]
Dis Colon Rectum. 1995 Feb;38(2):146-51
[
7851168.001
]
[Cites]
Eur J Surg Oncol. 1996 Dec;22(6):598-601
[
9005147.001
]
[Cites]
Am J Surg. 2005 Apr;189(4):446-9
[
15820458.001
]
[Cites]
Ai Zheng. 2006 May;25(5):619-24
[
16687086.001
]
[Cites]
Dis Colon Rectum. 2010 Apr;53(4):402-8
[
20305438.001
]
[Cites]
Dis Colon Rectum. 2007 Jul;50(7):1004-10
[
17468984.001
]
[Cites]
Trop Gastroenterol. 2007 Apr-Jun;28(2):76-8
[
18050846.001
]
[Cites]
Zentralbl Chir. 2007 Dec;132(6):560-3
[
18098086.001
]
[Cites]
Acta Chir Belg. 2008 Nov-Dec;108(6):756-8
[
19241934.001
]
[Cites]
Eur J Surg Oncol. 2009 Jul;35(7):757-62
[
18602790.001
]
[Cites]
Am Surg. 2006 Oct;72(10):917-20
[
17058735.001
]
(PMID = 21120314.001).
[ISSN]
1980-5322
[Journal-full-title]
Clinics (São Paulo, Brazil)
[ISO-abbreviation]
Clinics (Sao Paulo)
[Language]
eng
[Publication-type]
Case Reports; Letter
[Publication-country]
Brazil
[Other-IDs]
NLM/ PMC2972593
10.
Mannava S, Grachtchouk V, Wheeler LJ, Im M, Zhuang D, Slavina EG, Mathews CK, Shewach DS, Nikiforov MA:
Direct role of nucleotide metabolism in C-MYC-dependent proliferation of melanoma cells.
Cell Cycle
; 2008 Aug;7(15):2392-400
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Direct role of nucleotide metabolism in C-MYC-dependent proliferation of
melanoma
cells.
To identify C-MYC targets rate-limiting for proliferation
of malignant
melanoma
, we stably inhibited C-MYC in several human metastatic
melanoma
lines via lentivirus-based shRNAs approximately to the levels detected in normal melanocytes.
C-MYC depletion also resulted in reduction in the amounts of deoxyribonucleoside triphosphates (dNTPs) and inhibition of proliferation. shRNA-mediated suppression of TS, IMPDH2 or PRPS2 resulted in the decrease of dNTP pools and retardation of the cell cycle progression of
melanoma
cells in a manner similar to that of C-MYC-depletion in those cells.
Reciprocally, concurrent overexpression of cDNAs for TS, IMPDH2 and PRPS2 delayed proliferative arrest caused by inhibition of C-MYC in
melanoma
cells.
Moreover, all three proteins express at higher levels in cells from several metastatic
melanoma
lines compared to normal melanocytes.
MedlinePlus Health Information.
consumer health - Melanoma
.
COS Scholar Universe.
author profiles
.
The Lens.
Cited by Patents in
.
antibodies-online.
View related products from antibodies-online.com
(subscription/membership/fee required).
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Mol Cell. 2002 May;9(5):1031-44
[
12049739.001
]
[Cites]
Mutat Res. 2002 Feb 20;499(2):197-211
[
11827713.001
]
[Cites]
Curr Cancer Drug Targets. 2003 Jun;3(3):163-75
[
12769686.001
]
[Cites]
Genome Biol. 2003;4(10):R69
[
14519204.001
]
[Cites]
J Biol Chem. 2003 Nov 7;278(45):43893-6
[
13679382.001
]
[Cites]
Nat Rev Cancer. 2004 Jul;4(7):562-8
[
15229481.001
]
[Cites]
Int J Cancer. 2004 Dec 10;112(5):733-7
[
15386371.001
]
[Cites]
Cell Cycle. 2004 Aug;3(8):1005-7
[
15280655.001
]
[Cites]
Anal Biochem. 1992 Oct;206(1):178-82
[
1456431.001
]
[Cites]
Mol Cell Biol. 1993 Sep;13(9):5216-24
[
8395000.001
]
[Cites]
J Biol Chem. 1993 Dec 25;268(36):27277-85
[
8262968.001
]
[Cites]
Mol Cell Biol. 1995 May;15(5):2527-35
[
7739536.001
]
[Cites]
Cell Growth Differ. 1997 Oct;8(10):1039-48
[
9342182.001
]
[Cites]
Pharmacol Ther. 1997 Oct-Dec;76(1-3):29-43
[
9535167.001
]
[Cites]
Nat Genet. 1999 Feb;21(2):220-4
[
9988278.001
]
[Cites]
Oncogene. 1999 May 13;18(19):3004-16
[
10378696.001
]
[Cites]
Curr Med Chem. 1999 Jul;6(7):545-60
[
10390600.001
]
[Cites]
EMBO J. 1999 Oct 1;18(19):5321-33
[
10508165.001
]
[Cites]
Anticancer Res. 2004 Nov-Dec;24(6):3875-80
[
15736425.001
]
[Cites]
Cancer Res. 2005 Mar 15;65(6):2097-107
[
15781619.001
]
[Cites]
Cancer Res. 2005 Jul 15;65(14):6294-304
[
16024631.001
]
[Cites]
Nat Rev Mol Cell Biol. 2005 Aug;6(8):635-45
[
16064138.001
]
[Cites]
Curr Top Microbiol Immunol. 2006;302:33-50
[
16620024.001
]
[Cites]
Curr Top Microbiol Immunol. 2006;302:51-62
[
16620025.001
]
[Cites]
Curr Top Microbiol Immunol. 2006;302:123-43
[
16620027.001
]
[Cites]
Curr Top Microbiol Immunol. 2006;302:145-67
[
16620028.001
]
[Cites]
Cell Death Differ. 2006 Jun;13(6):951-61
[
16575405.001
]
[Cites]
Cancer Res. 2006 Jul 1;66(13):6598-605
[
16818632.001
]
[Cites]
Semin Cancer Biol. 2006 Aug;16(4):253-64
[
16904903.001
]
[Cites]
Semin Cancer Biol. 2006 Aug;16(4):313-7
[
16935001.001
]
[Cites]
Oncogene. 2006 Oct 30;25(51):6817-30
[
17072330.001
]
[Cites]
EMBO Rep. 2007 Jan;8(1):70-6
[
17159920.001
]
[Cites]
Oncogene. 2008 Mar 20;27(13):1905-15
[
17906696.001
]
[Cites]
Mol Cell Biol. 2002 Aug;22(16):5793-800
[
12138190.001
]
[Cites]
Proc Natl Acad Sci U S A. 2000 Feb 29;97(5):2229-34
[
10688915.001
]
[Cites]
Genes Dev. 2001 Aug 15;15(16):2023-30
[
11511533.001
]
[Cites]
Mol Cell. 2001 Jul;8(1):105-13
[
11511364.001
]
[Cites]
Prog Nucleic Acid Res Mol Biol. 2001;69:115-48
[
11550793.001
]
[CommentIn]
Cell Cycle. 2008 Aug;7(15):2275-6
[
18682683.001
]
(PMID = 18677108.001).
[ISSN]
1551-4005
[Journal-full-title]
Cell cycle (Georgetown, Tex.)
[ISO-abbreviation]
Cell Cycle
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / R01 CA083081; United States / NCI NIH HHS / CA / P30 CA046592; United States / NCI NIH HHS / CA / 5 P30 CA46592; United States / NCI NIH HHS / CA / R01 CA076581; United States / NCI NIH HHS / CA / R01-CA120244-A1; United States / NCI NIH HHS / CA / R01 CA120244
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Nucleotides; 0 / Proto-Oncogene Proteins c-myc; 0 / RNA, Small Interfering; EC 1.1.1.205 / IMP Dehydrogenase; EC 1.1.1.205 / IMPDH2 protein, human; EC 2.1.1.45 / Thymidylate Synthase; EC 2.7.6.1 / Ribose-Phosphate Pyrophosphokinase
[Other-IDs]
NLM/ NIHMS486377; NLM/ PMC3744895
11.
Faries MB, Hsueh EC, Ye X, Hoban M, Morton DL:
Effect of granulocyte/macrophage colony-stimulating factor on vaccination with an allogeneic whole-cell melanoma vaccine.
Clin Cancer Res
; 2009 Nov 15;15(22):7029-35
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Effect of granulocyte/macrophage colony-stimulating factor on vaccination with an allogeneic whole-cell
melanoma
vaccine.
We sought to assess the effect of the addition of granulocyte/macrophage colony-stimulating factor (GM-CSF) to vaccination with a
melanoma
vaccine.
EXPERIMENTAL DESIGN: Ninety-seven patients with resected
melanoma
(stage II-IV) were enrolled, stratified by stage, and randomized to receive a cellular
melanoma
vaccine with or without GM-CSF.
The primary endpoint was delayed-type hypersensitivity (DTH) response to
melanoma
cells.
These immune changes were accompanied by an increase in early
melanoma
deaths and a trend toward worse survival with GM-CSF.
MedlinePlus Health Information.
consumer health - Melanoma
.
MedlinePlus Health Information.
consumer health - Skin Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
CA Cancer J Clin. 1996 Jul-Aug;46(4):225-44
[
8673695.001
]
[Cites]
Int J Cancer. 1996 Jul 3;67(1):54-62
[
8690525.001
]
[Cites]
Prostate. 1999 Jun 1;39(4):291-7
[
10344219.001
]
[Cites]
J Clin Oncol. 2005 Feb 1;23(4):720-31
[
15613691.001
]
[Cites]
J Immunol. 2005 Sep 1;175(5):3015-24
[
16116189.001
]
[Cites]
Cancer Immunol Immunother. 2006 Mar;55(3):237-45
[
16047143.001
]
[Cites]
Clin Cancer Res. 2007 Jan 1;13(1):215-22
[
17200357.001
]
[Cites]
Ann Oncol. 2007 Feb;18(2):226-32
[
17116643.001
]
[Cites]
Cancer. 2007 Jul 1;110(1):203-14
[
17541944.001
]
[Cites]
Eur J Haematol. 2007 Oct;79(4):292-6
[
17655695.001
]
[Cites]
Cancer Immunol Immunother. 2009 Jan;58(1):49-59
[
18446337.001
]
[Cites]
Cancer Res. 2000 Jun 15;60(12):3239-46
[
10866317.001
]
[Cites]
Am J Nephrol. 2000 Jan-Feb;20(1):53-6
[
10644869.001
]
[Cites]
J Immunother. 2000 Mar-Apr;23(2):275-81
[
10746554.001
]
[Cites]
J Clin Oncol. 2000 Apr;18(8):1614-21
[
10764421.001
]
[Cites]
J Clin Oncol. 2002 Oct 15;20(20):4169-80
[
12377960.001
]
[Cites]
J Clin Oncol. 2002 Dec 1;20(23):4549-54
[
12454111.001
]
[Cites]
Cancer. 2003 Jan 1;97(1):186-200
[
12491520.001
]
[Cites]
J Immunother. 2003 Jul-Aug;26(4):367-73
[
12843799.001
]
[Cites]
Clin Cancer Res. 2003 Jul;9(7):2447-56
[
12855617.001
]
[Cites]
Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):8874-9
[
12847287.001
]
[Cites]
J Clin Oncol. 2003 Nov 1;21(21):4016-26
[
14581425.001
]
[Cites]
Cancer Immunol Immunother. 2004 Feb;53(2):64-72
[
14593498.001
]
[Cites]
Cancer Res. 2004 Sep 1;64(17):6337-43
[
15342423.001
]
[Cites]
J Immunol. 1988 Dec 1;141(11):3882-8
[
3141506.001
]
[Cites]
Cancer Immunol Immunother. 1989;29(4):247-54
[
2752392.001
]
[Cites]
Blood. 1991 Mar 15;77(6):1131-45
[
2001448.001
]
[Cites]
Blood. 1991 Aug 1;78(3):609-15
[
1830497.001
]
[Cites]
J Clin Lab Anal. 1992;6(5):329-36
[
1403355.001
]
[Cites]
Ann Surg. 1992 Oct;216(4):463-82
[
1417196.001
]
[Cites]
Antimicrob Agents Chemother. 1993 Mar;37(3):512-22
[
8460920.001
]
[Cites]
Proc Natl Acad Sci U S A. 1993 Apr 15;90(8):3539-43
[
8097319.001
]
[Cites]
Int J Cancer. 1994 Mar 15;56(6):853-7
[
7509778.001
]
[Cites]
J Clin Oncol. 1998 Sep;16(9):2913-20
[
9738558.001
]
(PMID = 19903777.001).
[ISSN]
1078-0432
[Journal-full-title]
Clinical cancer research : an official journal of the American Association for Cancer Research
[ISO-abbreviation]
Clin. Cancer Res.
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / P01 CA012582; United States / NCI NIH HHS / CA / R01 CA076489-05; United States / NCI NIH HHS / CA / CA12582; United States / NCI NIH HHS / CA / CA87071; United States / NCI NIH HHS / CA / CA076489-05; United States / NCI NIH HHS / CA / P01 CA012582-35; United States / NCI NIH HHS / CA / K08 CA087071; United States / NCI NIH HHS / CA / CA76489; United States / NCI NIH HHS / CA / R01 CA076489
[Publication-type]
Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
[Publication-country]
United States
[Chemical-registry-number]
0 / Adjuvants, Immunologic; 0 / Cancer Vaccines; 0 / Immunoglobulin G; 0 / Immunoglobulin M; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor
[Other-IDs]
NLM/ NIHMS219270; NLM/ PMC2920049
12.
Uchiyama S, Imamura N, Ohuchida J, Hiyoshi M, Nagano M, Marutsuka K, Akiyama Y, Chijiiwa K:
Late recurrence of malignant melanoma in the duodenum.
Hepatogastroenterology
; 2008 Sep-Oct;55(86-87):1619-21
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Late recurrence
of malignant
melanoma
in the duodenum.
Melanoma
is a malignancy originating from melanocytes.
The primary
melanoma
usually occurs on the skin, retina,
anal
canal or occasionally at other organs such as the esophagus, penis or vagina.
Although
melanoma
represents about one-third of all metastatic lesions in the gastrointestinal tract, metastasis of
melanoma
to the GI tract, detected radiologically or endoscopically, is relatively rare.
In most cases
of malignant
melanoma
, recurrence and death occur within 10 years after treatment of the primary lesion.
We herein report a case showing a recurrence 17 years after extirpation of primary
malignant
melanoma
in the foot.
A 65-year-old man, with a history of extirpation of a
malignant
melanoma
in the sole of his foot 17 years before, presented with anorexia and severe anemia, and multiple duodenal tumors were pointed out with upper gastrointestinal endoscopy.
Histologic examination of the endoscopic biopsy specimen revealed proliferation of large polygonal cells with distinct nucleoli, and
malignant
melanoma
was diagnosed immunohistochemically.
[MeSH-major]
Duodenal Neoplasms / pathology.
Melanoma
/ pathology. Neoplasm Recurrence, Local / pathology
MedlinePlus Health Information.
consumer health - Intestinal Cancer
.
MedlinePlus Health Information.
consumer health - Melanoma
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19102354.001).
[ISSN]
0172-6390
[Journal-full-title]
Hepato-gastroenterology
[ISO-abbreviation]
Hepatogastroenterology
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Greece
[Chemical-registry-number]
0 / CC chemokine receptor 9; 0 / Receptors, CCR
13.
Pourpak A, Dorr RT, Meyers RO, Powell MB, Stratton SP:
Cytotoxic activity of Apomine is due to a novel membrane-mediated cytolytic mechanism independent of apoptosis in the A375 human melanoma cell line.
Invest New Drugs
; 2007 Apr;25(2):107-14
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Cytotoxic activity of Apomine is due to a novel membrane-mediated cytolytic mechanism independent of apoptosis in the A375 human
melanoma
cell line.
Apomine, a novel bisphosphonate ester, has demonstrated anticancer activity in a variety
of cancer
cell lines; however, its mechanism of cytotoxicity is not well understood.
Previous work has demonstrated that Apomine induces cell death by activation of caspase-3 in several
cancer
cell types.
However, we have demonstrated that Apomine induces cell death in the A375 human
melanoma
cell line through a novel membrane-mediated mechanism that is independent of caspase-3 activation.
Interestingly, Apomine-mediated cell death in the A375 and UACC 3093 human
melanoma
cell lines is also independent of N-Ras farnesylation, which was a previously described mechanism of action for Apomine in other
cancer
cell types.
[MeSH-major]
Antineoplastic Agents / toxicity. Apoptosis / drug effects. Cell Membrane / drug effects. Diphosphonates / toxicity.
Melanoma
/ drug therapy
MedlinePlus Health Information.
consumer health - Melanoma
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Immunol Methods. 1988 Nov 25;115(1):61-9
[
3192948.001
]
[Cites]
Cancer Treat Rev. 2004 Nov;30(7):609-41
[
15531395.001
]
[Cites]
Biochim Biophys Acta. 2005 Jun 15;1735(1):59-67
[
15951237.001
]
[Cites]
Clin Cancer Res. 2002 Nov;8(11):3468-74
[
12429636.001
]
[Cites]
Cancer Lett. 2000 Apr 28;152(1):107-13
[
10754212.001
]
[Cites]
Leukemia. 2003 Feb;17(2):451-7
[
12592346.001
]
[Cites]
Nature. 2002 Jun 27;417(6892):949-54
[
12068308.001
]
[Cites]
Invest New Drugs. 2006 Jan;24(1):89-94
[
16379038.001
]
[Cites]
Biochem Biophys Res Commun. 2005 Apr 8;329(2):772-9
[
15737653.001
]
[Cites]
Int J Hyperthermia. 1989 May-Jun;5(3):329-40
[
2498438.001
]
[Cites]
Anticancer Drugs. 1997 Mar;8(3):245-56
[
9095329.001
]
[Cites]
Cancer Res. 1975 Nov;35(11 Pt 1):3009-13
[
1182696.001
]
[Cites]
Nucleic Acids Res. 1983 Mar 11;11(5):1475-89
[
6828386.001
]
[Cites]
Clin Cancer Res. 2001 May;7(5):1246-50
[
11350890.001
]
[Cites]
Cancer Genet Cytogenet. 1995 Sep;83(2):93-104
[
7553595.001
]
[Cites]
Biochem Biophys Res Commun. 2000 Apr 2;270(1):240-6
[
10733934.001
]
[Cites]
J Immunol Methods. 1983 Dec 16;65(1-2):55-63
[
6606682.001
]
[Cites]
J Natl Cancer Inst. 2001 Jul 18;93(14):1062-74
[
11459867.001
]
[Cites]
Cancer Genet Cytogenet. 1998 Dec;107(2):89-92
[
9844599.001
]
[Cites]
J Am Coll Surg. 2005 Mar;200(3):362-70
[
15737846.001
]
[Cites]
Int J Cancer. 2005 May 20;115(1):65-73
[
15688405.001
]
[Cites]
J Biol Chem. 2004 Feb 20;279(8):6465-73
[
14627708.001
]
[Cites]
Cancer Res. 2001 Jan 1;61(1):131-7
[
11196150.001
]
[Cites]
J Immunol Methods. 1983 Nov 25;64(3):313-20
[
6199426.001
]
[Cites]
J Cell Physiol. 1984 Jan;118(1):27-33
[
6418750.001
]
[Cites]
Cell Tissue Kinet. 1990 Nov;23(6):603-17
[
2276175.001
]
[Cites]
J Pharm Biomed Anal. 2006 Mar 3;40(4):975-80
[
16181759.001
]
[Cites]
J Supramol Struct. 1976;4(1):127-32
[
1256059.001
]
[Cites]
Toxicol Appl Pharmacol. 2000 Mar 1;163(2):195-202
[
10698678.001
]
[Cites]
Carcinogenesis. 1999 Sep;20(9):1747-53
[
10469620.001
]
[Cites]
Biochemistry. 2002 Nov 19;41(46):13698-704
[
12427032.001
]
[Cites]
Nutr Cancer. 1998;31(2):111-8
[
9770722.001
]
(PMID = 17024575.001).
[ISSN]
0167-6997
[Journal-full-title]
Investigational new drugs
[ISO-abbreviation]
Invest New Drugs
[Language]
eng
[Grant]
United States / NCI NIH HHS / CA / CA23074; United States / NCI NIH HHS / CA / CA27502
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural
[Publication-country]
United States
[Chemical-registry-number]
0 / Antineoplastic Agents; 0 / DNA, Neoplasm; 0 / Diphosphonates; 0 / apomine; EC 1.1.1.27 / L-Lactate Dehydrogenase; EC 2.4.2.30 / Poly(ADP-ribose) Polymerases; EC 3.4.22.- / Caspases; EC 3.6.5.2 / ras Proteins; VC2W18DGKR / Thymidine
14.
Andreu-Pérez P, Hernandez-Losa J, Moliné T, Gil R, Grueso J, Pujol A, Cortés J, Avila MA, Recio JA:
Methylthioadenosine (MTA) inhibits melanoma cell proliferation and in vivo tumor growth.
BMC Cancer
; 2010;10:265
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Methylthioadenosine (MTA) inhibits
melanoma
cell proliferation and in vivo tumor growth.
BACKGROUND:
Melanoma
is the most deadly form of skin
cancer
without effective treatment.
In this study we have assessed the therapeutic potential of MTA in
melanoma
treatment.
METHODS: To investigate the therapeutic potential of MTA we performed in vitro proliferation and viability assays using six different mouse and human
melanoma
cell lines wild type for RAS and BRAF or harboring different mutations in RAS pathway.
We also have tested its therapeutic capabilities in vivo in a xenograft mouse
melanoma
model and using variety of molecular techniques and tissue culture we investigated its anti-proliferative and pro-apoptotic properties.
RESULTS: In vitro experiments showed that MTA treatment inhibited
melanoma
cell proliferation and viability in a dose dependent manner, where BRAF mutant
melanoma
cell lines appear to be more sensitive.
CONCLUSIONS: MTA inhibits
melanoma
cell proliferation and in vivo tumor growth particularly in BRAF mutant
melanoma
cells.
These data reveal a naturally occurring drug potentially useful for
melanoma
treatment.
[MeSH-major]
Adenosine / pharmacology. Antineoplastic Agents / pharmacology. Cell Proliferation / drug effects.
Melanoma
/ drug therapy. Skin Neoplasms / drug therapy. Thionucleosides / pharmacology
MedlinePlus Health Information.
consumer health - Melanoma
.
MedlinePlus Health Information.
consumer health - Skin Cancer
.
Hazardous Substances Data Bank.
Adenosine
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Cancer Res. 1984 Jun;44(6):2297-301
[
6426777.001
]
[Cites]
J Biol Chem. 1984 May 10;259(9):5465-71
[
6425290.001
]
[Cites]
Exp Hematol. 1984 Dec;12(11):867-71
[
6510486.001
]
[Cites]
Anal Biochem. 1986 Nov 15;159(1):109-13
[
3812988.001
]
[Cites]
Cancer Res. 1987 Apr 1;47(7):1771-4
[
3102048.001
]
[Cites]
Cancer Res. 1987 Jul 15;47(14):3830-4
[
3474063.001
]
[Cites]
J Cell Physiol. 1987 Nov;133(2):372-6
[
3119605.001
]
[Cites]
Biochim Biophys Acta. 1991 Mar 26;1088(3):365-72
[
2015299.001
]
[Cites]
Mol Cell Biol. 1992 Jan;12(1):103-11
[
1729592.001
]
[Cites]
J Biol Chem. 1993 Feb 25;268(6):4244-9
[
8440708.001
]
[Cites]
Proc Natl Acad Sci U S A. 1995 Jul 3;92(14):6489-93
[
7604019.001
]
[Cites]
Exp Cell Res. 1998 May 1;240(2):282-92
[
9597001.001
]
[Cites]
Arch Biochem Biophys. 1964 Jul 20;106:95-100
[
14217209.001
]
[Cites]
Genes Dev. 2006 Aug 15;20(16):2149-82
[
16912270.001
]
[Cites]
Ann Neurol. 2006 Sep;60(3):323-34
[
16786535.001
]
[Cites]
Gastroenterology. 2007 Jul;133(1):207-18
[
17631143.001
]
[Cites]
J Biol Chem. 2007 Jul 20;282(29):21477-86
[
17548352.001
]
[Cites]
J Cell Biochem. 2009 Feb 1;106(2):210-9
[
19097084.001
]
[Cites]
PLoS One. 2009;4(3):e4771
[
19274086.001
]
[Cites]
PLoS One. 2009;4(5):e5735
[
19478948.001
]
[Cites]
Mol Pharmacol. 2009 Jul;76(1):192-200
[
19372210.001
]
[Cites]
Nat Genet. 2009 Aug;41(8):920-5
[
19578364.001
]
[Cites]
Int J Cancer. 2010 Apr 1;126(7):1549-61
[
19810100.001
]
[Cites]
Cell. 2001 Mar 9;104(5):731-41
[
11257227.001
]
[Cites]
J Hepatol. 2001 Mar;34(3):386-94
[
11322199.001
]
[Cites]
FASEB J. 2002 Jan;16(1):15-26
[
11772932.001
]
[Cites]
Hepatology. 2002 Feb;35(2):274-80
[
11826399.001
]
[Cites]
Oncogene. 2002 Feb 7;21(7):1000-8
[
11850817.001
]
[Cites]
Alcohol. 2002 Jul;27(3):193-8
[
12163149.001
]
[Cites]
Mol Endocrinol. 2002 Sep;16(9):2008-18
[
12198239.001
]
[Cites]
Hepatology. 2004 Apr;39(4):1088-98
[
15057913.001
]
[Cites]
Int J Biochem Cell Biol. 2004 Nov;36(11):2125-30
[
15313459.001
]
[Cites]
Cancer Res. 1983 Oct;43(10):4699-702
[
6411330.001
]
[Cites]
Biochem Biophys Res Commun. 1984 Oct 15;124(1):172-7
[
6497877.001
]
(PMID = 20529342.001).
[ISSN]
1471-2407
[Journal-full-title]
BMC cancer
[ISO-abbreviation]
BMC Cancer
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Antineoplastic Agents; 0 / Ribosomal Protein S6; 0 / Thionucleosides; 136601-57-5 / Cyclin D1; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Braf protein, mouse; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; K72T3FS567 / Adenosine
[Other-IDs]
NLM/ PMC2891639
15.
Celebi ME, Kingravi HA, Iyatomi H, Aslandogan YA, Stoecker WV, Moss RH, Malters JM, Grichnik JM, Marghoob AA, Rabinovitz HS, Menzies SW:
Border detection in dermoscopy images using statistical region merging.
Skin Res Technol
; 2008 Aug;14(3):347-53
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
BACKGROUND: As a result of advances in skin imaging technology and the development of suitable image processing techniques, during the last decade, there has been a significant increase of interest in the computer-aided
diagnosis of
melanoma
.
MedlinePlus Health Information.
consumer health - Melanoma
.
MedlinePlus Health Information.
consumer health - Skin Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Skin Res Technol. 2005 Feb;11(1):17-26
[
15691255.001
]
[Cites]
IEEE Trans Pattern Anal Mach Intell. 2004 Nov;26(11):1452-8
[
15521493.001
]
[Cites]
CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66
[
17237035.001
]
[Cites]
Skin Res Technol. 2007 Nov;13(4):454-62
[
17908199.001
]
[Cites]
Arch Dermatol. 1995 Mar;131(3):286-91
[
7887657.001
]
[Cites]
J Am Acad Dermatol. 1993 Oct;29(4):581-8
[
8408794.001
]
[Cites]
IEEE Trans Med Imaging. 1999 Feb;18(2):164-71
[
10232673.001
]
[Cites]
Comput Med Imaging Graph. 1998 Sep-Oct;22(5):375-89
[
9890182.001
]
[Cites]
Melanoma Res. 2006 Apr;16(2):183-90
[
16567974.001
]
(PMID = 19159382.001).
[ISSN]
1600-0846
[Journal-full-title]
Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI)
[ISO-abbreviation]
Skin Res Technol
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / R44 CA060294-02A2; United States / NCI NIH HHS / CA / R44 CA101639; United States / NCI NIH HHS / CA / 2R44 CA-101639-02A2
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
[Publication-country]
England
[Other-IDs]
NLM/ NIHMS317765; NLM/ PMC3160669
16.
Bauer GL, Praetorius C, Bergsteinsdóttir K, Hallsson JH, GÃsladóttir BK, Schepsky A, Swing DA, O'Sullivan TN, Arnheiter H, Bismuth K, Debbache J, Fletcher C, Warming S, Copeland NG, Jenkins NA, SteingrÃmsson E:
The role of MITF phosphorylation sites during coat color and eye development in mice analyzed by bacterial artificial chromosome transgene rescue.
Genetics
; 2009 Oct;183(2):581-94
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
In vertebrates, it regulates the development of several cell types including melanocytes and has also been shown to play an important role in
melanoma
.
MedlinePlus Health Information.
consumer health - Eye Care
.
COS Scholar Universe.
author profiles
.
PhosphoSitePlus.
gene/protein/disease-specific - PhosphoSitePlus® - comprehensive post-translational modification resource
.
Hazardous Substances Data Bank.
L-SERINE
.
KOMP Repository.
gene/protein/disease-specific - KOMP Repository
(subscription/membership/fee required).
Mouse Genome Informatics (MGI).
Mouse Genome Informatics (MGI)
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Methods Mol Biol. 2000;132:365-86
[
10547847.001
]
[Cites]
Hum Mol Genet. 2000 Jan 1;9(1):125-32
[
10587587.001
]
[Cites]
Genes Dev. 2000 Feb 1;14(3):301-12
[
10673502.001
]
[Cites]
Exp Cell Res. 2000 Mar 15;255(2):135-43
[
10694430.001
]
[Cites]
Genetics. 2000 May;155(1):291-300
[
10790403.001
]
[Cites]
Biochem J. 2001 Oct 1;359(Pt 1):1-16
[
11563964.001
]
[Cites]
J Biol Chem. 2002 Mar 29;277(13):11077-83
[
11792706.001
]
[Cites]
Proc Natl Acad Sci U S A. 2002 Apr 2;99(7):4477-82
[
11930005.001
]
[Cites]
Genome Biol. 2002 Jun 18;3(7):RESEARCH0034
[
12184808.001
]
[Cites]
Nucleic Acids Res. 2003 Aug 1;31(15):e80
[
12888532.001
]
[Cites]
Development. 2004 Jan;131(1):131-42
[
14660434.001
]
[Cites]
J Virol. 1982 Jul;43(1):26-36
[
6287001.001
]
[Cites]
Proc Natl Acad Sci U S A. 1991 Mar 15;88(6):2341-5
[
1826051.001
]
[Cites]
Cell. 1993 Jul 30;74(2):395-404
[
8343963.001
]
[Cites]
Genes Dev. 1994 Nov 15;8(22):2770-80
[
7958932.001
]
[Cites]
Nat Genet. 1994 Nov;8(3):256-63
[
7874168.001
]
[Cites]
Nature. 1998 Jan 15;391(6664):298-301
[
9440696.001
]
[Cites]
J Biol Chem. 1998 Jul 17;273(29):17983-6
[
9660747.001
]
[Cites]
Annu Rev Genet. 2004;38:365-411
[
15568981.001
]
[Cites]
Science. 2005 Feb 4;307(5710):720-4
[
15618488.001
]
[Cites]
Nucleic Acids Res. 2005;33(4):e36
[
15731329.001
]
[Cites]
Anal Biochem. 2006 Apr 15;351(2):308-10
[
16524557.001
]
[Cites]
Trends Mol Med. 2006 Sep;12(9):406-14
[
16899407.001
]
[Cites]
Pigment Cell Res. 2007 Feb;20(1):36-40
[
17250546.001
]
[Cites]
Pigment Cell Res. 2007 Jun;20(3):185-200
[
17516926.001
]
[Cites]
Genetics. 2008 Jan;178(1):259-72
[
18202372.001
]
[Cites]
Cell Res. 2008 Dec;18(12):1163-76
[
19002157.001
]
[Cites]
Methods Mol Biol. 2010;647:237-50
[
20694671.001
]
(PMID = 19635938.001).
[ISSN]
1943-2631
[Journal-full-title]
Genetics
[ISO-abbreviation]
Genetics
[Language]
ENG
[Grant]
United States / Intramural NIH HHS / /
[Publication-type]
Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Microphthalmia-Associated Transcription Factor; 452VLY9402 / Serine
[Other-IDs]
NLM/ PMC2766318
17.
Baron R, Zayats M, Willner I:
Dopamine-, L-DOPA-, adrenaline-, and noradrenaline-induced growth of Au nanoparticles: assays for the detection of neurotransmitters and of tyrosinase activity.
Anal Chem
; 2005 Mar 15;77(6):1566-71
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
The analysis of tyrosinase activity is important for detecting
melanoma
cells and Parkinson disease.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
Norepinephrine
.
Hazardous Substances Data Bank.
EPINEPHRINE
.
Hazardous Substances Data Bank.
DOPAMINE
.
Hazardous Substances Data Bank.
GOLD, ELEMENTAL
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15762558.001).
[ISSN]
0003-2700
[Journal-full-title]
Analytical chemistry
[ISO-abbreviation]
Anal. Chem.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
46627O600J / Levodopa; 7440-57-5 / Gold; EC 1.14.18.1 / Monophenol Monooxygenase; VTD58H1Z2X / Dopamine; X4W3ENH1CV / Norepinephrine; YKH834O4BH / Epinephrine
18.
Stone EM, Glazer ES, Chantranupong L, Cherukuri P, Breece RM, Tierney DL, Curley SA, Iverson BL, Georgiou G:
Replacing Mn(2+) with Co(2+) in human arginase i enhances cytotoxicity toward l-arginine auxotrophic cancer cell lines.
ACS Chem Biol
; 2010 Mar 19;5(3):333-42
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Replacing Mn(2+) with Co(2+) in human arginase i enhances cytotoxicity toward l-arginine auxotrophic
cancer
cell lines.
In vitro cytotoxicity experiments verified that the Co(2+)-substituted human Arg I displays an approximately 12- to 15-fold lower IC(50) value for the killing of human hepatocellular carcinoma and
melanoma
cell lines and thus constitutes a promising new candidate for the treatment of l-Arg auxotrophic tumors.
MedlinePlus Health Information.
consumer health - Cancer Chemotherapy
.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
MANGANESE, ELEMENTAL
.
Hazardous Substances Data Bank.
COBALT, ELEMENTAL
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Annu Rev Biochem. 1999;68:33-57
[
10872443.001
]
[Cites]
Science. 2006 Jan 27;311(5760):535-8
[
16439663.001
]
[Cites]
Anal Biochem. 2000 Nov 15;286(2):257-64
[
11067748.001
]
[Cites]
Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3226-31
[
11248060.001
]
[Cites]
Arch Biochem Biophys. 2001 May 1;389(1):135-43
[
11370664.001
]
[Cites]
J Control Release. 2002 Apr 23;80(1-3):259-71
[
11943403.001
]
[Cites]
J Am Chem Soc. 2002 May 15;124(19):5256-7
[
11996552.001
]
[Cites]
Biochemistry. 2003 Jul 1;42(25):7748-58
[
12820884.001
]
[Cites]
Eur J Biochem. 2004 May;271(10):1952-62
[
15128304.001
]
[Cites]
J Clin Oncol. 2004 May 15;22(10):1815-22
[
15143074.001
]
[Cites]
Curr Opin Biotechnol. 2004 Aug;15(4):291-7
[
15296927.001
]
[Cites]
Biochemistry. 1970 Oct 27;9(22):4352-9
[
5472710.001
]
[Cites]
Anal Biochem. 1989 Nov 1;182(2):319-26
[
2610349.001
]
[Cites]
Arch Biochem Biophys. 1991 Apr;286(1):217-21
[
1910285.001
]
[Cites]
Arch Biochem Biophys. 1994 Jul;312(1):31-7
[
8031143.001
]
[Cites]
Biochemistry. 1997 Aug 12;36(32):9847-58
[
9245417.001
]
[Cites]
Biochemistry. 1997 Aug 26;36(34):10558-65
[
9265637.001
]
[Cites]
Biochemistry. 1998 Jun 9;37(23):8539-50
[
9622506.001
]
[Cites]
Structure. 1999 Apr 15;7(4):435-48
[
10196128.001
]
[Cites]
J Clin Pathol. 1961 Jul;14:418-24
[
13688207.001
]
[Cites]
Biomol Eng. 2005 Jun;22(1-3):73-9
[
15857786.001
]
[Cites]
Biochemistry. 2006 Jan 31;45(4):1313-20
[
16430228.001
]
[Cites]
Biochemistry. 2006 Sep 5;45(35):10654-66
[
16939217.001
]
[Cites]
Proteins. 2006 Nov 15;65(3):637-42
[
16981206.001
]
[Cites]
Cancer Res. 2007 Jan 1;67(1):309-17
[
17210712.001
]
[Cites]
BioDrugs. 2008;22(1):53-8
[
18215091.001
]
[Cites]
Int J Cancer. 2009 Apr 1;124(7):1700-6
[
19089915.001
]
[Cites]
Proc Natl Acad Sci U S A. 2009 Jun 16;106 Suppl 1:9995-10000
[
19528653.001
]
[ErratumIn]
ACS Chem Biol. 2010 Aug 20;5(8):797
(PMID = 20050660.001).
[ISSN]
1554-8937
[Journal-full-title]
ACS chemical biology
[ISO-abbreviation]
ACS Chem. Biol.
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / CA 139059; United States / NCI NIH HHS / CA / R01 CA139059; United States / NCI NIH HHS / CA / CA139059-01; United States / NIBIB NIH HHS / EB / P30 EB009998; United States / NCI NIH HHS / CA / R01 CA139059-01
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Antineoplastic Agents; 3G0H8C9362 / Cobalt; 42Z2K6ZL8P / Manganese; EC 3.5.3.1 / Arginase
[Other-IDs]
NLM/ NIHMS170379; NLM/ PMC2842482
19.
Mishra PJ, Ha L, Rieker J, Sviderskaya EV, Bennett DC, Oberst MD, Kelly K, Merlino G:
Dissection of RAS downstream pathways in melanomagenesis: a role for Ral in transformation.
Oncogene
; 2010 Apr 22;29(16):2449-56
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Cutaneous
malignant
melanoma
is considered one of the most deadly human cancers, based on both its penchant for metastatic spread and its typical resistance to currently available therapy.
NRAS and BRAF mutations are rarely found in the same
melanoma
, suggesting that they may possess important overlapping oncogenic activities.
More surprisingly, we discovered that constitutive RalGEF activation had a major impact on several
malignant
phenotypes, particularly anchorage-independent growth, indicating that this often overlooked pathway should be more carefully evaluated as a possible therapeutic target.
MedlinePlus Health Information.
consumer health - Melanoma
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Nature. 2002 Jun 27;417(6892):949-54
[
12068308.001
]
[Cites]
Nat Genet. 2009 May;41(5):544-52
[
19282848.001
]
[Cites]
Cancer Cell. 2002 Jul;2(1):5-7
[
12150818.001
]
[Cites]
Genes Dev. 2002 Aug 15;16(16):2045-57
[
12183360.001
]
[Cites]
Cancer Res. 2002 Nov 15;62(22):6724-30
[
12438273.001
]
[Cites]
Cancer Res. 2002 Dec 1;62(23):6997-7000
[
12460918.001
]
[Cites]
Nat Genet. 2003 Jan;33(1):19-20
[
12447372.001
]
[Cites]
Nat Rev Cancer. 2003 Jan;3(1):11-22
[
12509763.001
]
[Cites]
Oncogene. 2003 May 19;22(20):3113-22
[
12789288.001
]
[Cites]
Trends Cell Biol. 2003 Aug;13(8):419-25
[
12888294.001
]
[Cites]
EMBO Rep. 2003 Aug;4(8):800-6
[
12856001.001
]
[Cites]
Cancer Res. 2004 Apr 1;64(7):2338-42
[
15059882.001
]
[Cites]
Cancer Cell. 2004 Aug;6(2):171-83
[
15324700.001
]
[Cites]
Cancer Res. 1987 Jun 15;47(12):3239-45
[
2438036.001
]
[Cites]
Mol Cell Biol. 1990 Jun;10(6):2503-12
[
2188091.001
]
[Cites]
EMBO J. 1996 Feb 15;15(4):810-6
[
8631302.001
]
[Cites]
Oncogene. 1998 Jul 2;16(26):3397-402
[
9692547.001
]
[Cites]
Anal Biochem. 1999 Jun 1;270(2):207-19
[
10334838.001
]
[Cites]
Cancer Cell. 2005 Jun;7(6):533-45
[
15950903.001
]
[Cites]
Nat Genet. 2005 Jul;37(7):745-9
[
15951821.001
]
[Cites]
Nature. 2005 Aug 4;436(7051):720-4
[
16079850.001
]
[Cites]
Cancer Res. 2005 Aug 15;65(16):7111-20
[
16103060.001
]
[Cites]
N Engl J Med. 2005 Nov 17;353(20):2135-47
[
16291983.001
]
[Cites]
Mol Cell Biol. 2006 Jan;26(2):727-34
[
16382162.001
]
[Cites]
J Invest Dermatol. 2006 Jan;126(1):154-60
[
16417231.001
]
[Cites]
Genes Dev. 2006 Aug 15;20(16):2149-82
[
16912270.001
]
[Cites]
Cancer Res. 2006 Oct 1;66(19):9483-91
[
17018604.001
]
[Cites]
Cell. 2006 Oct 6;127(1):157-70
[
17018283.001
]
[Cites]
Curr Biol. 2006 Dec 19;16(24):2385-94
[
17174914.001
]
[Cites]
Nature. 2007 Feb 22;445(7130):851-7
[
17314971.001
]
[Cites]
Proc Natl Acad Sci U S A. 2007 Jun 26;104(26):10968-73
[
17576930.001
]
[Cites]
Clin Cancer Res. 2007 Jul 1;13(13):3803-13
[
17606711.001
]
[Cites]
Mol Cell Biol. 2007 Nov;27(21):7538-50
[
17709381.001
]
[Cites]
Mol Cell Biol. 2007 Nov;27(22):8003-14
[
17875936.001
]
[Cites]
Melanoma Res. 2007 Dec;17(6):410-2
[
17992125.001
]
[Cites]
APMIS. 2007 Oct;115(10):1161-76
[
18042149.001
]
[Cites]
Nat Rev Cancer. 2008 Feb;8(2):133-40
[
18219307.001
]
[Cites]
Pigment Cell Melanoma Res. 2008 Feb;21(1):27-38
[
18353141.001
]
[Cites]
Blood. 2008 Apr 1;111(7):3364-72
[
18227351.001
]
[Cites]
J Natl Cancer Inst. 2008 Jun 4;100(11):784-95
[
18505964.001
]
[Cites]
Int J Biochem Cell Biol. 2009 Apr;41(4):757-61
[
18950730.001
]
[ErratumIn]
Oncogene. 2011 Apr 14;30(15):1850
(PMID = 20118982.001).
[ISSN]
1476-5594
[Journal-full-title]
Oncogene
[ISO-abbreviation]
Oncogene
[Language]
ENG
[Grant]
United States / Intramural NIH HHS / / ZIA BC008756-22; United States / Intramural NIH HHS / / ZIA BC008756-23; United States / Intramural NIH HHS / / Z99 CA999999; United Kingdom / Wellcome Trust / / 078327; United States / NCI NIH HHS / CA / N01CO12400; United States / NCI NIH HHS / CO / N01-CO-12400
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Cdkn2a protein, mouse; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / ral Guanine Nucleotide Exchange Factor; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Braf protein, mouse; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf; EC 2.7.11.1 / Proto-Oncogene Proteins c-raf; EC 3.1.3.67 / PTEN Phosphohydrolase
[Other-IDs]
NLM/ NIHMS357536; NLM/ PMC3287039
20.
van't Riet M, Giard RW, de Wilt JH, Vles W:
Melanoma of the anus disguised as hemorrhoids: surgical management illustrated by a case report.
Dig Dis Sci
; 2007 Jul;52(7):1745-7
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Melanoma
of the
anus
disguised as hemorrhoids: surgical management illustrated by a case report.
[MeSH-major]
Anus
Neoplasms /
diagnosis
.
Anus
Neoplasms / surgery. Hemorrhoids /
diagnosis
.
Melanoma
/
diagnosis
.
Melanoma
/ surgery
[MeSH-minor]
Diagnosis
, Differential. Humans. Male. Middle Aged
MedlinePlus Health Information.
consumer health - Anal Cancer
.
MedlinePlus Health Information.
consumer health - Hemorrhoids
.
MedlinePlus Health Information.
consumer health - Melanoma
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Clin Oncol. 2002 Dec 1;20(23):4555-8
[
12454112.001
]
[Cites]
Lancet Oncol. 2005 Jun;6(6):438-9
[
15925823.001
]
[Cites]
Br J Cancer. 2003 Dec 1;89(11):2019-22
[
14647131.001
]
[Cites]
Int J Colorectal Dis. 2004 Mar;19(2):121-3
[
12942268.001
]
[Cites]
Cancer. 2004 Apr 1;100(7):1478-83
[
15042682.001
]
[Cites]
Br J Surg. 2004 Sep;91(9):1183-7
[
15449271.001
]
[Cites]
Cancer. 1981 Apr 1;47(7):1891-900
[
6164474.001
]
[Cites]
Surgery. 1990 Jan;107(1):1-9
[
2296748.001
]
[Cites]
Dis Colon Rectum. 1990 Oct;33(10):874-7
[
1698595.001
]
[Cites]
World J Surg. 1992 May-Jun;16(3):478-85
[
1589984.001
]
[Cites]
Am Surg. 1993 Jul;59(7):400-4
[
8323072.001
]
[Cites]
Br J Surg. 1993 Sep;80(9):1194-5
[
8402131.001
]
[Cites]
Dis Colon Rectum. 1994 Sep;37(9):866-74
[
8076485.001
]
[Cites]
Dis Colon Rectum. 1995 Feb;38(2):146-51
[
7851168.001
]
[Cites]
Dis Colon Rectum. 1997 Jun;40(6):661-8
[
9194459.001
]
[Cites]
Am J Surg. 2005 Apr;189(4):446-9
[
15820458.001
]
[Cites]
J Am Coll Surg. 2003 Feb;196(2):206-11
[
12595048.001
]
(PMID = 17415639.001).
[ISSN]
0163-2116
[Journal-full-title]
Digestive diseases and sciences
[ISO-abbreviation]
Dig. Dis. Sci.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Other-IDs]
NLM/ PMC1914244
21.
Zubieta MR, Furman D, Barrio M, Bravo AI, Domenichini E, Mordoh J:
Galectin-3 expression correlates with apoptosis of tumor-associated lymphocytes in human melanoma biopsies.
Am J Pathol
; 2006 May;168(5):1666-75
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Galectin-3 expression correlates with apoptosis of tumor-associated lymphocytes in human
melanoma
biopsies.
The immune system recognizes diverse
melanoma
antigens.
Here, we have investigated 33 biopsies (eight primary and 25 metastases) from 24
melanoma
patients (15-72 years old) and describe the correlation between the expression of galectin-3 or galectin-1 and the level of apoptosis of tumor-associated lymphocytes using immunohistochemistry and an in situ nick translation assay.
Considering the complex process
of cancer
immunoediting, various interacting factors must be considered.
[MeSH-major]
Biomarkers / analysis. Biopsy. Galectin 1 / metabolism. Galectin 3 / metabolism. Lymphocytes, Tumor-Infiltrating / metabolism.
Melanoma
/ metabolism
MedlinePlus Health Information.
consumer health - Biopsy
.
MedlinePlus Health Information.
consumer health - Melanoma
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Ann Rheum Dis. 2004 Jun;63(6):636-43
[
15140769.001
]
[Cites]
J Clin Invest. 1993 Mar;91(3):1183-90
[
8450047.001
]
[Cites]
Proc Natl Acad Sci U S A. 2004 Oct 5;101 Suppl 2:14639-45
[
15381769.001
]
[Cites]
Am J Pathol. 2000 Mar;156(3):899-909
[
10702407.001
]
[Cites]
CA Cancer J Clin. 2000 Jan-Feb;50(1):7-33
[
10735013.001
]
[Cites]
J Immunol. 2000 Sep 1;165(5):2331-4
[
10946254.001
]
[Cites]
Clin Cancer Res. 2000 Sep;6(9):3560-4
[
10999744.001
]
[Cites]
Nature. 2001 Apr 26;410(6832):1107-11
[
11323675.001
]
[Cites]
J Immunol. 2001 Nov 15;167(10):5697-707
[
11698442.001
]
[Cites]
J Biol Chem. 2002 Mar 1;277(9):6852-7
[
11724777.001
]
[Cites]
J Exp Med. 2002 May 20;195(10):1303-16
[
12021310.001
]
[Cites]
Trends Immunol. 2002 Jun;23(6):313-20
[
12072371.001
]
[Cites]
Glycobiology. 2002 Oct;12(10):127R-36R
[
12244068.001
]
[Cites]
J Immunother. 2003 Jul-Aug;26(4):332-42
[
12843795.001
]
[Cites]
Cancer Res. 2003 Dec 1;63(23):8221-5
[
14678978.001
]
[Cites]
Cancer Res. 2003 Dec 1;63(23):8302-11
[
14678989.001
]
[Cites]
J Immunol. 2004 Feb 1;172(3):1602-11
[
14734741.001
]
[Cites]
J Biol Chem. 2004 Feb 6;279(6):4705-12
[
14617626.001
]
[Cites]
Cancer Cell. 2004 Mar;5(3):241-51
[
15050916.001
]
[Cites]
Exp Cell Res. 2004 May 1;295(2):315-29
[
15093732.001
]
[Cites]
Mol Cell Biol. 2004 May;24(10):4395-406
[
15121858.001
]
[Cites]
Anal Biochem. 1976 May 7;72:248-54
[
942051.001
]
[Cites]
J Immunol. 1984 Oct;133(4):1710-5
[
6206131.001
]
[Cites]
Nature. 1995 Dec 14;378(6558):736-9
[
7501023.001
]
[Cites]
Circulation. 1996 Sep 15;94(6):1255-62
[
8822977.001
]
[Cites]
Science. 1996 Nov 22;274(5291):1363-6
[
8910274.001
]
[Cites]
Cancer Res. 1997 Dec 1;57(23):5272-6
[
9393748.001
]
[Cites]
Biochim Biophys Acta. 1998 Jan 8;1379(1):97-106
[
9468337.001
]
[Cites]
J Immunol. 1999 Jul 1;163(1):443-7
[
10384147.001
]
[Cites]
J Exp Med. 1999 Aug 2;190(3):385-98
[
10430627.001
]
[Cites]
Cell Death Differ. 2004 Dec;11(12):1277-86
[
15297883.001
]
[Cites]
Am J Pathol. 2004 Dec;165(6):1853-63
[
15579430.001
]
[Cites]
Nat Rev Cancer. 2005 Jan;5(1):29-41
[
15630413.001
]
[Cites]
Oncogene. 2004 Sep 30;23(45):7527-36
[
15326483.001
]
(PMID = 16651632.001).
[ISSN]
0002-9440
[Journal-full-title]
The American journal of pathology
[ISO-abbreviation]
Am. J. Pathol.
[Language]
eng
[Publication-type]
Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Biomarkers; 0 / Galectin 1; 0 / Galectin 3; 0 / LGALS1 protein, human
[Other-IDs]
NLM/ PMC1606586
22.
Rizzi R, Mahata P, Mathieson L, Moscato P:
Hierarchical clustering using the arithmetic-harmonic cut: complexity and experiments.
PLoS One
; 2010;5(12):e14067
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
To this end, we implement a memetic algorithm for the problem and demonstrate the effectiveness of the arithmetic-harmonic cut on a number of datasets including a
cancer
type dataset and a corona virus dataset.
[MeSH-minor]
Algorithms. Cell Line, Tumor. Cluster Analysis. Colonic Neoplasms / metabolism. Gene Expression Profiling. Humans. Leukemia / metabolism.
Melanoma
/ metabolism. Models, Statistical. Models, Theoretical
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Nat Genet. 2000 Mar;24(3):227-35
[
10700174.001
]
[Cites]
Evol Comput. 2000 Spring;8(1):61-91
[
10753231.001
]
[Cites]
Proc Natl Acad Sci U S A. 2002 Apr 2;99(7):4465-70
[
11904358.001
]
[Cites]
IEEE Trans Pattern Anal Mach Intell. 2007 Nov;29(11):1944-57
[
17848776.001
]
[Cites]
Bioinformatics. 2004 Jun 12;20(9):1453-4
[
14871861.001
]
[Cites]
Science. 1999 Oct 15;286(5439):531-7
[
10521349.001
]
[Cites]
BMC Bioinformatics. 2003 Sep 20;4:43
[
14499005.001
]
(PMID = 21151943.001).
[ISSN]
1932-6203
[Journal-full-title]
PloS one
[ISO-abbreviation]
PLoS ONE
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Other-IDs]
NLM/ PMC2997101
23.
Ellison G, Donald E, McWalter G, Knight L, Fletcher L, Sherwood J, Cantarini M, Orr M, Speake G:
A comparison of ARMS and DNA sequencing for mutation analysis in clinical biopsy samples.
J Exp Clin Cancer Res
; 2010;29:132
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
METHODS: We have evaluated five real-time ARMS assays: BRAF 1799T>A, [this includes V600E and V600K] and NRAS 182A>G [Q61R] and 181C>A [Q61K] in
melanoma
, EGFR 2573T>G [L858R], 2235-2249del15 [E746-A750del] in non-small-cell lung
cancer
, and compared the results to DNA sequencing of the mutation 'hot-spots' in these genes in formalin-fixed paraffin-embedded tumour (FF-PET) DNA.
[MeSH-minor]
Carcinoma, Non-Small-Cell Lung / genetics. Clinical Trials, Phase II as Topic. Clinical Trials, Phase III as Topic. Humans. Lung Neoplasms / genetics.
Melanoma
/ genetics. Skin Neoplasms / genetics
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Nucleic Acids Res. 1989 Apr 11;17(7):2503-16
[
2785681.001
]
[Cites]
Hum Mutat. 2004 Apr;23(4):368-78
[
15024731.001
]
[Cites]
Anal Biochem. 1997 Feb 15;245(2):207-12
[
9056213.001
]
[Cites]
Br J Cancer. 1998 Apr;77(8):1267-74
[
9579832.001
]
[Cites]
Clin Chem. 1998 May;44(5):918-23
[
9590362.001
]
[Cites]
Nucleic Acids Res. 1999 Aug 15;27(16):e12
[
10454649.001
]
[Cites]
J Mol Diagn. 2005 Aug;7(3):413-21
[
16049314.001
]
[Cites]
Clin Chem. 2006 Apr;52(4):557-8
[
16595822.001
]
[Cites]
Cancer Sci. 2006 Jul;97(7):642-8
[
16827805.001
]
[Cites]
Science. 2006 Oct 13;314(5797):268-74
[
16959974.001
]
[Cites]
J Clin Oncol. 2006 Nov 1;24(31):5034-42
[
17075123.001
]
[Cites]
Nature. 2007 Mar 8;446(7132):153-8
[
17344846.001
]
[Cites]
Chest. 2007 Jun;131(6):1628-34
[
17565015.001
]
[Cites]
Br J Cancer. 2007 Sep 17;97(6):778-84
[
17848912.001
]
[Cites]
Clin Chem. 2008 Apr;54(4):757-60
[
18375489.001
]
[Cites]
Cancer Sci. 2008 May;99(5):929-35
[
18325048.001
]
[Cites]
Nat Med. 2008 May;14(5):579-84
[
18408729.001
]
[Cites]
Eur Respir J. 2009 Jun;33(6):1485-97
[
19483050.001
]
[Cites]
Br J Cancer. 2009 Nov 17;101(10):1724-30
[
19861964.001
]
[Cites]
Nat Rev Drug Discov. 2010 May;9(5):363-6
[
20431568.001
]
[Cites]
Mol Med. 2002 May;8(5):227-37
[
12359953.001
]
[Cites]
Pathol Res Pract. 1993 Feb;189(1):66-72
[
8390645.001
]
(PMID = 20925915.001).
[ISSN]
1756-9966
[Journal-full-title]
Journal of experimental & clinical cancer research : CR
[ISO-abbreviation]
J. Exp. Clin. Cancer Res.
[Language]
eng
[Publication-type]
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / DNA, Neoplasm
[Other-IDs]
NLM/ PMC2988723
24.
Björn E, Nygren Y, Nguyen TT, Ericson C, Nöjd M, Naredi P:
Determination of platinum in human subcellular microsamples by inductively coupled plasma mass spectrometry.
Anal Biochem
; 2007 Apr 1;363(1):135-42
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Samples of isolated DNA and exosome fractions from human ovarian (2008) and
melanoma
(T289)
cancer
cell lines were used.
[MeSH-minor]
Cell Line, Tumor. Female. Humans. Mass Spectrometry.
Melanoma
/ metabolism. Ovarian Neoplasms / metabolism. Sensitivity and Specificity. Subcellular Fractions
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
CIS-DIAMINEDICHLOROPLATINUM
.
Hazardous Substances Data Bank.
PLATINUM
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17286953.001).
[ISSN]
0003-2697
[Journal-full-title]
Analytical biochemistry
[ISO-abbreviation]
Anal. Biochem.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Antineoplastic Agents; 0 / DNA Adducts; 0 / DNA, Neoplasm; 0 / Organoplatinum Compounds; 49DFR088MY / Platinum; Q20Q21Q62J / Cisplatin
25.
Piantanelli A, Maponi P, Scalise L, Serresi S, Cialabrini A, Basso A:
Fractal characterisation of boundary irregularity in skin pigmented lesions.
Med Biol Eng Comput
; 2005 Jul;43(4):436-42
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Although
melanoma
is one of the most aggressive tumours, early detection and a high rate of diagnostic accuracy, followed by timely excision, can allow complete recovery in
melanoma
patients.
This result is important for screening, as it can inform the decision to excise precociously
malignant
lesions or to avoid unnecessary removal of benign ones.
[MeSH-major]
Fractals. Image Processing, Computer-Assisted / methods.
Melanoma
/
diagnosis
. Skin Diseases /
diagnosis
[MeSH-minor]
Diagnosis
, Differential. Humans. Nevus, Pigmented /
diagnosis
. Nevus, Pigmented / pathology
MedlinePlus Health Information.
consumer health - Melanoma
.
MedlinePlus Health Information.
consumer health - Skin Conditions
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Mech Ageing Dev. 2001 Sep 15;122(13):1461-75
[
11470133.001
]
[Cites]
Gynecol Oncol. 1999 Oct;75(1):78-83
[
10502430.001
]
[Cites]
Pathologica. 1995 Jun;87(3):310-7
[
8570291.001
]
[Cites]
Med Image Anal. 2003 Mar;7(1):47-64
[
12467721.001
]
[Cites]
Am J Dermatopathol. 1995 Aug;17(4):374-8
[
8600802.001
]
[Cites]
Curr Eye Res. 1993 Jan;12(1):23-7
[
8436007.001
]
[Cites]
Arch Dermatol. 1998 Dec;134(12):1563-70
[
9875194.001
]
[Cites]
Br J Dermatol. 2002 Sep;147(3):481-6
[
12207587.001
]
[Cites]
IEEE Trans Med Imaging. 2003 Aug;22(8):959-64
[
12906250.001
]
[Cites]
Mod Pathol. 1996 Mar;9(3):174-82
[
8685210.001
]
[Cites]
Cancer Res. 2000 Jul 15;60(14 ):3683-8
[
10919633.001
]
[Cites]
J Telemed Telecare. 2000;6(3):132-7
[
10912329.001
]
[Cites]
J Pathol. 1992 Apr;166(4):409-11
[
1517895.001
]
[Cites]
J Biomed Eng. 1992 May;14(3):229-34
[
1588780.001
]
[Cites]
Neurobiol Aging. 2002 Jan-Feb;23(1):23-6
[
11755014.001
]
[Cites]
J Am Acad Dermatol. 2003 May;48(5):679-93
[
12734496.001
]
[Cites]
Skin Res Technol. 1995 Nov;1(4):187-91
[
27326721.001
]
[Cites]
Cancer. 1987 Mar 15;59(6):1236-41
[
3815299.001
]
[Cites]
J Pathol. 1995 Sep;177(1):103-7
[
7472773.001
]
[Cites]
Arch Dermatol. 1993 Feb;129(2):157-74
[
8434973.001
]
[Cites]
Eur J Dermatol. 2001 May-Jun;11(3):270-6; quiz 277
[
11358742.001
]
[Cites]
J Pathol. 1997 May;182(1):1-8
[
9227334.001
]
[Cites]
Philos Trans R Soc Lond B Biol Sci. 2002 May 29;357(1421):619-26
[
12079523.001
]
[Cites]
Riv Biol. 2002 May-Aug;95(2):239-58
[
12449683.001
]
(PMID = 16255424.001).
[ISSN]
0140-0118
[Journal-full-title]
Medical & biological engineering & computing
[ISO-abbreviation]
Med Biol Eng Comput
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
26.
Zhou HT, Zhou ZX, Zhang HZ, Bi JJ, Zhao P:
Wide local excision could be considered as the initial treatment of primary anorectal malignant melanoma.
Chin Med J (Engl)
; 2010 Mar 5;123(5):585-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Wide local excision could be considered as the initial treatment of primary anorectal
malignant
melanoma
.
BACKGROUND: Anorectal
malignant
melanoma
was a rare disease with extremely poor prognosis.
The aim of this study was to explore the clinical characteristic,
diagnosis
and treatment strategies of anorectal
malignant
melanoma
.
METHODS: The data of 57 patients with anorectal
malignant
melanoma
was collected and retrospectively analyzed.
RESULTS: Rectal bleeding and
anal
mass were found to be common symptoms of anorectal
malignant
melanoma
.
The preoperative
diagnosis
rate of anorectal
malignant
melanoma
was 48.6%.
CONCLUSIONS: This study identified no survival advantage to abdominoperineal resection in treatment of anorectal
malignant
melanoma
, and we propose that wide local excision could be considered as the initial treatment of choice.
[MeSH-major]
Anus
Neoplasms / surgery.
Melanoma
/ surgery
MedlinePlus Health Information.
consumer health - Anal Cancer
.
MedlinePlus Health Information.
consumer health - Melanoma
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20367986.001).
[ISSN]
0366-6999
[Journal-full-title]
Chinese medical journal
[ISO-abbreviation]
Chin. Med. J.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
China
27.
Chang PL, Harkins L, Hsieh YH, Hicks P, Sappayatosok K, Yodsanga S, Swasdison S, Chambers AF, Elmets CA, Ho KJ:
Osteopontin expression in normal skin and non-melanoma skin tumors.
J Histochem Cytochem
; 2008 Jan;56(1):57-66
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Osteopontin expression in normal skin and non-
melanoma
skin tumors.
Osteopontin (OPN) is an adhesive, matricellular glycoprotein, whose expression is elevated in many types
of cancer
and has been shown to facilitate tumorigenesis in vivo.
To understand the role of OPN in human skin
cancer
, this study is designed to determine whether OPN is expressed in premalignant [solar/actinic keratosis (AK)] and in
malignant
skin lesions such as squamous cell carcinomas (SCC) and basal cell carcinomas (BCC), as well as in normal skin exposed or not exposed to sunlight.
MedlinePlus Health Information.
consumer health - Skin Cancer
.
COS Scholar Universe.
author profiles
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Exp Cell Res. 1995 Feb;216(2):335-41
[
7843278.001
]
[Cites]
Am J Pathol. 1995 Jan;146(1):95-100
[
7856741.001
]
[Cites]
Arch Dermatol. 1995 Jul;131(7):796-800
[
7611795.001
]
[Cites]
Matrix Biol. 1995 Jul;14(7):553-60
[
8535605.001
]
[Cites]
Nat Genet. 1996 Sep;14(1):78-81
[
8782823.001
]
[Cites]
Lung Cancer. 1996 Nov;15(3):311-23
[
8959677.001
]
[Cites]
Arch Biochem Biophys. 1997 Jul 15;343(2):157-63
[
9224725.001
]
[Cites]
Cancer Invest. 1998;16(5):329-44
[
9627681.001
]
[Cites]
J Investig Dermatol Symp Proc. 1996 Apr;1(2):136-42
[
9627707.001
]
[Cites]
J Bone Miner Res. 1998 Jul;13(7):1101-11
[
9661074.001
]
[Cites]
Clin Cancer Res. 1997 Apr;3(4):605-11
[
9815727.001
]
[Cites]
Curr Opin Cell Biol. 1998 Oct;10(5):640-6
[
9818175.001
]
[Cites]
Hum Pathol. 1998 Nov;29(11):1250-4
[
9824103.001
]
[Cites]
Arch Pathol Lab Med. 1998 Dec;122(12):1087-90
[
9870857.001
]
[Cites]
Invest Ophthalmol Vis Sci. 2006 Mar;47(3):802-6
[
16505010.001
]
[Cites]
J Pediatr Surg. 2006 Apr;41(4):624-32; discussion 624-32
[
16567167.001
]
[Cites]
Am J Pathol. 2006 Jul;169(1):233-46
[
16816376.001
]
[Cites]
Arch Dermatol. 2006 Jul;142(7):900-6
[
16847207.001
]
[Cites]
Cancer Res. 2006 Jul 15;66(14):7119-27
[
16849558.001
]
[Cites]
Zhonghua Wei Chang Wai Ke Za Zhi. 2007 Jan;10(1):73-6
[
17253181.001
]
[Cites]
J Histochem Cytochem. 2007 Apr;55(4):403-9
[
17210923.001
]
[Cites]
Pathol Res Pract. 1999;195(11):733-9
[
10605692.001
]
[Cites]
Br J Cancer. 2000 Jul;83(2):156-63
[
10901364.001
]
[Cites]
Biochem Biophys Res Commun. 2001 Jan 19;280(2):460-5
[
11162539.001
]
[Cites]
Clin Cancer Res. 2001 Dec;7(12):4060-6
[
11751502.001
]
[Cites]
Genes Chromosomes Cancer. 2002 Mar;33(3):270-8
[
11807984.001
]
[Cites]
J Invest Dermatol. 2001 Dec;117(6):1554-8
[
11886522.001
]
[Cites]
J Oral Pathol Med. 1999 Mar;28(3):97-101
[
10069535.001
]
[Cites]
Clin Cancer Res. 1999 Aug;5(8):2271-7
[
10473115.001
]
[Cites]
Am J Respir Crit Care Med. 1999 Oct;160(4):1269-73
[
10508818.001
]
[Cites]
Dent Mater J. 2004 Dec;23(4):650-5
[
15688734.001
]
[Cites]
Cancer Res. 2005 May 1;65(9):3958-65
[
15867397.001
]
[Cites]
Kidney Int. 2005 Jul;68(1):155-66
[
15954904.001
]
[Cites]
Trends Cell Biol. 2006 Feb;16(2):79-87
[
16406521.001
]
[Cites]
Int J Cancer. 2006 May 1;118(9):2255-61
[
16331611.001
]
[Cites]
Exp Cell Res. 2007 Apr 1;313(6):1149-60
[
17306792.001
]
[Cites]
Oncogene. 2007 May 3;26(20):2840-50
[
17160024.001
]
[Cites]
Bone. 2007 Jun;40(6):1517-28
[
17395559.001
]
[Cites]
Diabetes. 2007 Jun;56(6):1662-70
[
17360982.001
]
[Cites]
Clin Exp Metastasis. 2003;20(1):77-84
[
12650610.001
]
[Cites]
Cancer. 2003 Jul 1;98(1):119-27
[
12833464.001
]
[Cites]
Protein Expr Purif. 2003 Aug;30(2):238-45
[
12880773.001
]
[Cites]
Carcinogenesis. 2003 Nov;24(11):1749-58
[
12919959.001
]
[Cites]
Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):184-90
[
14734468.001
]
[Cites]
Cancer Epidemiol Biomarkers Prev. 2004 Mar;13(3):487-91
[
15006928.001
]
[Cites]
Br J Cancer. 2004 May 17;90(10):1877-81
[
15138464.001
]
[Cites]
J Dent Res. 2004 Sep;83(9):664-70
[
15329369.001
]
[Cites]
J Surg Res. 2004 Oct;121(2):228-41
[
15501463.001
]
[Cites]
Proc Natl Acad Sci U S A. 1986 Oct;83(19):7182-6
[
3532105.001
]
[Cites]
J Biol Chem. 1987 Feb 25;262(6):2900-7
[
3469201.001
]
[Cites]
Anal Biochem. 1987 Apr;162(1):156-9
[
2440339.001
]
[Cites]
Lancet. 1988 Apr 9;1(8589):795-7
[
2895318.001
]
[Cites]
J Exp Med. 1989 Jul 1;170(1):145-61
[
2787378.001
]
[Cites]
Genomics. 1989 Aug;5(2):375-7
[
2571582.001
]
[Cites]
Anticancer Res. 1989 Sep-Oct;9(5):1291-9
[
2686530.001
]
[Cites]
Genomics. 1990 Aug;7(4):491-502
[
1974876.001
]
[Cites]
Cancer Res. 1991 Apr 15;51(8):2144-50
[
2009532.001
]
[Cites]
Mol Carcinog. 1991;4(3):196-202
[
2064725.001
]
[Cites]
J Bone Miner Res. 1992 Jul;7(7):743-54
[
1642143.001
]
[Cites]
Mol Biol Cell. 1992 Oct;3(10):1169-80
[
1421573.001
]
[Cites]
J Histochem Cytochem. 1994 Mar;42(3):351-61
[
8308252.001
]
[Cites]
Endocrinology. 1994 Sep;135(3):863-9
[
8070379.001
]
[Cites]
Am J Pathol. 1994 Sep;145(3):610-23
[
8080043.001
]
[Cites]
Cancer. 1995 Jan 15;75(2 Suppl):607-12
[
7804986.001
]
[Cites]
Lab Invest. 1995 Jan;72(1):55-63
[
7837791.001
]
[Cites]
Lab Invest. 1995 Jan;72(1):64-9
[
7837792.001
]
[Cites]
Cell Growth Differ. 1997 Oct;8(10):1061-9
[
9342184.001
]
[Cites]
J Cell Biochem. 1997 Dec 1;67(3):386-96
[
9361193.001
]
[Cites]
J Clin Invest. 1998 Apr 1;101(7):1468-78
[
9525990.001
]
[Cites]
Int J Cancer. 1998 Apr 17;79(2):127-32
[
9583725.001
]
[Cites]
J Biol Chem. 1994 Sep 16;269(37):23280-5
[
8083234.001
]
[Cites]
JAMA. 2002 Apr 3;287(13):1671-9
[
11926891.001
]
[Cites]
J Natl Cancer Inst. 2002 Apr 3;94(7):513-21
[
11929952.001
]
[Cites]
J Am Soc Nephrol. 2002 May;13(5):1210-8
[
11961008.001
]
[Cites]
Cancer. 2002 Aug 1;95(3):506-12
[
12209742.001
]
(PMID = 17938278.001).
[ISSN]
0022-1554
[Journal-full-title]
The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society
[ISO-abbreviation]
J. Histochem. Cytochem.
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / R01 CA090920; United States / NCI NIH HHS / CA / R01 CA90920
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
106441-73-0 / Osteopontin
[Other-IDs]
NLM/ PMC2323122
28.
Chang TM:
Nanobiotechnological modification of hemoglobin and enzymes from this laboratory.
Biochim Biophys Acta
; 2008 Oct;1784(10):1435-40
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Other approaches include a polyhemoglobin-fibrinogen that acts as an oxygen carrier with platelet-like activity, and a polyhemoglobin-tyrosinase to retard the growth of a fatal skin
cancer
,
melanoma
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Biochem. 2002 Apr;131(4):611-7
[
11927000.001
]
[Cites]
Artif Cells Blood Substit Immobil Biotechnol. 2007;35(5):481-9
[
17922313.001
]
[Cites]
J Am Coll Surg. 2002 Oct;195(4):445-52; discussion 452-5
[
12375748.001
]
[Cites]
Nat Rev Drug Discov. 2004 Feb;3(2):152-9
[
15043006.001
]
[Cites]
Melanoma Res. 2004 Jun;14(3):197-202
[
15179188.001
]
[Cites]
Anal Biochem. 1971 Apr;40(2):450-8
[
5551554.001
]
[Cites]
Biochem Biophys Res Commun. 1971 Sep 17;44(6):1531-6
[
5160711.001
]
[Cites]
J Bioeng. 1976 Nov;1(1):25-32
[
1052520.001
]
[Cites]
Exp Hematol. 1980 May;8(5):584-92
[
7461058.001
]
[Cites]
Methods Enzymol. 1985;112:195-203
[
4046849.001
]
[Cites]
Trends Biochem Sci. 1989 Feb;14(2):42-4
[
2650040.001
]
[Cites]
Biomater Artif Cells Immobilization Biotechnol. 1993;21(5):609-21
[
8117850.001
]
[Cites]
Artif Cells Blood Substit Immobil Biotechnol. 1994;22(3):889-93
[
7994414.001
]
[Cites]
Artif Cells Blood Substit Immobil Biotechnol. 1996 May;24(3):169-83
[
8773737.001
]
[Cites]
Nat Biotechnol. 1998 Jul;16(7):667-71
[
9661202.001
]
[Cites]
J Pharmacol Exp Ther. 1999 Feb;288(2):665-70
[
9918573.001
]
[Cites]
Science. 1964 Oct 23;146(3643):524-5
[
14190240.001
]
[Cites]
Artif Cells Blood Substit Immobil Biotechnol. 2007;35(1):11-8
[
17364467.001
]
[Cites]
Artif Cells Blood Substit Immobil Biotechnol. 2007;35(1):31-43
[
17364469.001
]
[Cites]
Artif Cells Blood Substit Immobil Biotechnol. 2002 Jan;30(1):23-37
[
12000224.001
]
(PMID = 18565337.001).
[ISSN]
0006-3002
[Journal-full-title]
Biochimica et biophysica acta
[ISO-abbreviation]
Biochim. Biophys. Acta
[Language]
ENG
[Grant]
None / None / / 13745; Canada / Canadian Institutes of Health Research / / 13745
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Netherlands
[Chemical-registry-number]
0 / Blood Substitutes; 0 / Cross-Linking Reagents; 0 / Hemoglobins; 0 / Oxyhemoglobins; 0 / polyhemoglobin; 9001-32-5 / Fibrinogen; 9034-51-9 / Hemoglobin A; EC 1.11.1.6 / Catalase; EC 1.15.1.1 / Superoxide Dismutase
[Other-IDs]
NLM/ CAMS2513; NLM/ PMC3514548
29.
Old WM, Shabb JB, Houel S, Wang H, Couts KL, Yen CY, Litman ES, Croy CH, Meyer-Arendt K, Miranda JG, Brown RA, Witze ES, Schweppe RE, Resing KA, Ahn NG:
Functional proteomics identifies targets of phosphorylation by B-Raf signaling in melanoma.
Mol Cell
; 2009 Apr 10;34(1):115-31
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Functional proteomics identifies targets of phosphorylation by B-Raf signaling in
melanoma
.
Melanoma
and other cancers harbor oncogenic mutations in the protein kinase B-Raf, which leads to constitutive activation and dysregulation of MAP kinase signaling.
In order to elucidate molecular determinants responsible for B-Raf control
of cancer
phenotypes, we present a method for phosphoprotein profiling, using negative ionization mass spectrometry to detect phosphopeptides based on their fragment ion signature caused by release of PO(3)(-).
Ninety phosphorylation events were regulated by oncogenic B-Raf signaling, based on their responses to treating
melanoma
cells with MKK1/2 inhibitor.
We investigated MINERVA/FAM129B, a target belonging to a protein family with unknown category and function, and established the importance of this protein and its MAP kinase-dependent phosphorylation in controlling
melanoma
cell invasion into three-dimensional collagen matrix.
MedlinePlus Health Information.
consumer health - Melanoma
.
COS Scholar Universe.
author profiles
.
PhosphoSitePlus.
gene/protein/disease-specific - PhosphoSitePlus® - comprehensive post-translational modification resource
.
Faculty of 1000.
commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine.
(subscription/membership/fee required).
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
SciCrunch.
HGNC: Data: Gene Annotation
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Anal Chem. 2004 Jul 1;76(13):3556-68
[
15228325.001
]
[Cites]
Proc Natl Acad Sci U S A. 2004 Aug 17;101(33):12130-5
[
15302935.001
]
[Cites]
J Biol Chem. 1989 Dec 5;264(34):20518-25
[
2511205.001
]
[Cites]
Biochem J. 1994 Nov 1;303 ( Pt 3):701-4
[
7980435.001
]
[Cites]
Anal Biochem. 1996 Aug 1;239(2):180-92
[
8811904.001
]
[Cites]
EMBO J. 1997 Nov 3;16(21):6439-51
[
9351826.001
]
[Cites]
J Biol Chem. 1998 Jan 16;273(3):1496-505
[
9430688.001
]
[Cites]
Nat Struct Mol Biol. 2004 Dec;11(12):1192-7
[
15543157.001
]
[Cites]
Oncogene. 2005 May 12;24(21):3459-71
[
15735667.001
]
[Cites]
J Cell Biol. 2005 Aug 29;170(5):703-8
[
16129781.001
]
[Cites]
Mol Cell Proteomics. 2005 Sep;4(9):1240-50
[
15951569.001
]
[Cites]
Mol Cell Proteomics. 2005 Oct;4(10):1487-502
[
15979981.001
]
[Cites]
J Exp Med. 2006 Jul 10;203(7):1651-6
[
16801397.001
]
[Cites]
J Clin Oncol. 2006 Sep 10;24(26):4340-6
[
16908931.001
]
[Cites]
Nat Biotechnol. 2006 Oct;24(10):1285-92
[
16964243.001
]
[Cites]
Cell. 2006 Nov 3;127(3):635-48
[
17081983.001
]
[Cites]
Mol Cell Proteomics. 2007 Jan;6(1):1-17
[
17018520.001
]
[Cites]
Curr Biol. 2007 Jan 23;17(2):179-84
[
17174095.001
]
[Cites]
Nature. 2007 Feb 22;445(7130):851-7
[
17314971.001
]
[Cites]
Nat Methods. 2007 Mar;4(3):231-7
[
17293869.001
]
[Cites]
Cancer Res. 2003 Feb 15;63(4):756-9
[
12591721.001
]
[Cites]
Proc Natl Acad Sci U S A. 2003 Jan 7;100(1):183-8
[
12518064.001
]
[Cites]
Cancer Res. 2002 Dec 1;62(23):6997-7000
[
12460918.001
]
[Cites]
Nature. 2002 Jun 27;417(6892):949-54
[
12068308.001
]
[Cites]
Rapid Commun Mass Spectrom. 2001;15(17):1593-9
[
11544598.001
]
[Cites]
Anal Chem. 2001 Apr 1;73(7):1440-8
[
11321292.001
]
[Cites]
Methods Enzymol. 2001;332:417-31
[
11305115.001
]
[Cites]
EMBO J. 2000 Jun 15;19(12):2924-34
[
10856237.001
]
[Cites]
Mol Cancer Ther. 2006 May;5(5):1136-44
[
16731745.001
]
[Cites]
Proteomics. 2004 Jun;4(6):1551-61
[
15174125.001
]
[Cites]
Mol Cell Biol. 2004 Jun;24(12):5269-80
[
15169891.001
]
[Cites]
Cell. 2004 Mar 19;116(6):855-67
[
15035987.001
]
[Cites]
Mol Cell Biol. 2004 Apr;24(7):2923-31
[
15024080.001
]
[Cites]
Science. 2004 Mar 5;303(5663):1483-7
[
15001769.001
]
[Cites]
Biochem J. 2004 Jan 1;377(Pt 1):249-55
[
14570592.001
]
[Cites]
Leukemia. 2003 Aug;17(8):1605-12
[
12886250.001
]
[Cites]
Cancer Res. 2003 Jul 15;63(14):3955-7
[
12873990.001
]
[Cites]
Anal Chem. 2003 Apr 15;75(8):1895-904
[
12713048.001
]
[Cites]
Cancer Lett. 2008 Jul 8;265(2):157-66
[
18406052.001
]
[Cites]
Mol Cell Proteomics. 2006 Feb;5(2):337-46
[
16260767.001
]
[Cites]
Cancer Res. 2007 Apr 1;67(7):3177-84
[
17409425.001
]
[Cites]
Clin Cancer Res. 2007 Aug 15;13(16):4934-42
[
17652623.001
]
[Cites]
Nat Chem Biol. 2005 Oct;1(5):252-62
[
16408053.001
]
[CommentIn]
Mol Cell. 2009 Apr 24;34(2):139-40
[
19394291.001
]
(PMID = 19362540.001).
[ISSN]
1097-4164
[Journal-full-title]
Molecular cell
[ISO-abbreviation]
Mol. Cell
[Language]
ENG
[Grant]
United States / NCRR NIH HHS / RR / RR021005-01; United States / NIGMS NIH HHS / GM / GM065103-08; United States / NCI NIH HHS / CA / R01-CA126240; United States / NIGMS NIH HHS / GM / T32 GM008759; United States / NCI NIH HHS / CA / R01-CA118972; United States / NIGMS NIH HHS / GM / T32 GM065103-08; United States / NCRR NIH HHS / RR / S10 RR021005-01; United States / NCI NIH HHS / CA / R01 CA118972; United States / NCI NIH HHS / CA / R01 CA118972-02; United States / NCI NIH HHS / CA / R01 CA126240; United States / NCRR NIH HHS / RR / S10 RR021005; United States / NIGMS NIH HHS / GM / T32 GM065103
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural
[Publication-country]
United States
[Chemical-registry-number]
0 / Fam129B protein, human; 0 / Phosphoproteins; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf
[Other-IDs]
NLM/ NIHMS111623; NLM/ PMC2735263
30.
Nedosekin DA, Shashkov EV, Galanzha EI, Hennings L, Zharov VP:
Photothermal multispectral image cytometry for quantitative histology of nanoparticles and micrometastasis in intact, stained and selectively burned tissues.
Cytometry A
; 2010 Nov;77(11):1049-58
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Using this tool, individual carbon nanotubes, gold nanorods, and
melanoma
cells with intrinsic melanin markers were identified in unstained (e.g. sentinel lymph nodes) and conventionally-stained tissues.
MedlinePlus Health Information.
consumer health - Melanoma
.
MedlinePlus Health Information.
consumer health - Skin Cancer
.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
GOLD, ELEMENTAL
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
© 2010 International Society for Advancement of Cytometry.
[Cites]
BMC Cell Biol. 2007;8 Suppl 1:S8
[
17634098.001
]
[Cites]
Magn Reson Med. 2007 May;57(5):835-41
[
17457873.001
]
[Cites]
Biosens Bioelectron. 2007 Nov 30;23(4):449-58
[
17881213.001
]
[Cites]
Clin Chem. 2007 Nov;53(11):2002-9
[
17890442.001
]
[Cites]
Small. 2008 Jan;4(1):153-9
[
18081130.001
]
[Cites]
J Toxicol Sci. 2008 Feb;33(1):105-16
[
18303189.001
]
[Cites]
Mol Pharm. 2008 Mar-Apr;5(2):316-27
[
18217714.001
]
[Cites]
Environ Sci Technol. 2008 Aug 15;42(16):6264-70
[
18767697.001
]
[Cites]
Cytometry A. 2008 Oct;73(10):884-94
[
18677768.001
]
[Cites]
Nano Lett. 2008 Nov;8(11):3953-8
[
18834183.001
]
[Cites]
Analyst. 2009 Mar;134(3):425-39
[
19238274.001
]
[Cites]
Cytometry A. 2009 Apr;75(4):282-8
[
19012320.001
]
[Cites]
J Biophotonics. 2009 Feb;2(1-2):91-103
[
19343688.001
]
[Cites]
Nano Lett. 2009 Mar;9(3):1023-7
[
19199447.001
]
[Cites]
Clin Chim Acta. 2009 May;403(1-2):1-8
[
19361470.001
]
[Cites]
J Biomed Opt. 2009 Mar-Apr;14(2):021017
[
19405730.001
]
[Cites]
J Biomech Eng. 2009 Jul;131(7):074519
[
19640155.001
]
[Cites]
Ultrastruct Pathol. 2009 Jul-Aug;33(4):155-9
[
19728231.001
]
[Cites]
J Biophotonics. 2009 Sep;2(8-9):528-39
[
19743443.001
]
[Cites]
Photosynth Res. 2009 Aug-Sep;101(2-3):245-66
[
19714478.001
]
[Cites]
Nat Nanotechnol. 2009 Oct;4(10):688-94
[
19809462.001
]
[Cites]
Cancer Res. 2009 Oct 15;69(20):7926-34
[
19826056.001
]
[Cites]
J Mass Spectrom. 2009 Oct;44(10):1417-22
[
19753579.001
]
[Cites]
Nature. 2009 Oct 22;461(7267):1105-9
[
19847261.001
]
[Cites]
J R Soc Interface. 2010 Jan 6;7(42):49-59
[
19324670.001
]
[Cites]
Nat Nanotechnol. 2009 Dec;4(12):855-60
[
19915570.001
]
[Cites]
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2009 Jul-Aug;1(4):353-9
[
20049802.001
]
[Cites]
Mol Biosyst. 2010 Apr;6(4):641-7
[
20237641.001
]
[Cites]
Radiology. 2010 May;255(2):442-50
[
20413757.001
]
[Cites]
Chem Rev. 2010 May 12;110(5):2783-94
[
20387910.001
]
[Cites]
Opt Express. 2010 Apr 12;18(8):8605-20
[
20588705.001
]
[Cites]
Opt Express. 2010 Jul 5;18(14):14375-84
[
20639922.001
]
[Cites]
Nature. 2010 Jul 29;466(7306):647-51
[
20613725.001
]
[Cites]
ACS Nano. 2010 Jul 27;4(7):3689-96
[
20550178.001
]
[Cites]
J Biophotonics. 2010 Dec;3(12):791-806
[
20572284.001
]
[Cites]
Arch Toxicol. 2011 Jul;85(7):723-31
[
20499226.001
]
[Cites]
Opt Lett. 2003 Aug 1;28(15):1314-6
[
12906074.001
]
[Cites]
Biophys J. 2006 Jan 15;90(2):619-27
[
16239330.001
]
[Cites]
Phys Chem Chem Phys. 2006 Aug 14;8(30):3486-95
[
16871337.001
]
[Cites]
Histopathology. 2006 Oct;49(4):411-24
[
16978205.001
]
[Cites]
Environ Health Perspect. 2007 Mar;115(3):377-82
[
17431486.001
]
[Cites]
Toxicol Sci. 2007 Nov;100(1):203-14
[
17660506.001
]
(PMID = 20949577.001).
[ISSN]
1552-4930
[Journal-full-title]
Cytometry. Part A : the journal of the International Society for Analytical Cytology
[ISO-abbreviation]
Cytometry A
[Language]
ENG
[Grant]
United States / NIBIB NIH HHS / EB / R01 EB009230-03; None / None / / R01 EB000873-01A2; United States / NCI NIH HHS / CA / R21 CA139373-01; United States / NIBIB NIH HHS / EB / R01 EB009230-01A1; United States / NIBIB NIH HHS / EB / R01 EB000873-04; None / None / / R01 EB000873-03; United States / NIBIB NIH HHS / EB / R01 EB000873-01A2; None / None / / R21 CA139373-02; United States / NIBIB NIH HHS / EB / R01 EB009230; None / None / / R01 EB009230-01A1; United States / NCI NIH HHS / CA / R01 CA131164-02; None / None / / R01 EB000873-04; United States / NIBIB NIH HHS / EB / R01 EB000873-02; United States / NIBIB NIH HHS / EB / R01 EB000873-03; None / None / / R01 CA131164-02; None / None / / R01 EB009230-03; United States / NCI NIH HHS / CA / R01 CA131164-04; None / None / / R01 EB009230-02; United States / NCI NIH HHS / CA / R01 CA131164-03; None / None / / R21 CA139373-01; United States / NCI NIH HHS / CA / R01CA131164; United States / NIBIB NIH HHS / EB / R01EB009230; None / None / / R01 CA131164-03; United States / NIBIB NIH HHS / EB / R01EB000873; United States / NIBIB NIH HHS / EB / R01 EB000873; United States / NCI NIH HHS / CA / R01 CA131164-01A2; None / None / / R01 EB000873-02; None / None / / R01 CA131164-01A2; United States / NCI NIH HHS / CA / R21 CA139373-02; United States / NIBIB NIH HHS / EB / R01 EB009230-02; United States / NCI NIH HHS / CA / R01 CA131164; None / None / / R01 CA131164-04; United States / NCI NIH HHS / CA / R21 CA139373; United States / NCI NIH HHS / CA / R21CA139373
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
[Publication-country]
United States
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / Melanins; 0 / Nanotubes, Carbon; 7440-57-5 / Gold
[Other-IDs]
NLM/ NIHMS268710; NLM/ PMC3339495
31.
Howell RC, Schweitzer AD, Casadevall A, Dadachova EA:
Chemosorption of radiometals of interest to nuclear medicine by synthetic melanins.
Nucl Med Biol
; 2008 Apr;35(3):353-7
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Chemosorption of radiometals of interest to nuclear medicine by synthetic melanins.
INTRODUCTION: Melanins are high-molecular-weight pigments that are ubiquitous in nature and can also be synthesized in the laboratory from a variety of precursors.
Melanins possess numerous interesting physicochemical characteristics, including electromagnetic radiation absorption properties and ability to chelate metals.
We have recently reported that melanin has remarkable ionizing-radiation-shielding properties, possibly because it can interact with photons via Compton scattering.
We hypothesized that, if administered internally, melanin could play a beneficial role by scavenging various radionuclides, in addition to radiation shielding.
METHODS: Three melanins were synthesized from dopamine, 3,4-dihydroxyphenylalanine (l-Dopa) and a combination of l-cysteine and l-Dopa.
For control, synthetic melanin made from tyrosine polymerization (Sigma) was used.
Melanins were characterized by elemental analysis.
The chemosorption of 111In, 225Ac and 213Bi by melanins was studied at 37 degrees C for up to 48 h.
RESULTS: The C-to-N molar ratios for dopamine, l-Dopa and tyrosine melanins were very close at 7.92, 8.39 and 8.48, respectively, while in mixed l-cysteine/l-Dopa melanin, that ratio was much lower at 3.63.
This mixed melanin also contained 22.33% sulfur, thus confirming incorporation of S-containing motifs into its structure.
Dopamine, l-Dopa and tyrosine melanins were very similar in their abilities to decrease the activity of 111In, 225Ac and 213Bi and their radioactive daughters in supernatants by >10-fold in comparison with the starting levels, while mixed l-cysteine/l-Dopa melanin was able to chemosorb only 111In.
CONCLUSIONS: We have demonstrated that synthetic melanins made of diverse precursors can chemosorb 111In, 213Bi and 225Ac, with dopamine, l-Dopa and tyrosine melanins being the most efficient towards all three of these radionuclides.
Such properties of synthetic melanins can contribute to the development of the novel melanin-based radioprotective materials.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
DOPAMINE
.
Hazardous Substances Data Bank.
CYSTEINE
.
Hazardous Substances Data Bank.
L-TYROSINE
.
Hazardous Substances Data Bank.
BISMUTH, ELEMENTAL
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
FEMS Microbiol Lett. 2003 Mar 14;220(1):99-104
[
12644234.001
]
[Cites]
Anal Biochem. 1985 Feb 1;144(2):527-36
[
3993914.001
]
[Cites]
Bioessays. 1992 Jan;14(1):49-56
[
1546980.001
]
[Cites]
Infect Immun. 1996 Jul;64(7):2420-4
[
8698461.001
]
[Cites]
Pigment Cell Melanoma Res. 2008 Apr;21(2):192-9
[
18426412.001
]
[Cites]
Pigment Cell Res. 2006 Dec;19(6):572-94
[
17083485.001
]
[Cites]
PLoS One. 2007;2(5):e457
[
17520016.001
]
[Cites]
J Phys Chem B. 2007 Jul 19;111(28):7938-47
[
17580858.001
]
[Cites]
Appl Radiat Isot. 2005 May;62(5):667-79
[
15763472.001
]
(PMID = 18355691.001).
[ISSN]
0969-8051
[Journal-full-title]
Nuclear medicine and biology
[ISO-abbreviation]
Nucl. Med. Biol.
[Language]
ENG
[Grant]
United States / NIAID NIH HHS / AI / AI52733; United States / NIAID NIH HHS / AI / AI060507-04; United States / NIAID NIH HHS / AI / R01 AI060507-03; United States / NIAID NIH HHS / AI / R01 AI060507-03S1; United States / NIAID NIH HHS / AI / AI60507; United States / NIAID NIH HHS / AI / R01 AI052733; United States / NIAID NIH HHS / AI / R56 AI060507; United States / Howard Hughes Medical Institute / / ; United States / NIAID NIH HHS / AI / AI060507-03S1; United States / NIAID NIH HHS / AI / R01 AI060507; United States / NIAID NIH HHS / AI / AI060507-03; United States / NIAID NIH HHS / AI / R01 AI060507-04
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Indium Radioisotopes; 0 / Melanins; 42HK56048U / Tyrosine; 46627O600J / Levodopa; K848JZ4886 / Cysteine; NIK1K0956U / Actinium; U015TT5I8H / Bismuth; VTD58H1Z2X / Dopamine
[Other-IDs]
NLM/ NIHMS47415; NLM/ PMC2516407
32.
Hong H, Sun J, Cai W:
Anatomical and molecular imaging of skin cancer.
Clin Cosmet Investig Dermatol
; 2008;1:1-17
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Anatomical and molecular imaging of skin
cancer
.
Skin
cancer
is the most common form
of cancer
types.
It is generally divided into two categories:
melanoma
(∼ 5%) and nonmelanoma (∼ 95%), which can be further categorized into basal cell carcinoma, squamous cell carcinoma, and some rare skin
cancer
types.
Biopsy is still the gold standard for skin
cancer
evaluation in the clinic.
Various anatomical imaging techniques have been used to evaluate different types of skin
cancer
lesions, including laser scanning confocal microscopy, optical coherence tomography, high-frequency ultrasound, terahertz pulsed imaging, magnetic resonance imaging, and some other recently developed techniques such as photoacoustic microscopy.
However, anatomical imaging alone may not be sufficient in guiding skin
cancer diagnosis
and therapy.
Over the last decade, various molecular imaging techniques (in particular single photon emission computed tomography and positron emission tomography) have been investigated for skin
cancer
imaging.
The pathways or molecular targets that have been studied include glucose metabolism, integrin α(v)β(3), melanocortin-1 receptor, high molecular weight
melanoma
-associated antigen, and several other molecular markers.
It is likely that this situation will change in the near future and molecular imaging will truly play an important role in personalized medicine of
melanoma
patients.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Z Arztl Fortbild Qualitatssich. 1997 Jul;91(4):347-53
[
9340205.001
]
[Cites]
Radiographics. 1997 Nov-Dec;17(6):1559-65
[
9397463.001
]
[Cites]
J Clin Oncol. 1998 May;16(5):1770-6
[
9586890.001
]
[Cites]
NMR Biomed. 2008 Mar;21(3):296-300
[
18246539.001
]
[Cites]
J Biomed Opt. 2008 Jan-Feb;13(1):014003
[
18315361.001
]
[Cites]
Adv Exp Med Biol. 2008;624:215-26
[
18348459.001
]
[Cites]
Adv Exp Med Biol. 2008;624:227-40
[
18348460.001
]
[Cites]
Adv Exp Med Biol. 2008;624:296-318
[
18348465.001
]
[Cites]
J Biomed Opt. 2008 Mar-Apr;13(2):024013
[
18465976.001
]
[Cites]
J Nucl Med. 2008 Jun;49 Suppl 2:113S-28S
[
18523069.001
]
[Cites]
Opt Express. 2002 Jul 29;10(15):707-13
[
19451924.001
]
[Cites]
Biotechniques. 2005 Dec;39(6 Suppl):S6-13
[
20158503.001
]
[Cites]
J Nucl Med. 1990 Nov;31(11):1831-5
[
2230996.001
]
[Cites]
Ann Surg. 1986 Sep;204(3):223-35
[
3753057.001
]
[Cites]
Science. 1994 Apr 22;264(5158):569-71
[
7512751.001
]
[Cites]
Annu Rev Cell Dev Biol. 1996;12:697-715
[
8970741.001
]
[Cites]
Dermatol Surg. 1997 Jan;23(1):43-5
[
9107293.001
]
[Cites]
Proc Natl Acad Sci U S A. 1998 Oct 27;95(22):12814-8
[
9788997.001
]
[Cites]
Am J Pathol. 1998 Nov;153(5):1347-51
[
9811323.001
]
[Cites]
AJR Am J Roentgenol. 1999 Feb;172(2):457-61
[
9930803.001
]
[Cites]
Nucl Med Biol. 1999 Aug;26(6):687-93
[
10587108.001
]
[Cites]
Crit Rev Oncog. 2000;11(2):147-63
[
11005510.001
]
[Cites]
Cancer Res. 2000 Oct 15;60(20):5649-58
[
11059756.001
]
[Cites]
Cancer Res. 2001 Jun 1;61(11):4474-82
[
11389078.001
]
[Cites]
Nucl Med Biol. 2001 Jul;28(5):493-8
[
11516693.001
]
[Cites]
J Nucl Med. 2001 Dec;42(12):1847-55
[
11752084.001
]
[Cites]
Nucl Med Biol. 2006 Aug;33(6):723-33
[
16934691.001
]
[Cites]
Ann Surg Oncol. 2007 Feb;14(2):913-21
[
17146742.001
]
[Cites]
Br J Dermatol. 2007 Jan;156(1):81-4
[
17199571.001
]
[Cites]
J Nucl Med. 2007 Jan;48(1):64-72
[
17204700.001
]
[Cites]
J Nucl Med. 2007 Jan;48(1):73-80
[
17204701.001
]
[Cites]
Cancer Imaging. 2006;6:204-8
[
17208677.001
]
[Cites]
Bull Cancer. 2007 Jan;94(1):93-8
[
17237009.001
]
[Cites]
J Nucl Med. 2007 Feb;48(2):304-10
[
17268029.001
]
[Cites]
J Nucl Med. 2007 Mar;48(3):429-36
[
17332621.001
]
[Cites]
Bioconjug Chem. 2007 May-Jun;18(3):765-72
[
17348700.001
]
[Cites]
Dermatol Surg. 2007 Apr;33(4):421-5; discussion 425-6
[
17430375.001
]
[Cites]
Front Biosci. 2007;12:4514-24
[
17485393.001
]
[Cites]
Rofo. 2007 Jun;179(6):618-26
[
17492539.001
]
[Cites]
Nucl Med Biol. 2007 May;34(4):363-70
[
17499725.001
]
[Cites]
J Nucl Med. 2007 Jun;48(6):987-94
[
17504880.001
]
[Cites]
Surg Oncol Clin N Am. 2007 Apr;16(2):403-30
[
17560520.001
]
[Cites]
J Am Acad Dermatol. 2007 Oct;57(4):629-37
[
17610989.001
]
[Cites]
J Biomed Opt. 2007 May-Jun;12(3):034027
[
17614735.001
]
[Cites]
Arch Dermatol. 2007 Jul;143(7):883-6
[
17638732.001
]
[Cites]
Cancer Biother Radiopharm. 2007 Jun;22(3):333-41
[
17651039.001
]
[Cites]
Cutis. 2007 Mar;79(3):241-8
[
17674590.001
]
[Cites]
Dermatol Surg. 2007 Oct;33(10):1158-74
[
17903149.001
]
[Cites]
Dermatol Surg. 2007 Oct;33(10):1220-7; discussion 1226-7
[
17903155.001
]
[Cites]
J Radiol. 1998 Apr;79(4):313-7
[
9757255.001
]
[Cites]
Eur J Nucl Med. 1998 Oct;25(10):1383-9
[
9818277.001
]
[Cites]
Bioconjug Chem. 2006 May-Jun;17(3):662-9
[
16704203.001
]
[Cites]
J Dermatol Sci. 2006 Aug;43(2):135-41
[
16806842.001
]
[Cites]
J Am Acad Dermatol. 2006 Sep;55(3):408-12
[
16908344.001
]
[Cites]
J Nucl Med. 1999 Apr;40(4):591-603
[
10210218.001
]
[Cites]
Cancer Res. 1999 Jun 15;59(12):2917-23
[
10383155.001
]
[Cites]
Cancer Chemother Pharmacol. 1999;44(4):343-8
[
10447583.001
]
[Cites]
J Nucl Med. 1999 Jun;40(6):1061-71
[
10452325.001
]
[Cites]
J Am Acad Dermatol. 2000 Jul;43(1 Pt 1):42-8
[
10863222.001
]
[Cites]
Neoplasia. 2000 Jan-Apr;2(1-2):9-25
[
10933065.001
]
[Cites]
Cancer Res. 2001 Mar 1;61(5):1781-5
[
11280722.001
]
[Cites]
J Clin Oncol. 2001 May 15;19(10):2674-8
[
11352959.001
]
[Cites]
J Nucl Med. 2001 May;42(5 Suppl):1S-93S
[
11483694.001
]
[Cites]
Science. 2001 Oct 12;294(5541):339-45
[
11546839.001
]
[Cites]
Hybrid Hybridomics. 2001;20(5-6):351-60
[
11839253.001
]
[Cites]
Genes Dev. 2003 Mar 1;17(5):545-80
[
12629038.001
]
[Cites]
Nat Rev Cancer. 2002 Feb;2(2):91-100
[
12635172.001
]
[Cites]
Pigment Cell Res. 2003 Jun;16(3):266-72
[
12753400.001
]
[Cites]
Oncogene. 2003 May 19;22(20):3172-9
[
12789293.001
]
[Cites]
Lab Invest. 2003 Sep;83(9):1279-83
[
13679435.001
]
[Cites]
Nat Biotechnol. 2003 Nov;21(11):1361-7
[
14595364.001
]
[Cites]
Bioconjug Chem. 2003 Nov-Dec;14(6):1177-84
[
14624632.001
]
[Cites]
Bioconjug Chem. 2004 Jan-Feb;15(1):61-9
[
14733584.001
]
[Cites]
Cancer Res. 2004 Feb 15;64(4):1411-8
[
14973076.001
]
[Cites]
Magn Reson Imaging. 2004 Jul;22(6):843-50
[
15234453.001
]
[Cites]
Mod Pathol. 2005 Apr;18(4):469-74
[
15529179.001
]
[Cites]
J Nucl Med. 2005 Jan;46(1):121-9
[
15632042.001
]
[Cites]
Skin Res Technol. 2007 Nov;13(4):463-71
[
17908200.001
]
[Cites]
Dermatology. 2007;215(4):365-72
[
17912001.001
]
[Cites]
Panminerva Med. 2007 Sep;49(3):119-38
[
17912148.001
]
[Cites]
Nucl Med Biol. 2007 Nov;34(8):945-53
[
17998097.001
]
[Cites]
Expert Rev Anticancer Ther. 2007 Dec;7(12):1707-16
[
18062745.001
]
[Cites]
Int J Pharm. 2008 Apr 2;353(1-2):233-42
[
18191509.001
]
[Cites]
Bioconjug Chem. 2008 Feb;19(2):539-47
[
18197608.001
]
[Cites]
Skin Res Technol. 2008 Feb;14(1):18-25
[
18211598.001
]
[Cites]
Skin Res Technol. 2008 Feb;14(1):89-92
[
18211606.001
]
[Cites]
Br J Dermatol. 2008 Feb;158(2):329-33
[
18215250.001
]
[Cites]
Dermatol Surg. 2008 May;34(5):610-9
[
18261097.001
]
[Cites]
Anal Sci. 2008 Feb;24(2):185-92
[
18270407.001
]
[Cites]
Curr Opin Oncol. 2008 Mar;20(2):196-200
[
18300770.001
]
[Cites]
Int J Cosmet Sci. 2008 Feb;30(1):1-17
[
18377626.001
]
[Cites]
J Eur Acad Dermatol Venereol. 2008 May;22(5):606-15
[
18410618.001
]
[Cites]
J Nucl Med. 2008 May;49(5):823-9
[
18413404.001
]
[Cites]
Clin Nucl Med. 2008 May;33(5):353-5
[
18431156.001
]
[Cites]
J Nucl Med. 2008 Jun;49(6):879-86
[
18483090.001
]
[Cites]
Semin Cutan Med Surg. 2008 Mar;27(1):37-43
[
18486023.001
]
[Cites]
AJR Am J Roentgenol. 2008 Jul;191(1):285-9
[
18562760.001
]
[Cites]
Cancer Res. 1990 Feb 1;50(3 Suppl):904s-908s
[
2297740.001
]
[Cites]
Cancer Res. 1990 Feb 1;50(3 Suppl):941s-948s
[
2297746.001
]
[Cites]
Cancer Res. 1990 Jun 1;50(11):3445-52
[
2334941.001
]
[Cites]
Neoplasma. 1989;36(5):505-11
[
2812147.001
]
[Cites]
J Nucl Med. 1988 Mar;29(3):329-37
[
3346743.001
]
[Cites]
Biomed Pharmacother. 1986;40(10):392-8
[
3580508.001
]
[Cites]
Cancer Immunol Immunother. 1987;24(3):221-4
[
3594484.001
]
[Cites]
NCI Monogr. 1987;(3):3-9
[
3821916.001
]
[Cites]
Radiology. 1985 May;155(2):487-92
[
3983400.001
]
[Cites]
Cancer Res. 1985 Jul;45(7):3378-87
[
4005860.001
]
[Cites]
Br J Urol. 1994 Oct;74(4):521-2
[
7820438.001
]
[Cites]
Arch Dermatol. 1995 Mar;131(3):279-85
[
7887656.001
]
[Cites]
Int J Cancer. 1994 Sep 1;58(5):749-55
[
8077062.001
]
[Cites]
Melanoma Res. 1993 Dec;3(6):395-401
[
8161879.001
]
[Cites]
Br J Dermatol. 1993 May;128(5):525-32
[
8504043.001
]
[Cites]
Clin Nucl Med. 1997 Jan;22(1):25-9
[
8993869.001
]
[Cites]
Nucl Med Biol. 1997 Feb;24(2):171-8
[
9089709.001
]
[Cites]
Bioconjug Chem. 1997 May-Jun;8(3):347-53
[
9177840.001
]
[Cites]
Magn Reson Med. 2005 Mar;53(3):621-7
[
15723405.001
]
[Cites]
PLoS Med. 2005 Mar;2(3):e70
[
15783258.001
]
[Cites]
Mol Imaging. 2004 Oct;3(4):343-51
[
15802051.001
]
[Cites]
J Med Chem. 2005 Apr 21;48(8):2985-92
[
15828837.001
]
[Cites]
J Nucl Med. 2005 Aug;46(8):1333-41
[
16085591.001
]
[Cites]
Nat Med. 2005 Nov;11(11):1250-5
[
16258537.001
]
[Cites]
Mod Pathol. 2006 Feb;19 Suppl 2:S127-47
[
16446711.001
]
[Cites]
J Am Acad Dermatol. 2006 Apr;54(4):638-43
[
16546585.001
]
[Cites]
J Nucl Med. 2006 May;47(5):763-9
[
16644745.001
]
[Cites]
J Nucl Med. 2006 Jun;47(6):957-67
[
16741305.001
]
[Cites]
Clin Cancer Res. 2006 Jul 1;12(13):3942-9
[
16818691.001
]
[Cites]
Nat Biotechnol. 2006 Jul;24(7):848-51
[
16823374.001
]
[Cites]
J Nucl Med. 2006 Sep;47(9):1434-9
[
16954550.001
]
[Cites]
Mol Cancer Ther. 2006 Nov;5(11):2624-33
[
17121909.001
]
[Cites]
J Dermatol Sci. 2007 Mar;45(3):167-73
[
17215110.001
]
[Cites]
Conf Proc IEEE Eng Med Biol Soc. 2005;1:190-2
[
17282143.001
]
[Cites]
Melanoma Res. 2007 Apr;17(2):117-27
[
17496787.001
]
[Cites]
Tech Vasc Interv Radiol. 2006 Sep;9(3):125-32
[
17561215.001
]
[Cites]
Arch Dermatol. 2007 Jun;143(6):727-34
[
17576938.001
]
[Cites]
J Dtsch Dermatol Ges. 2007 Aug;5(8):689-707
[
17659044.001
]
[Cites]
Int J Dermatol. 2007 Sep;46(9):895-904
[
17822489.001
]
[Cites]
Eur J Nucl Med Mol Imaging. 2008 Jan;35(1):186-208
[
17846765.001
]
[Cites]
Proc Natl Acad Sci U S A. 2007 Oct 30;104(44):17489-93
[
17954911.001
]
[Cites]
Expert Rev Anticancer Ther. 2007 Nov;7(11):1633-42
[
18020929.001
]
[Cites]
Br J Dermatol. 2007 Dec;157 Suppl 2:56-8
[
18067634.001
]
[Cites]
Mol Cancer Ther. 2008 Jan;7(1):101-9
[
18202013.001
]
[Cites]
Cancer. 2002 Feb 15;94(4 Suppl):1196-201
[
11877745.001
]
[Cites]
Phys Med Biol. 2002 Apr 7;47(7):R67-84
[
11996068.001
]
[Cites]
J Med Chem. 2002 Jul 4;45(14):3048-56
[
12086490.001
]
[Cites]
Ann Surg Oncol. 2002 Aug;9(7):646-53
[
12167578.001
]
[Cites]
Phys Med Biol. 2002 Nov 7;47(21):3847-52
[
12452576.001
]
[Cites]
J Nucl Med. 2002 Dec;43(12):1699-706
[
12468522.001
]
[Cites]
J Invest Dermatol. 2003 Jan;120(1):72-8
[
12535200.001
]
[Cites]
J Nucl Med. 2003 Aug;44(8):1210-8
[
12902409.001
]
[Cites]
Cancer Res. 1992 May 1;52(9):2545-8
[
1314697.001
]
[Cites]
Science. 1992 Aug 28;257(5074):1248-51
[
1325670.001
]
[Cites]
Br J Dermatol. 2003 Nov;149(5):1035-40
[
14632811.001
]
[Cites]
Optometry. 2003 Dec;74(12):760-4
[
14677727.001
]
[Cites]
Klin Monbl Augenheilkd. 2003 Dec;220(12):822-9
[
14704937.001
]
[Cites]
J Nucl Med. 2004 Jan;45(1):116-23
[
14734683.001
]
[Cites]
Nuklearmedizin. 2004 Feb;43(1):26-32
[
14978538.001
]
[Cites]
Br J Dermatol. 2004 Apr;150(4):677-86
[
15099363.001
]
[Cites]
Ann Surg Oncol. 2004 Aug;11(8):731-8
[
15249335.001
]
[Cites]
J Nucl Med. 2004 Aug;45(8):1323-7
[
15299056.001
]
[Cites]
J Invest Dermatol. 2004 Sep;123(3):458-63
[
15304083.001
]
[Cites]
Br J Dermatol. 2004 Aug;151(2):424-32
[
15327550.001
]
[Cites]
Cancer J. 2004 Jul-Aug;10(4):262-70
[
15383207.001
]
[Cites]
Vestn Rentgenol Radiol. 2004 Mar-Apr;(2):44-54
[
15458273.001
]
[Cites]
Photodermatol Photoimmunol Photomed. 2004 Dec;20(6):283-8
[
15533235.001
]
[Cites]
Phys Med Biol. 2004 Nov 7;49(21):N363-9
[
15584535.001
]
[Cites]
Arch Dermatol. 2005 Feb;141(2):217-24
[
15724019.001
]
[Cites]
Arch Dermatol. 2005 Feb;141(2):269-70
[
15724029.001
]
[Cites]
Curr Opin Oncol. 2005 Mar;17(2):154-9
[
15725921.001
]
[Cites]
J Nucl Med. 2005 May;46(5):887-95
[
15872364.001
]
[Cites]
Curr Opin Oncol. 1992 Apr;4(2):380-5
[
1591311.001
]
[Cites]
Nucl Med Biol. 2005 Jul;32(5):485-93
[
15982579.001
]
[Cites]
Cancer Metastasis Rev. 2005 Jun;24(2):195-222
[
15986132.001
]
[Cites]
Clin Cancer Res. 2005 Aug 1;11(15):5616-21
[
16061880.001
]
[Cites]
J Dermatol Sci. 2005 Nov;40(2):85-94
[
16139481.001
]
[Cites]
Radiology. 1992 Aug;184(2):427-34
[
1620841.001
]
[Cites]
J Biomed Opt. 2005 Sep-Oct;10(5):054010
[
16292970.001
]
[Cites]
J Am Acad Dermatol. 2005 Dec;53(6):979-85
[
16310058.001
]
[Cites]
Arch Dermatol. 2006 Mar;142(3):393; author reply 393
[
16549724.001
]
[Cites]
Cancer. 2006 Jul 1;107(1):193-200
[
16615102.001
]
(PMID = 21437135.001).
[ISSN]
1178-7015
[Journal-full-title]
Clinical, cosmetic and investigational dermatology
[ISO-abbreviation]
Clin Cosmet Investig Dermatol
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
New Zealand
[Other-IDs]
NLM/ PMC3048596
[Keywords]
NOTNLM ; anatomical imaging / antibody / melanoma / molecular imaging / positron emission tomography / skin cancer
33.
Belli F, Gallino GF, Lo Vullo S, Mariani L, Poiasina E, Leo E:
Melanoma of the anorectal region: the experience of the National Cancer Institute of Milano.
Eur J Surg Oncol
; 2009 Jul;35(7):757-62
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Melanoma
of the anorectal region: the experience of the National
Cancer
Institute of Milano.
AIMS: This study describes the experience of the National
Cancer
Institute of Milano in the treatment of anorectal
melanoma
over the last 32 years.
However, even when a radical surgery was undergone, the prognosis of patients with
anal melanoma
remains dismal.
CONCLUSION: Prognosis of
anal melanoma
remains poor.
[MeSH-major]
Anus
Neoplasms / surgery.
Melanoma
/ surgery. Rectal Neoplasms / surgery
MedlinePlus Health Information.
consumer health - Anal Cancer
.
MedlinePlus Health Information.
consumer health - Melanoma
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18602790.001).
[ISSN]
1532-2157
[Journal-full-title]
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
[ISO-abbreviation]
Eur J Surg Oncol
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
34.
Soman N, Marsh J, Lanza G, Wickline S:
New mechanisms for non-porative ultrasound stimulation of cargo delivery to cell cytosol with targeted perfluorocarbon nanoparticles.
Nanotechnology
; 2008 May 7;19(18)
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Melanoma
cells were incubated with nanogold particles and this was followed by insonication with continuous wave ultrasound (2.25 MHz, 5 min, 0.6 MPa).
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 21494419.001).
[ISSN]
1361-6528
[Journal-full-title]
Nanotechnology
[ISO-abbreviation]
Nanotechnology
[Language]
ENG
[Grant]
United States / NHLBI NIH HHS / HL / R01 HL059865; United States / NHLBI NIH HHS / HL / HL078631-03; United States / NHLBI NIH HHS / HL / HL078631-01; United States / NINDS NIH HHS / NS / R01 NS059302; United States / NCI NIH HHS / CA / U54 CA119342; United States / NCI NIH HHS / CA / U54 CA136398; United States / NHLBI NIH HHS / HL / HL078631-02; United States / NHLBI NIH HHS / HL / R01 HL078631; United States / NCI NIH HHS / CA / CA136398-010003; United States / NINDS NIH HHS / NS / R01 NS059302-01; United States / NINDS NIH HHS / NS / NS059302-02; United States / NCI NIH HHS / CA / CA119342-040001; United States / NHLBI NIH HHS / HL / HL078631-04
[Publication-type]
JOURNAL ARTICLE
[Publication-country]
England
35.
Sauer CJ, Klaase JM, Gerritsen JJ, Mastboom WJ:
[A malignant tumour in the breast is not always primary breast cancer].
Ned Tijdschr Geneeskd
; 2005 Apr 2;149(14):729-34
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[A
malignant
tumour in the breast is not always primary breast
cancer
].
[Transliterated title]
Een
maligne
mammatumor: niet altijd een primair mammacarcinoom.
In a 75-year-old woman with a swelling in her left breast, a 39-year-old woman with an
anal
fissure due to diarrhoea and a 65-year-old woman with chest pain, a mammary tumour was diagnosed that did not originate in mammary tissue.
These were a recurrent
melanoma
, a carcinoma of the thyroid and a B-cell lymphoma, respectively.
Breast
cancer
is one of the most frequently occurring neoplasms in women.
Most of these cases concern haematological malignancies and metastases from
melanoma
and lung
cancer
.
[MeSH-major]
Breast Neoplasms /
diagnosis
. Breast Neoplasms / secondary
[MeSH-minor]
Adult. Aged. Carcinoma /
diagnosis
. Carcinoma / secondary. Fatal Outcome. Female. Humans. Lymphoma, B-Cell /
diagnosis
. Lymphoma, B-Cell / pathology.
Melanoma
/
diagnosis
.
Melanoma
/ secondary. Neoplasm Recurrence, Local /
diagnosis
. Neoplasm Recurrence, Local / pathology. Thyroid Neoplasms /
diagnosis
. Thyroid Neoplasms / pathology. Treatment Outcome
Genetic Alliance.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentIn]
Ned Tijdschr Geneeskd. 2005 Jun 18;149(25):1426; author reply 1426
[
15997699.001
]
(PMID = 15835620.001).
[ISSN]
0028-2162
[Journal-full-title]
Nederlands tijdschrift voor geneeskunde
[ISO-abbreviation]
Ned Tijdschr Geneeskd
[Language]
dut
[Publication-type]
Case Reports; English Abstract; Journal Article
[Publication-country]
Netherlands
36.
Kong R, Reddy RK, Bhargava R:
Characterization of tumor progression in engineered tissue using infrared spectroscopic imaging.
Analyst
; 2010 Jul;135(7):1569-78
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Here, we apply Fourier transform infrared (FT-IR) spectroscopic imaging to examine an engineered tissue model of
melanoma
.
Second, we introduce
malignant
melanocytes to simulate tumor formation and growth.
The development of this analytical approach combining engineered tissue with spectroscopy, imaging and computation will allow for quality control and standardization in tissue engineering and novel scientific insight in
cancer
progression.
[MeSH-major]
Melanoma
/ chemistry. Skin Neoplasms / chemistry. Spectroscopy, Fourier Transform Infrared / methods. Tissue Engineering
MedlinePlus Health Information.
consumer health - Melanoma
.
MedlinePlus Health Information.
consumer health - Skin Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Cell Mol Biol (Noisy-le-grand). 1998 Feb;44(1):189-202
[
9551650.001
]
[Cites]
Science. 1996 Dec 20;274(5295):2057-9
[
8953032.001
]
[Cites]
Arch Dermatol. 1999 Aug;135(8):913-8
[
10456339.001
]
[Cites]
Lancet. 2005 Feb 19-25;365(9460):687-701
[
15721476.001
]
[Cites]
Annu Rev Phys Chem. 2005;56:429-74
[
15796707.001
]
[Cites]
ScientificWorldJournal. 2005 Mar 18;5:173-82
[
15798877.001
]
[Cites]
Nat Biotechnol. 2005 Apr;23(4):469-74
[
15793574.001
]
[Cites]
Biochim Biophys Acta. 2005 Aug 5;1724(3):262-9
[
15935560.001
]
[Cites]
Cancer Res. 2005 Sep 1;65(17):7568-72
[
16140919.001
]
[Cites]
Nat Rev Cancer. 2005 Sep;5(9):675-88
[
16148884.001
]
[Cites]
Clin Cancer Res. 2006 Apr 1;12(7 Pt 2):2308s-2311s
[
16609050.001
]
[Cites]
Biochim Biophys Acta. 2006 Jul;1758(7):923-33
[
16730643.001
]
[Cites]
Analyst. 2006 Aug;131(8):875-85
[
17028718.001
]
[Cites]
Anal Bioanal Chem. 2007 Mar;387(5):1591-9
[
17160382.001
]
[Cites]
Mayo Clin Proc. 2007 Mar;82(3):364-80
[
17352373.001
]
[Cites]
Tissue Antigens. 2007 Apr;69 Suppl 1:252-8
[
17445214.001
]
[Cites]
J Biomed Opt. 2007 Jul-Aug;12(4):044010
[
17867814.001
]
[Cites]
Appl Spectrosc. 2009 May;63(5):512-7
[
19470207.001
]
[Cites]
Analyst. 2009 Jun;134(6):1208-14
[
19475150.001
]
[Cites]
Appl Radiat Isot. 2009 Jul;67(7-8 Suppl):S54-8
[
19380232.001
]
[Cites]
J Biomed Opt. 2009 May-Jun;14(3):034011
[
19566304.001
]
[Cites]
Tumour Biol. 2009;30(3):109-20
[
19440007.001
]
[Cites]
Int J Cancer. 2009 Oct 15;125(8):1796-804
[
19569239.001
]
[Cites]
J R Soc Interface. 2010 Feb 6;7(43):229-58
[
19864266.001
]
[Cites]
PLoS One. 2009;4(12):e8461
[
20041153.001
]
[Cites]
Analyst. 2009 Aug;134(8):1669-74
[
20448936.001
]
[Cites]
Anal Bioanal Chem. 2007 Oct;389(4):1155-69
[
17786414.001
]
[Cites]
Conf Proc IEEE Eng Med Biol Soc. 2006;1:2766-9
[
17945738.001
]
[Cites]
Annu Rev Pathol. 2006;1:119-50
[
18039110.001
]
[Cites]
Analyst. 2008 Feb;133(2):197-205
[
18227942.001
]
[Cites]
Analyst. 2008 Mar;133(3):372-8
[
18299752.001
]
[Cites]
Dis Markers. 2008;25(6):323-37
[
19208950.001
]
[Cites]
J Biophotonics. 2009 Feb;2(1-2):104-13
[
19343689.001
]
[Cites]
Anal Chim Acta. 2009 May 29;642(1-2):246-56
[
19427483.001
]
[Cites]
Cell. 2000 Jan 7;100(1):57-70
[
10647931.001
]
[Cites]
Cancer Res. 2000 Mar 1;60(5):1254-60
[
10728684.001
]
[Cites]
Science. 2001 Nov 23;294(5547):1708-12
[
11721053.001
]
[Cites]
Regul Toxicol Pharmacol. 2001 Dec;34(3):234-48
[
11754528.001
]
[Cites]
J Biomed Opt. 2002 Jan;7(1):148-56
[
11818022.001
]
[Cites]
Lancet Oncol. 2002 Jan;3(1):35-43
[
11905603.001
]
[Cites]
Differentiation. 2002 Dec;70(9-10):522-36
[
12492494.001
]
[Cites]
J Biomed Opt. 2003 Apr;8(2):185-90
[
12683844.001
]
[Cites]
Eur J Cell Biol. 2003 Nov;82(11):539-48
[
14703010.001
]
[Cites]
J Control Release. 2004 Jun 18;97(2):269-81
[
15196754.001
]
[Cites]
Appl Spectrosc. 2004 Aug;58(8):995-1000
[
15324507.001
]
[Cites]
Biochim Biophys Acta. 1995 Jan 25;1270(1):1-6
[
7827129.001
]
[Cites]
Anal Chem. 1995 Oct 1;67(19):3377-81
[
8686889.001
]
[Cites]
Biomaterials. 1996 Feb;17(3):311-20
[
8745328.001
]
[Cites]
Cell Mol Biol (Noisy-le-grand). 1998 Feb;44(1):203-10
[
9551651.001
]
(PMID = 20498913.001).
[ISSN]
1364-5528
[Journal-full-title]
The Analyst
[ISO-abbreviation]
Analyst
[Language]
eng
[Grant]
United States / NCI NIH HHS / CA / R01 CA138882; United States / NCI NIH HHS / CA / R01 CA138882-01A1; United States / NCI NIH HHS / CA / R01CA138882
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
[Publication-country]
England
[Other-IDs]
NLM/ NIHMS259193; NLM/ PMC3030988
37.
Liu X, Palma J, Kinders R, Shi Y, Donawho C, Ellis PA, Rodriguez LE, Colon-Lopez M, Saltarelli M, LeBlond D, Lin CT, Frost DJ, Luo Y, Giranda VL:
An enzyme-linked immunosorbent poly(ADP-ribose) polymerase biomarker assay for clinical trials of PARP inhibitors.
Anal Biochem
; 2008 Oct 15;381(2):240-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Many established
cancer
therapies involve DNA-damaging chemotherapy or radiotherapy.
The DNA repair capacity of the tumor represents a common mechanism used by
cancer
cells to survive DNA-damaging therapy.
[MeSH-minor]
Animals. Biomarkers / analysis. Clinical Trials as Topic. Dacarbazine / analogs & derivatives. Dacarbazine / pharmacology. Disease Models, Animal. Female. Humans.
Melanoma
, Experimental / enzymology. Mice. Poly(ADP-ribose) Polymerase Inhibitors
Hazardous Substances Data Bank.
DACARBAZINE
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18674509.001).
[ISSN]
1096-0309
[Journal-full-title]
Analytical biochemistry
[ISO-abbreviation]
Anal. Biochem.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Antineoplastic Agents; 0 / Benzimidazoles; 0 / Biomarkers; 0 / Enzyme Inhibitors; 0 / Poly(ADP-ribose) Polymerase Inhibitors; 01O4K0631N / veliparib; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; EC 2.4.2.30 / Poly(ADP-ribose) Polymerases
38.
Patrick RJ, Fenske NA, Messina JL:
Primary mucosal melanoma.
J Am Acad Dermatol
; 2007 May;56(5):828-34
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Primary mucosal
melanoma
.
The distribution of head and neck, female genital tract,
anal
/rectal, and urinary tract sites is 55.4%, 18.0%, 23.8%, and 2.8%, respectively.
The median age at presentation is the seventh decade, and women are given
the diagnosis
more frequently than men.
[MeSH-major]
Genital Neoplasms, Female /
diagnosis
. Head and Neck Neoplasms /
diagnosis
.
Melanoma
/
diagnosis
. Rectal Neoplasms /
diagnosis
. Skin Neoplasms /
diagnosis
[MeSH-minor]
Aged, 80 and over.
Anus
Neoplasms /
diagnosis
. Female. Humans. Male. Mucous Membrane
MedlinePlus Health Information.
consumer health - Head and Neck Cancer
.
MedlinePlus Health Information.
consumer health - Melanoma
.
MedlinePlus Health Information.
consumer health - Skin Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17349716.001).
[ISSN]
1097-6787
[Journal-full-title]
Journal of the American Academy of Dermatology
[ISO-abbreviation]
J. Am. Acad. Dermatol.
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
United States
[Number-of-references]
44
39.
Kornspan JD, Tarshis M, Rottem S:
Invasion of melanoma cells by Mycoplasma hyorhinis: enhancement by protease treatment.
Infect Immun
; 2010 Feb;78(2):611-7
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Invasion of
melanoma
cells by Mycoplasma hyorhinis: enhancement by protease treatment.
Mycoplasma hyorhinis (strain MCLD) was recently isolated from a
melanoma
cell culture.
Adherence
of M
. hyorhinis to
melanoma
cells followed saturation kinetics.
Furthermore, although M. hyorhinis has been considered to remain attached to the surface of the host cells, we show for the first time, qualitatively by confocal laser scanning microscopy and quantitatively by a gentamicin resistance assay, that MCLD is able to invade
melanoma
cells.
Both adherence to and invasion of
melanoma
cells by M. hyorhinis strain MCLD were dramatically enhanced by mild proteolytic digestion with proteinase K (2.5 microg/mg cell protein for 2.5 min at 37 degrees C) that affected the surface-exposed proteins of this organism, mainly the major 47-kDa lipoprotein.
We suggest that the intracellular location
of M
. hyorhinis strain MCLD is a privileged niche, which may explain the survival
of M
. hyorhinis in tissue cultures.
The enhanced binding to and invasion of
melanoma
cells by protease treatment may be due to either the activation or the enhanced exposure of an adhesin(s) on the mycoplasmal cell surface.
[MeSH-major]
Endopeptidase K / metabolism.
Melanoma
/ microbiology. Mycoplasma Infections / enzymology. Mycoplasma hyorhinis / pathogenicity
MedlinePlus Health Information.
consumer health - Melanoma
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Trends Microbiol. 1999 Dec;7(12):493-9
[
10603485.001
]
[Cites]
Infect Immun. 2008 Dec;76(12):5768-76
[
18794296.001
]
[Cites]
Infect Immun. 2000 Jul;68(7):4238-44
[
10858241.001
]
[Cites]
Int J Med Microbiol. 2000 Mar;290(1):15-25
[
11043978.001
]
[Cites]
World J Gastroenterol. 2001 Apr;7(2):266-9
[
11819772.001
]
[Cites]
Physiol Rev. 2003 Apr;83(2):417-32
[
12663864.001
]
[Cites]
Eur J Immunol. 2004 Jul;34(7):2032-40
[
15214051.001
]
[Cites]
Infect Immun. 2004 Sep;72(9):5004-11
[
15321992.001
]
[Cites]
Anal Biochem. 1976 May 7;72:248-54
[
942051.001
]
[Cites]
Biochim Biophys Acta. 1980 May 27;604(1):65-90
[
6992872.001
]
[Cites]
J Biol Chem. 1981 Feb 25;256(4):1604-7
[
6257680.001
]
[Cites]
J Biol Stand. 1983 Jul;11(3):247-50
[
6885831.001
]
[Cites]
Isr J Med Sci. 1984 Sep;20(9):848-53
[
6511362.001
]
[Cites]
J Biol Chem. 1989 Jun 5;264(16):9289-93
[
2470754.001
]
[Cites]
In Vitro Cell Dev Biol. 1990 Jan;26(1):91-6
[
2307642.001
]
[Cites]
J Gen Microbiol. 1992 Mar;138(3):407-22
[
1593256.001
]
[Cites]
Mol Microbiol. 1992 Aug;6(15):2099-106
[
1406251.001
]
[Cites]
Acta Vet Scand. 1994;35(1):93-8
[
8209825.001
]
[Cites]
J Clin Microbiol. 1995 Mar;33(3):680-3
[
7751376.001
]
[Cites]
Vet Pathol. 1995 Mar;32(2):107-11
[
7771049.001
]
[Cites]
FEMS Microbiol Lett. 1995 Oct 15;132(3):189-94
[
7590171.001
]
[Cites]
Emerg Infect Dis. 1997 Jan-Mar;3(1):21-32
[
9126441.001
]
[Cites]
Infect Immun. 1998 Oct;66(10):4804-10
[
9746582.001
]
[Cites]
Ann N Y Acad Sci. 1960 Jan 15;79:433-49
[
14400338.001
]
[Cites]
Infect Immun. 2007 Dec;75(12):5716-9
[
17938226.001
]
[Cites]
Mol Cancer Ther. 2008 Mar;7(3):530-7
[
18347140.001
]
[Cites]
FEMS Microbiol Lett. 2008 Oct;287(2):243-9
[
18754786.001
]
[Cites]
J Bacteriol. 2000 Mar;182(5):1356-63
[
10671459.001
]
(PMID = 19917715.001).
[ISSN]
1098-5522
[Journal-full-title]
Infection and immunity
[ISO-abbreviation]
Infect. Immun.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
EC 3.4.21.64 / Endopeptidase K
[Other-IDs]
NLM/ PMC2812198
41.
Yeh JJ, Weiser MR, Shia J, Hwu WJ:
Response of stage IV anal mucosal melanoma to chemotherapy.
Lancet Oncol
; 2005 Jun;6(6):438-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Response of stage IV
anal
mucosal
melanoma
to chemotherapy.
[MeSH-major]
Anus
Neoplasms /
diagnosis
.
Melanoma
/
diagnosis
[MeSH-minor]
Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy.
Diagnosis
, Differential. Female. Humans. Middle Aged. Neoplasm Staging. Tomography, X-Ray Computed
MedlinePlus Health Information.
consumer health - Anal Cancer
.
MedlinePlus Health Information.
consumer health - Melanoma
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15925823.001).
[ISSN]
1470-2045
[Journal-full-title]
The Lancet. Oncology
[ISO-abbreviation]
Lancet Oncol.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
England
42.
Ye J, Fox SA, Cudic M, Rezler EM, Lauer JL, Fields GB, Terentis AC:
Determination of penetratin secondary structure in live cells with Raman microscopy.
J Am Chem Soc
; 2010 Jan 27;132(3):980-8
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
As a first demonstration of principle, penetratin, a 16-residue CPP derived from the Antennapedia homeodomain protein of Drosophila, was measured in single, living
melanoma
cells.
MedlinePlus Health Information.
consumer health - Melanoma
.
COS Scholar Universe.
author profiles
.
FlyBase.
FlyBase
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Biochim Biophys Acta. 1992 Apr 8;1120(2):123-43
[
1373323.001
]
[Cites]
Exp Cell Res. 1991 Aug;195(2):361-7
[
2070819.001
]
[Cites]
Biochemistry. 1995 Apr 25;34(16):5440-51
[
7727402.001
]
[Cites]
J Biol Chem. 1996 Jul 26;271(30):18188-93
[
8663410.001
]
[Cites]
Biochim Biophys Acta. 1997 Apr 17;1335(1-2):199-208
[
9133657.001
]
[Cites]
J Biol Chem. 1997 Jun 20;272(25):16010-7
[
9188504.001
]
[Cites]
Biochemistry. 1997 Jul 1;36(26):8053-9
[
9201953.001
]
[Cites]
Biochemistry. 1998 Apr 21;37(16):5654-65
[
9548951.001
]
[Cites]
Trends Cell Biol. 1998 Feb;8(2):84-7
[
9695814.001
]
[Cites]
Adv Drug Deliv Rev. 2005 Feb 28;57(4):559-77
[
15722164.001
]
[Cites]
Biophys J. 2005 Jun;88(6):4274-88
[
15764662.001
]
[Cites]
Br J Cancer. 2005 Jun 20;92(12):2166-70
[
15928665.001
]
[Cites]
J Biol Chem. 2006 Jan 13;281(2):1233-40
[
16272160.001
]
[Cites]
J Pept Sci. 2006 Mar;12(3):233-8
[
16161022.001
]
[Cites]
Anal Biochem. 2006 Jun 15;353(2):157-66
[
16674909.001
]
[Cites]
Biochemistry. 2006 Jun 20;45(24):7682-92
[
16768464.001
]
[Cites]
FASEB J. 2006 Sep;20(11):1775-84
[
16940149.001
]
[Cites]
J Am Chem Soc. 2006 Oct 18;128(41):13324-5
[
17031922.001
]
[Cites]
Environ Microbiol. 2007 Aug;9(8):1878-89
[
17635536.001
]
[Cites]
J Pept Sci. 2008 Apr;14(4):469-76
[
18069724.001
]
[Cites]
Mol Pharm. 2008 Mar-Apr;5(2):287-93
[
18197626.001
]
[Cites]
Biochem Biophys Res Commun. 2008 Jul 11;371(4):621-5
[
18423373.001
]
[Cites]
J Cell Biochem. 2008 Jul 1;104(4):1427-38
[
18348254.001
]
[Cites]
J Mol Biol. 2008 Sep 19;381(5):1133-44
[
18656895.001
]
[Cites]
J Am Chem Soc. 2008 Oct 15;130(41):13540-1
[
18803379.001
]
[Cites]
J Phys Chem B. 2009 Jan 29;113(4):1107-19
[
19125640.001
]
[Cites]
Biochemistry. 2009 Jun 2;48(21):4587-95
[
19364134.001
]
[Cites]
Curr Opin Cell Biol. 2000 Aug;12(4):400-6
[
10873818.001
]
[Cites]
FEBS Lett. 2000 Oct 6;482(3):265-8
[
11024473.001
]
[Cites]
Proc Natl Acad Sci U S A. 2000 Nov 21;97(24):13003-8
[
11087855.001
]
[Cites]
Anal Biochem. 2000 Dec 15;287(2):252-60
[
11112271.001
]
[Cites]
J Am Chem Soc. 2001 Aug 15;123(32):7919-20
[
11493071.001
]
[Cites]
J Biol Chem. 2002 Jan 25;277(4):2437-43
[
11711547.001
]
[Cites]
Curr Opin Biotechnol. 2002 Feb;13(1):52-6
[
11849958.001
]
[Cites]
J Pept Sci. 2002 Apr;8(4):151-71
[
11991205.001
]
[Cites]
Biochim Biophys Acta. 2002 Jun 13;1563(1-2):53-63
[
12007625.001
]
[Cites]
Biophys J. 2002 Jul;83(1):523-32
[
12080139.001
]
[Cites]
Biopolymers. 2003;72(1):1-9
[
12400086.001
]
[Cites]
J Biol Chem. 2003 Jan 3;278(1):585-90
[
12411431.001
]
[Cites]
Biophys Chem. 2003 Mar 25;103(3):271-88
[
12727289.001
]
[Cites]
Eur J Biochem. 2003 Jul;270(14):3055-63
[
12846839.001
]
[Cites]
Biochem Biophys Res Commun. 2003 Jul 18;307(1):100-7
[
12849987.001
]
[Cites]
Biophys J. 2003 Aug;85(2):982-95
[
12885645.001
]
[Cites]
J Mol Recognit. 2003 Sep-Oct;16(5):227-33
[
14523933.001
]
[Cites]
J Mol Recognit. 2003 Sep-Oct;16(5):272-9
[
14523940.001
]
[Cites]
Eur J Biochem. 2004 Mar;271(6):1187-97
[
15009197.001
]
[Cites]
J Biol Chem. 2004 Mar 26;279(13):12625-35
[
14707144.001
]
[Cites]
J Cell Biochem. 2004 Aug 15;92(6):1180-92
[
15258901.001
]
[Cites]
Analyst. 2004 Oct;129(10):880-5
[
15457314.001
]
[Cites]
J Mol Biol. 1970 Jun 14;50(2):509-24
[
5476924.001
]
[Cites]
J Mol Biol. 1970 Jul 28;51(2):203-13
[
5530393.001
]
[Cites]
J Am Chem Soc. 1974 Jul 24;96(15):4750-2
[
4852643.001
]
[Cites]
Methods Enzymol. 1986;130:311-31
[
3773738.001
]
[Cites]
Adv Protein Chem. 1986;38:181-364
[
3541539.001
]
[Cites]
Int J Pept Protein Res. 1990 Mar;35(3):161-214
[
2191922.001
]
[Cites]
Nature. 1990 Sep 20;347(6290):301-3
[
2205805.001
]
[Cites]
J Biol Chem. 1994 Apr 8;269(14):10444-50
[
8144628.001
]
(PMID = 20041639.001).
[ISSN]
1520-5126
[Journal-full-title]
Journal of the American Chemical Society
[ISO-abbreviation]
J. Am. Chem. Soc.
[Language]
ENG
[Grant]
United States / NIBIB NIH HHS / EB / R01 EB000289; United States / NIGMS NIH HHS / GM / GM073621; United States / NIGMS NIH HHS / GM / S06 GM073621-01; United States / NIGMS NIH HHS / GM / S06 GM073621; United States / NIBIB NIH HHS / EB / R01 EB000289-10; United States / NIBIB NIH HHS / EB / EB000289-10; United States / NIGMS NIH HHS / GM / GM073621-01; United States / NIBIB NIH HHS / EB / EB000289
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Carrier Proteins; 0 / penetratin
[Other-IDs]
NLM/ NIHMS168012; NLM/ PMC2818876
43.
Satzger I, Küttler U, Völker B, Schenck F, Kapp A, Gutzmer R:
Anal mucosal melanoma with KIT-activating mutation and response to imatinib therapy--case report and review of the literature.
Dermatology
; 2010;220(1):77-81
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Anal
mucosal
melanoma
with KIT-activating mutation and response to imatinib therapy--case report and review of the literature.
Recently 12 cases of metastatic
melanoma
and KIT-activating mutations have been published to be successfully treated with c-KIT blockers such as imatinib, sunitinib, dasatinib or sorafenib.
We report here on one of our patients with KIT-activating mutation in metastatic
anal
mucosal
melanoma
, who showed a response to imatinib therapy and summarize the available literature regarding this new therapeutic option.
[MeSH-major]
Antineoplastic Agents / therapeutic use.
Anus
Neoplasms / drug therapy.
Melanoma
/ drug therapy. Piperazines / therapeutic use. Protein Kinase Inhibitors / therapeutic use. Pyrimidines / therapeutic use. Skin Neoplasms / pathology
MedlinePlus Health Information.
consumer health - Anal Cancer
.
MedlinePlus Health Information.
consumer health - Cancer Chemotherapy
.
MedlinePlus Health Information.
consumer health - Melanoma
.
MedlinePlus Health Information.
consumer health - Skin Cancer
.
Hazardous Substances Data Bank.
IMATINIB MESYLATE
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright 2009 S. Karger AG, Basel.
(PMID = 19996579.001).
[ISSN]
1421-9832
[Journal-full-title]
Dermatology (Basel, Switzerland)
[ISO-abbreviation]
Dermatology (Basel)
[Language]
eng
[Publication-type]
Case Reports; Journal Article; Review
[Publication-country]
Switzerland
[Chemical-registry-number]
0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
[Number-of-references]
18
44.
Bonetti M, Gigliarano C, Muliere P:
The Gini concentration test for survival data.
Lifetime Data Anal
; 2009 Dec;15(4):493-518
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Use of the test is illustrated on the classic data arising from the Eastern Cooperative Oncology Group
melanoma
clinical trial E1690.
[MeSH-minor]
Clinical Trials as Topic / statistics & numerical data.
Melanoma
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Biometrics. 1989 Sep;45(3):899-904
[
2790128.001
]
[Cites]
Biometrics. 1992 Dec;48(4):1223-34
[
1290799.001
]
[Cites]
Lifetime Data Anal. 1997;3(1):5-12
[
9384622.001
]
[Cites]
J Clin Oncol. 2000 Jun;18(12 ):2444-58
[
10856105.001
]
[Cites]
Biometrics. 2005 Jun;61(2):403-12
[
16011686.001
]
[Cites]
Biometrics. 1992 Mar;48(1):87-99
[
1581495.001
]
[Cites]
Stat Med. 1987 Jun;6(4):483-9
[
3629049.001
]
[Cites]
N Engl J Med. 2007 Nov 22;357(21):2189-94
[
18032770.001
]
(PMID = 19728088.001).
[ISSN]
1572-9249
[Journal-full-title]
Lifetime data analysis
[ISO-abbreviation]
Lifetime Data Anal
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
45.
Di Domenico F, Foppoli C, Blarzino C, Perluigi M, Paolini F, Morici S, Coccia R, Cini C, De Marco F:
Expression of human papilloma virus type 16 E5 protein in amelanotic melanoma cells regulates endo-cellular pH and restores tyrosinase activity.
J Exp Clin Cancer Res
; 2009;28:4
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Expression of human papilloma virus type 16 E5 protein in amelanotic
melanoma
cells regulates endo-cellular pH and restores tyrosinase activity.
[MeSH-major]
Melanoma
, Amelanotic / metabolism. Monophenol Monooxygenase / metabolism. Oncogene Proteins, Viral / metabolism. Skin Neoplasms / metabolism
MedlinePlus Health Information.
consumer health - Skin Cancer
.
COS Scholar Universe.
author profiles
.
Cellosaurus - a cell line knowledge resource.
culture/stock collections - Cellosaurus - a cell line knowledge resource
.
Hazardous Substances Data Bank.
DOPAMINE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Exp Biol. 2000 Jan;203(Pt 1):61-70
[
10600674.001
]
[Cites]
Oncogene. 2000 Aug 3;19(33):3727-32
[
10949926.001
]
[Cites]
Br J Cancer. 2000 Jul;83(2):184-7
[
10901368.001
]
[Cites]
FEBS Lett. 2000 Jul 28;478(1-2):57-60
[
10922469.001
]
[Cites]
Exp Cell Res. 2001 Jan 15;262(2):197-208
[
11139343.001
]
[Cites]
Oncogene. 2000 Dec 7;19(52):6023-32
[
11146554.001
]
[Cites]
Exp Cell Res. 2001 Aug 1;268(1):26-35
[
11461115.001
]
[Cites]
J Gen Virol. 2001 Oct;82(Pt 10):2353-62
[
11562529.001
]
[Cites]
Oncogene. 2001 Nov 26;20(54):7866-73
[
11753669.001
]
[Cites]
Oncogene. 2002 Jan 10;21(2):248-59
[
11803468.001
]
[Cites]
Nat Rev Cancer. 2002 May;2(5):342-50
[
12044010.001
]
[Cites]
Oncol Res. 2002;13(1):3-8
[
12201672.001
]
[Cites]
Biochem Pharmacol. 2002 Nov 15;64(10):1503-12
[
12417263.001
]
[Cites]
Cancer Res. 2003 Jan 15;63(2):441-8
[
12543800.001
]
[Cites]
Virology. 2003 May 25;310(1):100-8
[
12788634.001
]
[Cites]
J Biol Chem. 2004 Feb 27;279(9):7971-81
[
14634018.001
]
[Cites]
Cell. 1983 May;33(1):153-9
[
6678608.001
]
[Cites]
J Immunol Methods. 1986 Nov 20;94(1-2):57-63
[
3782817.001
]
[Cites]
Proc Natl Acad Sci U S A. 1988 Nov;85(21):7972-6
[
2973058.001
]
[Cites]
J Virol. 1989 Oct;63(10):4417-21
[
2476573.001
]
[Cites]
J Virol. 1990 Jul;64(7):3226-33
[
2161939.001
]
[Cites]
Pigment Cell Res. 1990 Mar-Apr;3(2):49-54
[
2117268.001
]
[Cites]
Anal Biochem. 1991 Feb 1;192(2):316-21
[
1827963.001
]
[Cites]
J Biol Regul Homeost Agents. 1991 Apr-Jun;5(2):65-70
[
1716817.001
]
[Cites]
J Virol. 1991 Dec;65(12):7078-83
[
1658398.001
]
[Cites]
Biochemistry. 1993 Apr 20;32(15):3902-6
[
8385991.001
]
[Cites]
J Invest Dermatol. 1993 Jun;100(6):806-11
[
8496620.001
]
[Cites]
J Virol. 1993 Aug;67(8):4521-32
[
8392596.001
]
[Cites]
J Virol. 1993 Oct;67(10):6170-8
[
7690419.001
]
[Cites]
Virology. 1994 Aug 15;203(1):73-80
[
8030286.001
]
[Cites]
J Virol. 1995 May;69(5):3185-92
[
7707548.001
]
[Cites]
J Gen Virol. 1995 May;76 ( Pt 5):1239-45
[
7730808.001
]
[Cites]
J Virol. 1995 Dec;69(12):8051-6
[
7494320.001
]
[Cites]
Biochim Biophys Acta. 1996 Oct 9;1288(2):F55-78
[
8876633.001
]
[Cites]
Cancer Res. 1998 Apr 1;58(7):1521-3
[
9537258.001
]
[Cites]
Exp Cell Res. 1998 May 25;241(1):76-83
[
9633515.001
]
[Cites]
Int J Cancer. 2005 Jan 10;113(2):276-83
[
15386416.001
]
[Cites]
J Virol. 2004 Dec;78(24):13613-26
[
15564472.001
]
[Cites]
Arch Virol. 2005 Feb;150(2):231-46
[
15503216.001
]
[Cites]
Virology. 2005 Feb 5;332(1):102-13
[
15661144.001
]
[Cites]
Int J Biochem Cell Biol. 2005 Apr;37(4):852-63
[
15694844.001
]
[Cites]
Virology. 2005 Jun 20;337(1):76-84
[
15914222.001
]
[Cites]
Neoplasia. 2006 Jul;8(7):543-50
[
16867216.001
]
[Cites]
Oncogene. 2008 Feb 14;27(8):1071-8
[
17704805.001
]
[Cites]
Virol J. 2008;5:30
[
18302753.001
]
[Cites]
Oncogene. 2008 Apr 17;27(18):2532-41
[
17982485.001
]
[Cites]
Virology. 2000 Jul 5;272(2):315-25
[
10873774.001
]
(PMID = 19133143.001).
[ISSN]
1756-9966
[Journal-full-title]
Journal of experimental & clinical cancer research : CR
[ISO-abbreviation]
J. Exp. Clin. Cancer Res.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Italy
[Chemical-registry-number]
0 / Antimetabolites, Antineoplastic; 0 / Melanins; 0 / Oncogene Proteins, Viral; 0 / Proton Pump Inhibitors; 0 / RNA, Messenger; 0 / oncogene protein E5, Human papillomavirus type 16; 37491-68-2 / 3,4-dihydroxybenzylamine; 5072-26-4 / Buthionine Sulfoximine; EC 1.14.18.1 / Monophenol Monooxygenase; VTD58H1Z2X / Dopamine
[Other-IDs]
NLM/ PMC2654431
46.
Misra UK, Pizzo SV:
Epac1-induced cellular proliferation in prostate cancer cells is mediated by B-Raf/ERK and mTOR signaling cascades.
J Cell Biochem
; 2009 Nov 1;108(4):998-1011
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Epac1-induced cellular proliferation in prostate
cancer
cells is mediated by B-Raf/ERK and mTOR signaling cascades.
In this report, we employed the analogue 8-CPT-2-O-Me-cAMP to study binding to EPAC and subsequent activation of B-Raf/ERK and mTOR signaling in human
cancer
cells.
This compound significantly stimulated DNA synthesis, protein synthesis, and cellular proliferation of human 1-LN prostate
cancer
cells.
RNAi directed against EPAC gene expression as well as inhibitors of ERK, PI 3-kinase, and mTOR were employed to further demonstrate the role of these pathways in regulating prostate
cancer
cell proliferation.
These studies were then extended to several other human prostate
cancer
cell lines and
melanoma
cells with comparable results.
We conclude that B-Raf/ERK and mTOR signaling play an essential role in cAMP-dependent, but PKA-independent, proliferation
of cancer
cells.
Genetic Alliance.
consumer health - Prostate cancer
.
MedlinePlus Health Information.
consumer health - Prostate Cancer
.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
THEOPHYLLINE
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
(c) 2009 Wiley-Liss, Inc.
(PMID = 19725049.001).
[ISSN]
1097-4644
[Journal-full-title]
Journal of cellular biochemistry
[ISO-abbreviation]
J. Cell. Biochem.
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / R01 CA131235; United States / NCI NIH HHS / CA / CA 131235-01A2
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural
[Publication-country]
United States
[Chemical-registry-number]
0 / Enzyme Inhibitors; 0 / Guanine Nucleotide Exchange Factors; 0 / Intracellular Signaling Peptides and Proteins; 0 / RAPGEF3 protein, human; 35873-49-5 / 8-cyclopentyl-1,3-dimethylxanthine; C137DTR5RG / Theophylline; E0399OZS9N / Cyclic AMP; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf; EC 2.7.11.11 / Cyclic AMP-Dependent Protein Kinases; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases
[Other-IDs]
NLM/ NIHMS662516; NLM/ PMC4354900
47.
Feng Z, Zhao G, Yu L, Gough D, Howell SB:
Preclinical efficacy studies of a novel nanoparticle-based formulation of paclitaxel that out-performs Abraxane.
Cancer Chemother Pharmacol
; 2010 Apr;65(5):923-30
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
METHODS: Efficacy was quantified by delay in tumor growth of NCI H460 human lung
cancer
, 2008 human ovarian
cancer
and B16
melanoma
xenografts growing in athymic mice following administration of equitoxic doses of PGG-PTX and Abraxane administered on either a single dose or every 7 day schedule.
[MeSH-minor]
Albumin-Bound Paclitaxel. Albumins / chemistry. Albumins / therapeutic use. Animals. Carcinoma, Non-Small-Cell Lung / drug therapy. Cell Line, Tumor. Disease Models, Animal. Dose-Response Relationship, Drug. Drug Evaluation, Preclinical. Female. Humans. Lung Neoplasms / drug therapy.
Melanoma
, Experimental / drug therapy. Mice. Ovarian Neoplasms / drug therapy. Transplantation, Heterologous. Treatment Outcome
MedlinePlus Health Information.
consumer health - Cancer Chemotherapy
.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
TAXOL
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Anticancer Drugs. 1996 Aug;7(6):642-8
[
8913432.001
]
[Cites]
N Engl J Med. 1995 Apr 13;332(15):1004-14
[
7885406.001
]
[Cites]
Anticancer Res. 1997 Nov-Dec;17(6D):4269-74
[
9494519.001
]
[Cites]
Clin Cancer Res. 1999 Apr;5(4):891-7
[
10213226.001
]
[Cites]
J Clin Oncol. 2004 Nov 15;22(22):4523-31
[
15542803.001
]
[Cites]
Clin Cancer Res. 2005 Jun 1;11(11):4136-43
[
15930349.001
]
[Cites]
J Pharm Biomed Anal. 2005 Sep 1;39(1-2):170-6
[
16085137.001
]
[Cites]
J Clin Oncol. 2005 Nov 1;23(31):7794-803
[
16172456.001
]
[Cites]
Clin Lung Cancer. 2005 Nov;7(3):215-20
[
16354318.001
]
[Cites]
Clin Cancer Res. 2006 Feb 15;12(4):1317-24
[
16489089.001
]
[Cites]
Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2248-54
[
16609041.001
]
[Cites]
Invest New Drugs. 2007 Aug;25(4):369-75
[
17345004.001
]
[Cites]
Br J Cancer. 2008 May 20;98(10):1608-13
[
18475293.001
]
[Cites]
J Thorac Oncol. 2008 Jun;3(6):623-30
[
18520802.001
]
[Cites]
J Thorac Oncol. 2008 Jul;3(7):728-34
[
18594318.001
]
[Cites]
Cancer Chemother Pharmacol. 2010 Feb;65(3):515-26
[
19593566.001
]
[Cites]
Adv Exp Med Biol. 2003;519:81-99
[
12675210.001
]
[Cites]
Clin Cancer Res. 2000 Jul;6(7):2829-34
[
10914731.001
]
[Cites]
Cancer Chemother Pharmacol. 2000;46(5):416-22
[
11127947.001
]
[Cites]
Eur J Cancer. 2001 Sep;37(13):1590-8
[
11527683.001
]
[Cites]
Pharm Res. 2001 Aug;18(8):1157-66
[
11587488.001
]
[Cites]
Clin Cancer Res. 2002 Feb;8(2):573-81
[
11839679.001
]
[Cites]
Eur J Cancer. 2004 Jan;40(2):291-7
[
14728945.001
]
[Cites]
Expert Opin Investig Drugs. 2004 Nov;13(11):1501-8
[
15500397.001
]
[Cites]
Cancer Treat Rep. 1987 Jan;71(1):53-9
[
2878719.001
]
[Cites]
Cancer Res. 1993 Dec 15;53(24):5877-81
[
7903197.001
]
[Cites]
Int J Cancer. 1998 Feb 9;75(4):600-8
[
9466663.001
]
(PMID = 19685054.001).
[ISSN]
1432-0843
[Journal-full-title]
Cancer chemotherapy and pharmacology
[ISO-abbreviation]
Cancer Chemother. Pharmacol.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Germany
[Chemical-registry-number]
0 / Albumin-Bound Paclitaxel; 0 / Albumins; 0 / Antineoplastic Agents; 0 / Proteins; 0 / poly(gamma-glutamylglutamine)paclitaxel; P88XT4IS4D / Paclitaxel
[Other-IDs]
NLM/ PMC2824123
48.
Buecher B, Gauthier-Villars M, Desjardins L, Lumbroso-Le Rouic L, Levy C, De Pauw A, Bombled J, Tirapo C, Houdayer C, Bressac-de Paillerets B, Stoppa-Lyonnet D:
Contribution of CDKN2A/P16 ( INK4A ), P14 (ARF), CDK4 and BRCA1/2 germline mutations in individuals with suspected genetic predisposition to uveal melanoma.
Fam Cancer
; 2010 Dec;9(4):663-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Contribution of CDKN2A/P16 ( INK4A ), P14 (ARF), CDK4 and BRCA1/2 germline mutations in individuals with suspected genetic predisposition to uveal
melanoma
.
Uveal
melanoma
arises from melanocytes of the uveal tract (iris, ciliary body and choroid) and represents the most common intraocular malignancy in adults.
Some rare clinical situations (young age at
diagnosis
, bilateral or multifocal forms, association with cutaneous
malignant
melanoma
and/or familial aggregations of melanomas) are suggestive of genetic susceptibility.
The aim of this study was to evaluate the contribution of CDKN2A/P16INK4A, P14ARF and CDK4 gene germline mutations in a series of patients with uveal
melanoma
recruited in a single institution with a clinical presentation indicative of genetic predisposition.
The contribution of BRCA1/2 gene germline mutations in patients with uveal
melanoma
and a personal and/or family history of breast/ovarian cancers was also evaluated.
These results indicate that the CDKN2A/P16INK4A, P14ARF, CDK4 genes are not responsible for the vast majority of genetic susceptibility to uveal
melanoma
.
They also suggest that one case of uveal
melanoma
in a family with a history of breast
cancer
is not sufficient to justify BRCA1/2 genetic testing when the classical criteria for molecular analysis are not present.
International studies are ongoing in
melanoma
-prone families in an attempt to identify uveal
melanoma
susceptibility loci and genes.
[MeSH-major]
Cyclin-Dependent Kinase 4 / genetics. Cyclin-Dependent Kinase Inhibitor p16 / genetics. Genetic Predisposition to Disease. Germ-Line Mutation / genetics.
Melanoma
/ genetics. Tumor Suppressor Protein p14ARF / genetics. Uveal Neoplasms / genetics
Genetic Alliance.
consumer health - Uveal melanoma
.
MedlinePlus Health Information.
consumer health - Melanoma
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Br J Cancer. 2000 Feb;82(4):818-22
[
10732752.001
]
[Cites]
Invest Ophthalmol Vis Sci. 1999 Mar;40(3):779-83
[
10067984.001
]
[Cites]
Int J Cancer. 1999 Jul 30;82(3):325-8
[
10399947.001
]
[Cites]
Hum Mutat. 2002 Sep;20(3):218-26
[
12203994.001
]
[Cites]
Invest Ophthalmol Vis Sci. 2008 Dec;49(12):5230-4
[
18719078.001
]
[Cites]
Cancer Res. 2001 Jul 1;61(13):5303-6
[
11431374.001
]
[Cites]
J Natl Cancer Inst. 1999 Aug 4;91(15):1310-6
[
10433620.001
]
[Cites]
Nat Genet. 1996 Jan;12(1):97-9
[
8528263.001
]
[Cites]
Invest Ophthalmol Vis Sci. 2003 Feb;44(2):458-62
[
12556369.001
]
[Cites]
Ophthalmology. 1996 Feb;103(2):256-62
[
8594511.001
]
[Cites]
Int J Cancer. 2002 Mar 1;98(1):42-4
[
11857383.001
]
[Cites]
Ophthalmology. 2007 Dec;114(12):2309-15
[
17498805.001
]
[Cites]
Genomics. 1999 Dec 15;62(3):369-76
[
10644434.001
]
[Cites]
Ophthalmology. 2003 May;110(5):956-61
[
12750097.001
]
[Cites]
Am J Hum Genet. 1997 Jul;61(1):120-8
[
9245992.001
]
[Cites]
Ophthalmology. 2007 Apr;114(4):774-9
[
17207529.001
]
[Cites]
Genes Chromosomes Cancer. 2003 Nov;38(3):265-8
[
14506702.001
]
[Cites]
Fam Cancer. 2010 Sep;9(3):431-8
[
20157784.001
]
[Cites]
Cancer Res. 2006 Oct 15;66(20):9818-28
[
17047042.001
]
[Cites]
Nature. 2009 Jan 29;457(7229):599-602
[
19078957.001
]
[Cites]
Virchows Arch. 2008 Mar;452(3):331-6
[
18205010.001
]
[Cites]
J Natl Cancer Inst. 2005 Sep 21;97(18):1377-82
[
16174859.001
]
[Cites]
Br J Cancer. 2008 Jul 22;99(2):364-70
[
18612309.001
]
[Cites]
J Biol Chem. 1997 Jul 25;272(30):18869-74
[
9228064.001
]
[Cites]
Cancer Res. 1994 Jul 15;54(14):3817-23
[
8033101.001
]
[Cites]
Semin Oncol. 1996 Dec;23(6):768-72
[
8970601.001
]
[Cites]
Anal Biochem. 1989 Aug 1;180(2):276-8
[
2554754.001
]
[Cites]
Acta Ophthalmol Scand. 2003 Aug;81(4):389-95
[
12859267.001
]
(PMID = 20842456.001).
[ISSN]
1573-7292
[Journal-full-title]
Familial cancer
[ISO-abbreviation]
Fam. Cancer
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Netherlands
[Chemical-registry-number]
0 / BRCA1 Protein; 0 / BRCA1 protein, human; 0 / BRCA2 Protein; 0 / BRCA2 protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / DNA, Neoplasm; 0 / Tumor Suppressor Protein p14ARF; EC 2.7.11.22 / CDK4 protein, human; EC 2.7.11.22 / Cyclin-Dependent Kinase 4
49.
Yuan J, Ku GY, Gallardo HF, Orlandi F, Manukian G, Rasalan TS, Xu Y, Li H, Vyas S, Mu Z, Chapman PB, Krown SE, Panageas K, Terzulli SL, Old LJ, Houghton AN, Wolchok JD:
Safety and immunogenicity of a human and mouse gp100 DNA vaccine in a phase I trial of patients with melanoma.
Cancer Immun
; 2009 Jun 05;9:5
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Safety and immunogenicity of a human and mouse gp100 DNA vaccine in a phase I trial of patients with
melanoma
.
A differentiation antigen commonly expressed on
melanoma
cells, gp100 is the target of infiltrating T cells.
We conducted a phase I randomized cross-over trial of
melanoma
patients with either xenogeneic (mouse) or human gp100 plasmid DNA injected intramuscularly at three dosages (100, 500 or 1,500 microg) every three weeks for three doses.
All patients had no evidence of disease; 10 (53%) had stage III disease, 3 each (16%) had stage IIB and IV disease, 2 (11%) had choroidal and 1 (5%) had
anal
mucosal involvement.
MedlinePlus Health Information.
consumer health - Melanoma
.
MedlinePlus Health Information.
consumer health - Skin Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Gene Ther. 2003 Sep;10(20):1754-65
[
12939642.001
]
[Cites]
Surgery. 2000 Aug;128(2):273-80
[
10923004.001
]
[Cites]
Proc Natl Acad Sci U S A. 1980 Jul;77(7):4260-4
[
6933476.001
]
[Cites]
J Exp Med. 1982 Dec 1;156(6):1755-66
[
7175440.001
]
[Cites]
J Invest Dermatol. 1988 Apr;90(4):459-66
[
3280698.001
]
[Cites]
J Immunol. 1995 Apr 15;154(8):3961-8
[
7706734.001
]
[Cites]
J Exp Med. 1995 Aug 1;182(2):459-65
[
7543139.001
]
[Cites]
Proc Natl Acad Sci U S A. 1996 Apr 2;93(7):2879-83
[
8610135.001
]
[Cites]
Science. 1996 Jul 19;273(5273):352-4
[
8662521.001
]
[Cites]
Cancer Res. 1996 Oct 15;56(20):4749-57
[
8840994.001
]
[Cites]
J Immunother. 1997 Jan;20(1):15-25
[
9101410.001
]
[Cites]
Am J Pathol. 1997 Jun;150(6):2143-52
[
9176405.001
]
[Cites]
J Clin Invest. 1998 Sep 15;102(6):1258-64
[
9739060.001
]
[Cites]
J Immunol. 1999 May 15;162(10):5813-20
[
10229815.001
]
[Cites]
Surgery. 1999 Aug;126(2):112-20
[
10455872.001
]
[Cites]
Clin Cancer Res. 2005 Nov 15;11(22):8114-21
[
16299244.001
]
[Cites]
Cancer Immun. 2006;6:8
[
16626110.001
]
[Cites]
Vaccine. 2006 May 22;24(21):4582-5
[
16188351.001
]
[Cites]
Cytotherapy. 2006;8(5):498-508
[
17050255.001
]
[Cites]
J Immunol. 2007 Apr 1;178(7):4112-9
[
17371966.001
]
[Cites]
J Exp Med. 2007 Jun 11;204(6):1405-16
[
17535971.001
]
[Cites]
Mol Ther. 2007 Nov;15(11):2044-50
[
17726460.001
]
[Cites]
Eur J Immunol. 2008 Feb;38(2):350-63
[
18200635.001
]
[Cites]
CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96
[
18287387.001
]
[Cites]
Oncologist. 2008;13 Suppl 4:2-9
[
19001145.001
]
[Cites]
Oncologist. 2008;13 Suppl 4:10-5
[
19001146.001
]
[Cites]
Mol Ther. 2008 Dec;16(12):2022-9
[
18797450.001
]
[Cites]
Proc Natl Acad Sci U S A. 2008 Dec 23;105(51):20410-5
[
19074257.001
]
[Cites]
Clin Cancer Res. 2002 May;8(5):967-72
[
12006508.001
]
[Cites]
J Exp Med. 1999 Dec 6;190(11):1717-22
[
10587362.001
]
[Cites]
J Immunol. 1999 Dec 15;163(12):6867-75
[
10586088.001
]
[Cites]
Annu Rev Immunol. 2004;22:745-63
[
15032595.001
]
(PMID = 19496531.001).
[ISSN]
1424-9634
[Journal-full-title]
Cancer immunity
[ISO-abbreviation]
Cancer Immun.
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / P01 CA033049-24; United States / NCI NIH HHS / CA / CA033049-24; United States / NCI NIH HHS / CA / P01CA33049; United States / NCI NIH HHS / CA / P01 CA033049; United States / NCI NIH HHS / CA / R01 CA056821; United States / NCCIH NIH HHS / AT / P50AT002779
[Publication-type]
Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Antigens, Neoplasm; 0 / Cancer Vaccines; 0 / HLA-A2 Antigen; 0 / Membrane Glycoproteins; 0 / PMEL protein, human; 0 / Peptides; 0 / Si protein, mouse; 0 / Vaccines, DNA; 0 / gp100 Melanoma Antigen; 0 / gp100(280-288) melanoma antigen peptide
[Other-IDs]
NLM/ NIHMS201057; NLM/ PMC2888533
50.
Zykova TA, Zhu F, Lu C, Higgins L, Tatsumi Y, Abe Y, Bode AM, Dong Z:
Lymphokine-activated killer T-cell-originated protein kinase phosphorylation of histone H2AX prevents arsenite-induced apoptosis in RPMI7951 melanoma cells.
Clin Cancer Res
; 2006 Dec 1;12(23):6884-93
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Lymphokine-activated killer T-cell-originated protein kinase phosphorylation of histone H2AX prevents arsenite-induced apoptosis in RPMI7951
melanoma
cells.
PURPOSE: Arsenic is a valuable therapeutic tool in
cancer
treatment.
Lymphokine-activated killer T-cell-originated protein kinase (TOPK) is highly expressed in
cancer
cells, but its specific function is still unknown.
We investigated the role of TOPK in arsenic-induced apoptosis in RPMI7951 human
melanoma
cells.
EXPERIMENTAL DESIGN: Expression of TOPK was evaluated in different
melanoma
cell lines, and liquid chromatography-tandem mass spectrometry analysis was used to identify proteins binding with TOPK.
RESULTS:
Melanoma
cell lines expressing high levels of TOPK were more resistant to arsenite (As(3+))-induced apoptosis.
As(3+) treatment induced phosphorylation of TOPK and histone H2AX in RPMI7951 human
melanoma
cells.
Melanoma
cell lines with high levels of TOPK are more resistant to As(3+)-induced apoptosis.
MedlinePlus Health Information.
consumer health - Melanoma
.
COS Scholar Universe.
author profiles
.
The Lens.
Cited by Patents in
.
antibodies-online.
View related products from antibodies-online.com
(subscription/membership/fee required).
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Mol Pharmacol. 2002 Sep;62(3):529-38
[
12181429.001
]
[Cites]
Cancer Res. 2002 Jul 15;62(14):3893-903
[
12124315.001
]
[Cites]
Science. 2002 May 3;296(5569):922-7
[
11934988.001
]
[Cites]
Nature. 2002 Jun 27;417(6892):949-54
[
12068308.001
]
[Cites]
Environ Health Perspect. 2002 Oct;110 Suppl 5:757-9
[
12426127.001
]
[Cites]
Cytokine. 2002 Nov 7;20(3):113-20
[
12453469.001
]
[Cites]
Clin Cancer Res. 2003 Jan;9(1):235-42
[
12538475.001
]
[Cites]
Genomics. 2003 Feb;81(2):112-25
[
12620389.001
]
[Cites]
Carcinogenesis. 2003 May;24(5):967-74
[
12771042.001
]
[Cites]
Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8247-52
[
12821780.001
]
[Cites]
J Inorg Biochem. 2003 Aug 1;96(2-3):271-8
[
12888263.001
]
[Cites]
Cell. 2003 Aug 8;114(3):359-70
[
12914700.001
]
[Cites]
Cell. 2003 Aug 8;114(3):371-83
[
12914701.001
]
[Cites]
Blood Cells Mol Dis. 2004 Jan-Feb;32(1):240-5
[
14757441.001
]
[Cites]
J Biol Chem. 2004 May 21;279(21):22747-58
[
15028728.001
]
[Cites]
DNA Repair (Amst). 2004 Aug-Sep;3(8-9):959-67
[
15279782.001
]
[Cites]
J Biol Chem. 2004 Oct 29;279(44):45810-4
[
15308627.001
]
[Cites]
Anal Biochem. 1976 May 7;72:248-54
[
942051.001
]
[Cites]
Hum Pathol. 1984 Dec;15(12):1147-65
[
6500548.001
]
[Cites]
Biomed Environ Mass Spectrom. 1988 Oct;16(1-12):99-111
[
3072035.001
]
[Cites]
Anal Chem. 1991 Jul 15;63(14):1467-73
[
1928722.001
]
[Cites]
Blood. 1998 Jun 1;91(11):4300-10
[
9596679.001
]
[Cites]
Anal Biochem. 1998 Oct 1;263(1):93-101
[
9750149.001
]
[Cites]
Cancer Res. 1999 Mar 1;59(5):1041-8
[
10070961.001
]
[Cites]
Cell Growth Differ. 1999 Mar;10(3):163-71
[
10099830.001
]
[Cites]
J Natl Cancer Inst. 1999 May 5;91(9):772-8
[
10328107.001
]
[Cites]
Carcinogenesis. 2005 Jan;26(1):53-63
[
15471901.001
]
[Cites]
J Invest Dermatol. 2005 Apr;124(4):807-17
[
15816840.001
]
[Cites]
Anal Chem. 2005 Jul 1;77(13):3931-46
[
15987094.001
]
[Cites]
Proc Natl Acad Sci U S A. 2006 Jan 3;103(1):57-62
[
16371460.001
]
[Cites]
Leuk Res. 2006 Apr;30(4):437-47
[
16171862.001
]
[Cites]
Biochem Biophys Res Commun. 2004 Dec 17;325(3):997-1004
[
15541388.001
]
[Cites]
Br J Cancer. 1999 Nov;81(5):796-9
[
10555748.001
]
[Cites]
Proc Natl Acad Sci U S A. 2000 May 9;97(10):5167-72
[
10779557.001
]
[Cites]
Leuk Lymphoma. 2000 Jun;38(1-2):153-63
[
10811458.001
]
[Cites]
J Biol Chem. 2000 Jul 14;275(28):21525-31
[
10781613.001
]
[Cites]
Oncologist. 2001;6 Suppl 2:17-21
[
11331436.001
]
[Cites]
Nature. 2001 May 24;411(6836):494-8
[
11373684.001
]
[Cites]
Free Radic Biol Med. 2001 Aug 1;31(3):321-30
[
11461769.001
]
[Cites]
J Clin Oncol. 2001 Sep 15;19(18):3852-60
[
11559723.001
]
[Cites]
Crit Rev Oncol Hematol. 2002 Apr;42(1):5-24
[
11923065.001
]
[Cites]
J Biol Chem. 2001 Dec 21;276(51):47759-62
[
11673449.001
]
[Cites]
Blood Cells Mol Dis. 2001 Sep-Oct;27(5):825-9
[
11783945.001
]
[Cites]
Curr Opin Genet Dev. 2002 Apr;12(2):162-9
[
11893489.001
]
(PMID = 17145805.001).
[ISSN]
1078-0432
[Journal-full-title]
Clinical cancer research : an official journal of the American Association for Cancer Research
[ISO-abbreviation]
Clin. Cancer Res.
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / CA111356-01; United States / NCI NIH HHS / CA / CA77646; United States / NCI NIH HHS / CA / CA111536; United States / NCI NIH HHS / CA / R01 CA077646; United States / NCI NIH HHS / CA / R01 CA077646-05; United States / NCI NIH HHS / CA / R01 CA111356; United States / NCI NIH HHS / CA / CA111536-01A1; United States / NCI NIH HHS / CA / R01 CA111536-01A1; United States / NCI NIH HHS / CA / R01 CA111536; United States / NCI NIH HHS / CA / CA111356; United States / NCI NIH HHS / CA / R01 CA111356-01; United States / NCI NIH HHS / CA / CA077646-05
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Arsenites; 0 / H2AFX protein, human; 0 / Histones; 0 / RNA, Small Interfering; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.12.2 / Mitogen-Activated Protein Kinase Kinases; EC 2.7.12.2 / PDZ-binding kinase; N5509X556J / arsenite
[Other-IDs]
NLM/ NIHMS10643; NLM/ PMC2238807
51.
Giricz O, Lauer-Fields JL, Fields GB:
The normalization of gene expression data in melanoma: investigating the use of glyceraldehyde 3-phosphate dehydrogenase and 18S ribosomal RNA as internal reference genes for quantitative real-time PCR.
Anal Biochem
; 2008 Sep 1;380(1):137-9
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
The normalization of gene expression data in
melanoma
: investigating the use of glyceraldehyde 3-phosphate dehydrogenase and 18S ribosomal RNA as internal reference genes for quantitative real-time PCR.
We examined a panel of 26
melanoma
and fibroblast samples (tissues and cultured cells) to evaluate the suitability of two commonly used housekeeping genes, glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and 18S ribosomal RNA (rRNA), for quantitative real-time PCR.
Although no overall trends were observed in the expression of the 18S rRNA, GAPDH was up-regulated in
melanoma
tissue and cultured cells compared with the corresponding normal samples.
In
melanoma
and fibroblast cell lines and tissues, absolute quantification appears to be more appropriate than normalizing messenger RNA (mRNA) expression via GAPDH or 18S rRNA housekeeping genes.
MedlinePlus Health Information.
consumer health - Melanoma
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Cell. 2004 Mar 19;116(6):855-67
[
15035987.001
]
[Cites]
Mol Ther. 2002 Dec;6(6):783-92
[
12498774.001
]
[Cites]
Biol Cell. 2004 Oct;96(8):579-94
[
15519693.001
]
[Cites]
Nat Med. 2006 Feb;12(2):168-9
[
16462795.001
]
[Cites]
BMC Cancer. 2006;6:49
[
16515701.001
]
[Cites]
Prostate. 2006 Oct 1;66(14):1521-34
[
16921506.001
]
[Cites]
Nat Protoc. 2006;1(3):1559-82
[
17406449.001
]
[Cites]
Pigment Cell Res. 2007 Dec;20(6):466-84
[
17935490.001
]
[Cites]
Biotechniques. 2008 Apr;44(5):619-26
[
18474036.001
]
[Cites]
Arch Dermatol Res. 1999 Dec;291(12):659-61
[
10651167.001
]
[Cites]
J Mol Diagn. 2001 May;3(2):55-61
[
11333300.001
]
[Cites]
Anal Biochem. 2001 Aug 1;295(1):17-21
[
11476540.001
]
[Cites]
Physiol Genomics. 2001 Dec 21;7(2):95-6
[
11773595.001
]
[Cites]
Br J Dermatol. 2002 Apr;146 Suppl 61:1-6
[
11966724.001
]
[Cites]
Nucleic Acids Res. 2001 May 1;29(9):e45
[
11328886.001
]
[Cites]
Curr Opin Oncol. 1997 Mar;9(2):178-82
[
9161798.001
]
(PMID = 18554498.001).
[ISSN]
1096-0309
[Journal-full-title]
Analytical biochemistry
[ISO-abbreviation]
Anal. Biochem.
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / CA 98799; United States / NIBIB NIH HHS / EB / R01 EB000289; United States / NIBIB NIH HHS / EB / EB 00289; United States / NCI NIH HHS / CA / R01 CA098799-06; United States / NIBIB NIH HHS / EB / EB000289-08; United States / NCI NIH HHS / CA / R01 CA098799; United States / NIBIB NIH HHS / EB / R01 EB000289-08; United States / NCI NIH HHS / CA / CA098799-06
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / RNA, Messenger; 0 / RNA, Ribosomal, 18S; EC 1.2.1.- / Glyceraldehyde-3-Phosphate Dehydrogenases
[Other-IDs]
NLM/ NIHMS59889; NLM/ PMC2515093
52.
Yaramov N, Sokolov M, Angelov K, Petrov B, Pavlov V:
[Malignant melanoma of the anus and rectum].
Khirurgiia (Sofiia)
; 2010;(2-3):5-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[
Malignant
melanoma
of the
anus
and rectum].
There is approximately 300 cases
of malignant
melanoma
written in the world literature.
We write up 13 operated from us for 15 years cases of
melanoma
of the
anus
and rectum.
[MeSH-major]
Anal
Canal / surgery.
Anus
Neoplasms / surgery.
Melanoma
/ surgery. Rectal Neoplasms / surgery. Rectum / surgery
MedlinePlus Health Information.
consumer health - Anal Cancer
.
MedlinePlus Health Information.
consumer health - Melanoma
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 21972686.001).
[ISSN]
0450-2167
[Journal-full-title]
Khirurgiiï¸ a︡
[ISO-abbreviation]
Khirurgiia (Sofiia)
[Language]
bul
[Publication-type]
English Abstract; Journal Article
[Publication-country]
Bulgaria
53.
Hanley KZ, Weiss SW, Logani S:
Melanoma with cartilaginous differentiation: Diagnostic challenge on fine-needle aspiration with emphasis on differential diagnosis.
Diagn Cytopathol
; 2009 Jan;37(1):51-5
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Melanoma
with cartilaginous differentiation: Diagnostic challenge on fine-needle aspiration with emphasis on differential
diagnosis
.
Fine-needle aspiration (FNA) is a minimally invasive, fast, and accurate diagnostic method for the evaluation of patients with locally recurrent or distant metastases
of malignant
melanoma
.
In the vast majority of cases,
the diagnosis
is straightforward with the characteristic cytologic features well documented in the literature.
Divergent differentiation (chondroid, neural, myofibroblastic, and osteocartilagenous) in a
melanoma
is rare and can potentially create diagnostic challenges if the evaluator is unaware of the same.
We report a case of a 46-year-old female with a history of primary
anal melanoma
who presented with a groin mass.
The FNA of the groin mass showed a neoplasm rich in chondroid matrix and raised the possibility of a second primary mesenchymal neoplasm rather than metastasis from the patient's known primary
anal melanoma
.
A review of the histologic features of the
anal melanoma
showed divergent chondroid differentiation in the
anal melanoma
with the metastatic deposit in the groin exhibiting extensive chondroid differentiation.
[MeSH-major]
Anus
Neoplasms / pathology. Cartilage / pathology. Inguinal Canal / pathology. Lymph Nodes / pathology.
Melanoma
/ secondary
[MeSH-minor]
Adenoma, Pleomorphic /
diagnosis
. Adenoma, Pleomorphic / pathology. Biopsy, Fine-Needle.
Diagnosis
, Differential. Female. Humans. Lymphatic Metastasis. Middle Aged
MedlinePlus Health Information.
consumer health - Anal Cancer
.
MedlinePlus Health Information.
consumer health - Melanoma
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
(c) 2008 Wiley-Liss, Inc.
(PMID = 18973120.001).
[ISSN]
1097-0339
[Journal-full-title]
Diagnostic cytopathology
[ISO-abbreviation]
Diagn. Cytopathol.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
United States
54.
Di Serio C, Cozzi A, Angeli I, Doria L, Micucci I, Pellerito S, Mirone P, Masotti G, Moroni F, Tarantini F:
Kynurenic acid inhibits the release of the neurotrophic fibroblast growth factor (FGF)-1 and enhances proliferation of glia cells, in vitro.
Cell Mol Neurobiol
; 2005 Sep;25(6):981-93
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Studies were performed in several models of FGF-1 secretion (FGF-1 transfected NIH 3T3 cells exposed to heat shock, A375
melanoma
cells exposed to serum starvation, growth factor deprived human endothelial cells).
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
QUINOLINIC ACID
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Neurochem. 2005 May;93(3):762-5
[
15836634.001
]
[Cites]
J Neurosci. 2001 Oct 1;21(19):7463-73
[
11567036.001
]
[Cites]
Anal Biochem. 1988 Aug 1;172(2):518-25
[
3189792.001
]
[Cites]
Cancer Res. 2004 Mar 15;64(6):1987-96
[
15026334.001
]
[Cites]
J Leukoc Biol. 2000 Aug;68(2):260-6
[
10947071.001
]
[Cites]
Neuroscience. 2000;97(2):243-51
[
10799756.001
]
[Cites]
J Neurochem. 1992 Dec;59(6):2076-80
[
1431895.001
]
[Cites]
J Comp Neurol. 1996 Mar 11;366(3):379-89
[
8907353.001
]
[Cites]
J Neurochem. 1989 Apr;52(4):1319-28
[
2538568.001
]
[Cites]
Neuroscience. 2001;102(3):687-95
[
11226705.001
]
[Cites]
J Neurochem. 2002 Sep;82(6):1465-71
[
12354294.001
]
[Cites]
Anal Biochem. 1990 Mar;185(2):363-76
[
2339792.001
]
[Cites]
Science. 1983 Jan 21;219(4582):316-8
[
6849138.001
]
[Cites]
J Biol Chem. 1998 Aug 28;273(35):22209-16
[
9712834.001
]
[Cites]
Proc Natl Acad Sci U S A. 1992 Nov 15;89(22):10691-5
[
1279690.001
]
[Cites]
J Neurochem. 1991 Nov;57(5):1630-5
[
1833509.001
]
[Cites]
Oncogene. 1994 May;9(5):1473-7
[
8152810.001
]
[Cites]
Adv Cancer Res. 1992;59:115-65
[
1381547.001
]
[Cites]
Eur J Neurosci. 2001 Jun;13(11):2141-7
[
11422455.001
]
[Cites]
Neurol Res. 2002 Jan;24(1):81-92
[
11783758.001
]
[Cites]
Neuroscience. 1994 Jul;61(2):237-43
[
7969905.001
]
[Cites]
Pharmacol Rev. 1993 Sep;45(3):309-79
[
8248282.001
]
[Cites]
Eur J Pharmacol. 1981 Jul 10;72(4):411-2
[
6268428.001
]
[Cites]
J Neurochem. 2002 Apr;81(2):365-78
[
12064484.001
]
[Cites]
J Neurotrauma. 1995 Oct;12(5):853-70
[
8594213.001
]
[Cites]
Eur J Pharmacol. 1992 Mar 31;213(3):375-80
[
1535598.001
]
[Cites]
Thromb Haemost. 1999 Aug;82(2):748-54
[
10605778.001
]
[Cites]
J Cereb Blood Flow Metab. 1999 Jul;19(7):771-7
[
10413032.001
]
[Cites]
J Neurochem. 2001 Aug;78(4):842-53
[
11520905.001
]
[Cites]
Trends Pharmacol Sci. 2000 Apr;21(4):149-54
[
10740291.001
]
[Cites]
Brain Res. 1988 Jun 28;454(1-2):164-9
[
3409000.001
]
[Cites]
Eur J Pharmacol. 1999 Jun 30;375(1-3):87-100
[
10443567.001
]
[Cites]
J Biol Chem. 2001 Feb 16;276(7):5147-51
[
11087725.001
]
[Cites]
Eur J Pharmacol. 1989 Apr 12;163(1):123-6
[
2568264.001
]
[Cites]
J Neurochem. 1988 Jul;51(1):177-80
[
3379401.001
]
[Cites]
J Neurochem. 1995 Sep;65(3):1176-83
[
7643095.001
]
[Cites]
Neuroscience. 1985 Jul;15(3):597-617
[
2866466.001
]
(PMID = 16392031.001).
[ISSN]
0272-4340
[Journal-full-title]
Cellular and molecular neurobiology
[ISO-abbreviation]
Cell. Mol. Neurobiol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Culture Media, Conditioned; 0 / Excitatory Amino Acid Antagonists; 104781-85-3 / Fibroblast Growth Factor 1; F6F0HK1URN / Quinolinic Acid; H030S2S85J / Kynurenic Acid
55.
Tanaka S, Ohta T, Fujimoto T, Makino Y, Murakami I:
Endoscopic mucosal resection of primary anorectal malignant melanoma: a case report.
Acta Med Okayama
; 2008 Dec;62(6):421-4
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Endoscopic mucosal resection of primary anorectal
malignant
melanoma
: a case report.
Anorectal
melanoma
is a rare
malignant
tumor with a poor prognosis.
In this report, we present a patient with anorectal
melanoma
who has survived for 9 years after endoscopic mucosal resection.
An 85-year-old man was referred to our hospital for further examination and treatment of an
anal
tumor 2 cm in size.
Endoscopic mucosal resection was performed, and the tumor was diagnosed as a
malignant
melanoma
.
Although
melanoma
recurred 4 times thereafter, endoscopic mucosal resection was performed for each recurrent lesion.
[MeSH-major]
Anal
Canal / surgery. Endoscopy / methods.
Melanoma
/ surgery. Rectal Neoplasms / surgery. Rectum / surgery
MedlinePlus Health Information.
consumer health - Endoscopy
.
MedlinePlus Health Information.
consumer health - Melanoma
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19122689.001).
[ISSN]
0386-300X
[Journal-full-title]
Acta medica Okayama
[ISO-abbreviation]
Acta Med. Okayama
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Japan
56.
Srinivasan N, Bane SM, Ahire SD, Ingle AD, Kalraiya RD:
Poly N-acetyllactosamine substitutions on N- and not O-oligosaccharides or Thomsen-Friedenreich antigen facilitate lung specific metastasis of melanoma cells via galectin-3.
Glycoconj J
; 2009 May;26(4):445-56
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Poly N-acetyllactosamine substitutions on N- and not O-oligosaccharides or Thomsen-Friedenreich antigen facilitate lung specific metastasis of
melanoma
cells via galectin-3.
Metastatic variants of B16
melanoma
were chosen to identify specific ligands that mediate lung colonization via galectin-3.
Immobilized galectin-3 promoted adhesion of
melanoma
cells in a metastasis dependent manner.
[MeSH-major]
Antigens, Tumor-Associated, Carbohydrate / metabolism. Galectin 3 / metabolism. Lung Neoplasms / secondary.
Melanoma
/ metabolism.
Melanoma
/ pathology. Oligosaccharides / metabolism. Polysaccharides / metabolism
MedlinePlus Health Information.
consumer health - Lung Cancer
.
MedlinePlus Health Information.
consumer health - Melanoma
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Proc Natl Acad Sci U S A. 1980 Jan;77(1):399-403
[
6928631.001
]
[Cites]
Cancer Metastasis Rev. 1988 Jun;7(2):143-88
[
3293836.001
]
[Cites]
Methods Enzymol. 1990;182:663-70
[
2314261.001
]
[Cites]
Cancer Res. 1996 Dec 1;56(23):5309-18
[
8968075.001
]
[Cites]
Nature. 1970 Aug 15;227(5259):680-5
[
5432063.001
]
[Cites]
Biochem Biophys Res Commun. 2005 May 13;330(3):999-1004
[
15809094.001
]
[Cites]
Clin Exp Metastasis. 2005;22(1):11-24
[
16132574.001
]
[Cites]
J Clin Invest. 1991 Mar;87(3):1037-45
[
1999484.001
]
[Cites]
J Immunol. 2006 Feb 1;176(3):1943-50
[
16424226.001
]
[Cites]
Biochim Biophys Acta. 2004 May 27;1663(1-2):52-60
[
15157607.001
]
[Cites]
Cancer Res. 2003 Jul 1;63(13):3805-11
[
12839977.001
]
[Cites]
Proc Natl Acad Sci U S A. 1995 Sep 12;92(19):8754-8
[
7568011.001
]
[Cites]
J Biol Chem. 1999 Jun 11;274(24):16717-26
[
10358011.001
]
[Cites]
Science. 1987 May 1;236(4801):582-5
[
2953071.001
]
[Cites]
Clin Exp Metastasis. 2008;25(2):171-81
[
18058027.001
]
[Cites]
Biochim Biophys Acta. 1999 Dec 6;1473(1):21-34
[
10580127.001
]
[Cites]
J Biol Chem. 2007 Jul 27;282(30):22150-62
[
17537730.001
]
[Cites]
Proc Natl Acad Sci U S A. 1979 Sep;76(9):4350-4
[
388439.001
]
[Cites]
Anticancer Res. 1996 Nov-Dec;16(6B):3577-84
[
9042224.001
]
[Cites]
Cell. 2006 Nov 17;127(4):679-95
[
17110329.001
]
[Cites]
Br J Cancer. 2007 Dec 3;97(11):1538-44
[
17971775.001
]
[Cites]
Cancer Metastasis Rev. 1989 Aug;8(2):98-101
[
2673568.001
]
[Cites]
Biochim Biophys Acta. 2006 Sep;1760(9):1393-402
[
16806716.001
]
[Cites]
Anal Biochem. 1977 Dec;83(2):346-56
[
603028.001
]
[Cites]
Proc Natl Acad Sci U S A. 1986 Mar;83(6):1752-6
[
3081900.001
]
[Cites]
Clin Exp Metastasis. 2008;25(4):345-56
[
17891505.001
]
[Cites]
Biochim Biophys Acta. 2007 Sep;1770(9):1427-35
[
17600626.001
]
[Cites]
Glycoconj J. 2007 Nov;24(8):411-20
[
17457671.001
]
[Cites]
Allergol Int. 2007 Mar;56(1):57-65
[
17259811.001
]
[Cites]
Cancer Res. 1995 Aug 1;55(15):3267-71
[
7542167.001
]
[Cites]
J Natl Cancer Inst. 1977 Jun;58(6):1867-72
[
864765.001
]
[Cites]
J Biol Chem. 1982 Nov 25;257(22):13421-7
[
6216250.001
]
[Cites]
Cell. 2007 Apr 6;129(1):123-34
[
17418791.001
]
[Cites]
Am J Pathol. 2008 Feb;172(2):395-405
[
18202191.001
]
[Cites]
J Biol Chem. 2008 Apr 11;283(15):10109-23
[
18216021.001
]
[Cites]
Glycobiology. 1999 Mar;9(3):235-41
[
10024661.001
]
[Cites]
Cancer Res. 2001 Jun 15;61(12):4851-7
[
11406562.001
]
[Cites]
J Cell Biol. 1999 Nov 1;147(3):467-70
[
10545492.001
]
[Cites]
Glycoconj J. 1994 Oct;11(5):462-8
[
7696849.001
]
[Cites]
Neoplasia. 2005 May;7(5):522-7
[
15967104.001
]
[Cites]
Biochemistry. 1993 Jan 12;32(1):260-7
[
8418845.001
]
[Cites]
Cancer Res. 2000 Jan 1;60(1):134-42
[
10646865.001
]
[Cites]
Cancer Biol Ther. 2002 Sep-Oct;1(5):459-65
[
12496470.001
]
[Cites]
Nat Rev Cancer. 2005 Jan;5(1):29-41
[
15630413.001
]
[Cites]
Methods Enzymol. 1990;184:138-60
[
2388567.001
]
[Cites]
J Biol Chem. 1986 Aug 5;261(22):10119-26
[
3733704.001
]
[Cites]
Nat Rev Cancer. 2003 Jun;3(6):453-8
[
12778135.001
]
[Cites]
J Biol Chem. 1988 Sep 5;263(25):12461-71
[
2970459.001
]
[Cites]
Cell Growth Differ. 2001 Dec;12(12):623-30
[
11751457.001
]
[Cites]
J Biol Chem. 1987 May 25;262(15):7383-90
[
2438278.001
]
[Cites]
Cancer Res. 1980 Jul;40(7):2281-7
[
7388794.001
]
(PMID = 18949555.001).
[ISSN]
1573-4986
[Journal-full-title]
Glycoconjugate journal
[ISO-abbreviation]
Glycoconj. J.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Antigens, Tumor-Associated, Carbohydrate; 0 / Benzyl Compounds; 0 / Galectin 3; 0 / Immobilized Proteins; 0 / Oligosaccharides; 0 / Polysaccharides; 3554-90-3 / Thomsen-Friedenreich antigen; 3554-93-6 / benzyl-alpha-N-acetylgalactosamine; 82441-98-3 / poly-N-acetyllactosamine; KM15WK8O5T / Acetylgalactosamine
57.
Barbus R, Rancea A, Fetica B, Spârchez Z, Kacsó G:
Malignant melanoma of the anal canal: a case report.
J Contemp Brachytherapy
; 2009 Oct;1(3):151-153
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Malignant
melanoma
of the
anal
canal: a case report.
: This article is one case report of 49 year-old woman diagnosed with
malignant
melanoma
of the
anal
canal.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 27807457.001).
[ISSN]
1689-832X
[Journal-full-title]
Journal of contemporary brachytherapy
[ISO-abbreviation]
J Contemp Brachytherapy
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Poland
[Keywords]
NOTNLM ; adjuvant brachytherapy / anal melanoma / conservative resection
58.
Celebi ME, Schaefer G, Iyatomi H, Stoecker WV, Malters JM, Grichnik JM:
An improved objective evaluation measure for border detection in dermoscopy images.
Skin Res Technol
; 2009 Nov;15(4):444-50
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
BACKGROUND: Dermoscopy is one of the major imaging modalities used in
the diagnosis
of
melanoma
and other pigmented skin lesions.
MedlinePlus Health Information.
consumer health - Melanoma
.
MedlinePlus Health Information.
consumer health - Skin Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Skin Res Technol. 2002 Nov;8(4):240-9
[
12423543.001
]
[Cites]
Skin Res Technol. 2008 Aug;14(3):347-53
[
19159382.001
]
[Cites]
Arch Dermatol. 1995 Mar;131(3):286-91
[
7887657.001
]
[Cites]
Comput Med Imaging Graph. 1998 Sep-Oct;22(5):375-89
[
9890182.001
]
[Cites]
IEEE Trans Med Imaging. 1999 Feb;18(2):164-71
[
10232673.001
]
[Cites]
Skin Res Technol. 2005 Feb;11(1):17-26
[
15691255.001
]
[Cites]
Skin Res Technol. 2005 Aug;11(3):179-84
[
15998328.001
]
[Cites]
Melanoma Res. 2006 Apr;16(2):183-90
[
16567974.001
]
[Cites]
IEEE Trans Pattern Anal Mach Intell. 2007 Jun;29(6):929-44
[
17431294.001
]
[Cites]
Comput Med Imaging Graph. 2007 Sep;31(6):362-73
[
17387001.001
]
[Cites]
Skin Res Technol. 2007 Nov;13(4):454-62
[
17908199.001
]
[Cites]
IEEE Trans Biomed Eng. 2008 Jan;55(1):157-61
[
18232357.001
]
[Cites]
CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96
[
18287387.001
]
[Cites]
Comput Med Imaging Graph. 2008 Oct;32(7):566-79
[
18703311.001
]
[Cites]
Comput Med Imaging Graph. 2008 Dec;32(8):670-7
[
18804955.001
]
[Cites]
Comput Med Imaging Graph. 2009 Mar;33(2):148-53
[
19121917.001
]
[Cites]
J Am Acad Dermatol. 1993 Oct;29(4):581-8
[
8408794.001
]
(PMID = 19832956.001).
[ISSN]
1600-0846
[Journal-full-title]
Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI)
[ISO-abbreviation]
Skin Res Technol
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / R44 CA060294-02A2; United States / NCI NIH HHS / CA / R44 CA101639; United States / NCI NIH HHS / CA / #2R44 CA-101639-02A2
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Other-IDs]
NLM/ NIHMS317720; NLM/ PMC3159921
59.
Briggs JJ, Haugen MH, Johansen HT, Riker AI, Abrahamson M, Fodstad Ø, Maelandsmo GM, Solberg R:
Cystatin E/M suppresses legumain activity and invasion of human melanoma.
BMC Cancer
; 2010;10:17
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Cystatin E/M suppresses legumain activity and invasion of human
melanoma
.
In breast
cancer
, several recent studies have indicated that loss of the cysteine protease inhibitor cystatin E/M leads to increased growth and metastasis.
Although cystatin E/M is normally expressed in the skin, its role in cysteine protease regulation and progression
of malignant
melanoma
has not been studied.
METHODS: A panel of various non-
melanoma
and
melanoma
cell lines was used.
Two
melanoma
cell lines lacking detectable secretion of cystatin E/M were transfected with a cystatin E/M expression plasmid (pCST6), and migration and invasiveness were studied by a Matrigel invasion assay.
RESULTS: Cystatin E/M was undetectable in media from all established
melanoma
cell lines examined, whereas strong immunobands were detected in two of five primary
melanoma
lines and in two of six lines derived from patients with metastatic disease.
Among the four
melanoma
lines secreting cystatin E/M, the glycosylated form (17 kD) was predominant compared to the non-glycosylated form (14 kD).
In the
melanoma
lines where cystatin E/M was secreted, cystatin C was generally absent or expressed at a very low level.
When
melanoma
cells lacking secretion of cystatin E/M were transfected with pCST6, their intracellular legumain activity was significantly inhibited.
Furthermore, invasion was suppressed in cystatin E/M over-expressing
melanoma
cell lines as measured by the transwell Matrigel assay.
CONCLUSIONS: These results suggest that the level of cystatin E/M regulates legumain activity and hence the invasive potential of human
melanoma
cells.
[MeSH-major]
Cystatin M / biosynthesis. Cysteine Endopeptidases / biosynthesis. Gene Expression Regulation, Neoplastic.
Melanoma
/ metabolism. Skin Neoplasms / metabolism
MedlinePlus Health Information.
consumer health - Melanoma
.
MedlinePlus Health Information.
consumer health - Skin Cancer
.
COS Scholar Universe.
author profiles
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Oncogene. 2007 May 10;26(21):3089-94
[
17099723.001
]
[Cites]
Oncogene. 2007 Apr 19;26(18):2621-34
[
17043644.001
]
[Cites]
Cancer Sci. 2008 Aug;99(8):1626-32
[
18754876.001
]
[Cites]
Biochem J. 2000 Dec 1;352 Pt 2:327-34
[
11085925.001
]
[Cites]
Cancer. 2001 Mar 1;91(5):972-82
[
11251949.001
]
[Cites]
Cancer Res. 2001 Apr 15;61(8):3493-500
[
11309313.001
]
[Cites]
J Invest Dermatol. 2001 May;116(5):693-701
[
11348457.001
]
[Cites]
Biol Chem. 2001 May;382(5):777-83
[
11517930.001
]
[Cites]
Biochim Biophys Acta. 2002 Apr 1;1596(1):108-20
[
11983426.001
]
[Cites]
Br J Dermatol. 2002 Jul;147(1):87-94
[
12100189.001
]
[Cites]
Biol Chem. 2003 Feb;384(2):281-7
[
12675521.001
]
[Cites]
Cancer Res. 2003 Jun 1;63(11):2957-64
[
12782603.001
]
[Cites]
Oral Oncol. 2003 Sep;39(6):559-68
[
12798398.001
]
[Cites]
Biochem Soc Symp. 2003;(70):179-99
[
14587292.001
]
[Cites]
Oncogene. 2004 Mar 18;23(12):2206-15
[
14676833.001
]
[Cites]
Oncogene. 2004 Jun 10;23(27):4681-9
[
15122332.001
]
[Cites]
Cancer Res. 2004 Jun 15;64(12):4069-77
[
15205313.001
]
[Cites]
Thromb Haemost. 2004 Jul;92(1):13-22
[
15213840.001
]
[Cites]
Cancer Res. 2004 Oct 1;64(19):6957-64
[
15466187.001
]
[Cites]
Anal Biochem. 1976 May 7;72:248-54
[
942051.001
]
[Cites]
J Histochem Cytochem. 1979 Aug;27(8):1131-9
[
90074.001
]
[Cites]
Methods Enzymol. 1981;80 Pt C:535-61
[
7043200.001
]
[Cites]
Scand J Clin Lab Invest. 1988 Oct;48(6):573-82
[
3064278.001
]
[Cites]
Cancer Metastasis Rev. 1990 Dec;9(4):333-52
[
2097084.001
]
[Cites]
J Biol Chem. 1993 Jul 25;268(21):15737-44
[
8340398.001
]
[Cites]
Am J Pathol. 1994 Aug;145(2):301-9
[
7519824.001
]
[Cites]
Am J Pathol. 1994 Dec;145(6):1285-90
[
7992833.001
]
[Cites]
Cancer Res. 1995 Jul 15;55(14):3149-57
[
7541714.001
]
[Cites]
Biol Chem Hoppe Seyler. 1995 Mar;376(3):157-64
[
7612192.001
]
[Cites]
Int J Cancer. 1995 Jul 17;62(2):155-61
[
7622289.001
]
[Cites]
Comp Biochem Physiol B Biochem Mol Biol. 1996 Jul;114(3):303-11
[
8761177.001
]
[Cites]
Biol Chem Hoppe Seyler. 1996 Feb;377(2):71-86
[
8868064.001
]
[Cites]
Int J Cancer. 1996 Nov 27;68(5):682-7
[
8938153.001
]
[Cites]
J Biol Chem. 1997 Jan 10;272(2):903-10
[
8995380.001
]
[Cites]
J Biol Chem. 1997 Mar 21;272(12):8090-8
[
9065484.001
]
[Cites]
J Biol Chem. 1997 Apr 18;272(16):10853-8
[
9099741.001
]
[Cites]
Biol Chem. 1998 Feb;379(2):113-23
[
9524062.001
]
[Cites]
Cancer Res. 1998 Jul 1;58(13):2733-6
[
9661883.001
]
[Cites]
J Biol Chem. 1998 Sep 18;273(38):24797-804
[
9733783.001
]
[Cites]
Int J Cancer. 1999 Mar 1;80(5):781-90
[
10048982.001
]
[Cites]
J Biol Chem. 1999 Jul 2;274(27):19195-203
[
10383426.001
]
[Cites]
Anal Biochem. 1999 Sep 10;273(2):278-83
[
10469498.001
]
[Cites]
Eur J Cell Biol. 2004 Dec;83(11-12):761-73
[
15679120.001
]
[Cites]
Clin Cancer Res. 2005 Mar 15;11(6):2293-9
[
15788679.001
]
[Cites]
J Immunol. 2005 Jun 1;174(11):7066-74
[
15905550.001
]
[Cites]
Life Sci. 2006 Jan 18;78(8):898-907
[
16150465.001
]
[Cites]
Cancer Lett. 2006 Apr 28;235(2):159-76
[
15893421.001
]
[Cites]
Anal Biochem. 2006 Jun 1;353(1):57-62
[
16620747.001
]
[Cites]
J Biol Chem. 2006 Jun 9;281(23):15893-9
[
16565075.001
]
[Cites]
Cancer Res. 2006 Aug 1;66(15):7490-501
[
16885346.001
]
[Cites]
Cancer Res. 2006 Aug 15;66(16):7899-909
[
16912163.001
]
[Cites]
Lab Invest. 2006 Dec;86(12):1233-42
[
17043665.001
]
[Cites]
Lab Invest. 2008 Sep;88(9):910-25
[
18607344.001
]
(PMID = 20074384.001).
[ISSN]
1471-2407
[Journal-full-title]
BMC cancer
[ISO-abbreviation]
BMC Cancer
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Culture Media, Serum-Free; 0 / Cystatin M; 0 / Drug Combinations; 0 / Laminin; 0 / Proteoglycans; 119978-18-6 / matrigel; 9007-34-5 / Collagen; EC 3.4.- / Cysteine Proteases; EC 3.4.22.- / Cysteine Endopeptidases; EC 3.4.22.34 / asparaginylendopeptidase
[Other-IDs]
NLM/ PMC2822816
60.
Dong X, Mattingly CA, Tseng MT, Cho MJ, Liu Y, Adams VR, Mumper RJ:
Doxorubicin and paclitaxel-loaded lipid-based nanoparticles overcome multidrug resistance by inhibiting P-glycoprotein and depleting ATP.
Cancer Res
; 2009 May 1;69(9):3918-26
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Doxorubicin nanoparticles showed 6- to 8-fold lower IC(50) values in P-gp-overexpressing human
cancer
cells than those of free doxorubicin.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
DOXORUBICIN
.
Hazardous Substances Data Bank.
TAXOL
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Adv Drug Deliv Rev. 2002 Sep 13;54(5):759-79
[
12204601.001
]
[Cites]
Cancer Chemother Pharmacol. 2002 Jul;50(1):6-8
[
12111105.001
]
[Cites]
J Control Release. 2003 Aug 28;91(1-2):75-83
[
12932639.001
]
[Cites]
J Control Release. 2004 Sep 30;99(2):259-69
[
15380635.001
]
[Cites]
J Pharm Sci. 1982 Oct;71(10):1121-5
[
6958860.001
]
[Cites]
Anal Biochem. 1985 Oct;150(1):76-85
[
3843705.001
]
[Cites]
Biochem J. 1987 May 15;244(1):159-64
[
3663110.001
]
[Cites]
J Natl Cancer Inst. 1992 Dec 16;84(24):1909-15
[
1361008.001
]
[Cites]
J Clin Oncol. 1994 Sep;12(9):1771-7
[
8083699.001
]
[Cites]
Br J Cancer. 1997;76(2):198-205
[
9231919.001
]
[Cites]
Crit Rev Oncog. 1996;7(3-4):227-44
[
9258604.001
]
[Cites]
J Immunol Methods. 1997 Oct 27;208(2):151-8
[
9433470.001
]
[Cites]
J Control Release. 1998 Jul 31;54(2):223-33
[
9724909.001
]
[Cites]
J Control Release. 2005 Jul 20;105(3):269-78
[
15939500.001
]
[Cites]
Biotechnol Annu Rev. 2005;11:127-52
[
16216776.001
]
[Cites]
J Pharmacol Exp Ther. 2006 Jun;317(3):1372-81
[
16547167.001
]
[Cites]
J Control Release. 2006 May 30;112(3):312-9
[
16626835.001
]
[Cites]
Pharm Res. 2006 Jul;23(7):1574-85
[
16786442.001
]
[Cites]
Int J Pharm. 2006 Aug 31;320(1-2):150-6
[
16713148.001
]
[Cites]
Drug Dev Ind Pharm. 2006 Sep;32(8):973-80
[
16954110.001
]
[Cites]
Am J Physiol Cell Physiol. 2007 Jan;292(1):C157-63
[
16870828.001
]
[Cites]
Eur J Pharm Biopharm. 2009 May;72(1):9-17
[
19111929.001
]
[Cites]
J Biomed Nanotechnol. 2009 Apr;5(2):151-61
[
20055093.001
]
[Cites]
Pharm Res. 1999 Nov;16(11):1710-6
[
10571276.001
]
[Cites]
J Control Release. 2001 Apr 28;71(3):227-37
[
11295216.001
]
[Cites]
J Pharmacol Exp Ther. 2001 Nov;299(2):620-8
[
11602674.001
]
[Cites]
Br J Cancer. 2001 Dec 14;85(12):1987-97
[
11747344.001
]
[Cites]
Nat Rev Cancer. 2002 Jan;2(1):48-58
[
11902585.001
]
[Cites]
J Pharm Sci. 2003 Jun;92(6):1250-61
[
12761814.001
]
(PMID = 19383919.001).
[ISSN]
1538-7445
[Journal-full-title]
Cancer research
[ISO-abbreviation]
Cancer Res.
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / CA115197-05; United States / NCI NIH HHS / CA / R01 CA115197; United States / NCI NIH HHS / CA / R01 CA115197-05
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural
[Publication-country]
United States
[Chemical-registry-number]
0 / Fluoresceins; 0 / P-Glycoprotein; 148504-34-1 / calcein AM; 80168379AG / Doxorubicin; 8L70Q75FXE / Adenosine Triphosphate; P88XT4IS4D / Paclitaxel
[Other-IDs]
NLM/ NIHMS139361; NLM/ PMC2758164
61.
Balachandra B, Marcus V, Jass JR:
Poorly differentiated tumours of the anal canal: a diagnostic strategy for the surgical pathologist.
Histopathology
; 2007 Jan;50(1):163-74
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Poorly differentiated tumours of the
anal
canal: a diagnostic strategy for the surgical pathologist.
Poorly differentiated malignancies affecting the
anal
canal are uncommon but pose diagnostic difficulties because of the wide range of normal cell types that may occur within a limited anatomical region.
The range of lesions that may present as poorly differentiated tumours includes squamous cell carcinoma, adenocarcinoma, small and large cell neuroendocrine carcinoma, neuroendocrine carcinoma expressing epithelial cytokeratins and other patterns of mixed differentiation, undifferentiated carcinoma,
malignant
melanoma
, lymphoma and secondary tumours.
This review discusses the differential
diagnosis of
these neoplasms with the aid of short illustrative case studies.
[MeSH-major]
Anal
Canal / pathology.
Anus
Neoplasms / pathology
[MeSH-minor]
Adenocarcinoma / pathology. Aged. Carcinoma, Squamous Cell / pathology.
Diagnosis
, Differential. Female. Humans. Lymphoma / pathology. Male.
Melanoma
/ pathology. Middle Aged. Pathology, Surgical / methods
MedlinePlus Health Information.
consumer health - Anal Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17204029.001).
[ISSN]
0309-0167
[Journal-full-title]
Histopathology
[ISO-abbreviation]
Histopathology
[Language]
eng
[Publication-type]
Case Reports; Journal Article; Review
[Publication-country]
England
[Number-of-references]
72
62.
Pfefferkorn CM, McGlinchey RP, Lee JC:
Effects of pH on aggregation kinetics of the repeat domain of a functional amyloid, Pmel17.
Proc Natl Acad Sci U S A
; 2010 Dec 14;107(50):21447-52
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[MeSH-major]
Amyloid / chemistry. Hydrogen-Ion Concentration. Protein Conformation. gp100
Melanoma
Antigen / chemistry
Hazardous Substances Data Bank.
(L)-Tryptophan
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Biol Chem. 2007 Apr 13;282(15):11266-80
[
17303571.001
]
[Cites]
J Biol Chem. 1982 Aug 10;257(15):8738-44
[
6807981.001
]
[Cites]
Nat Rev Mol Cell Biol. 2007 Oct;8(10):786-97
[
17878918.001
]
[Cites]
Arch Biochem Biophys. 2008 Jan 1;469(1):100-17
[
17588526.001
]
[Cites]
J Biol Chem. 2008 Jan 25;283(4):2307-22
[
17991747.001
]
[Cites]
J Alzheimers Dis. 2008 May;13(4):407-19
[
18487849.001
]
[Cites]
Proc Natl Acad Sci U S A. 2008 Jul 1;105(26):8926-31
[
18579777.001
]
[Cites]
Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13345-50
[
18757753.001
]
[Cites]
Q Rev Biophys. 2008 Aug-Nov;41(3-4):265-97
[
19079806.001
]
[Cites]
Proc Natl Acad Sci U S A. 2008 Dec 16;105(50):19726-31
[
19033461.001
]
[Cites]
J Biol Chem. 2009 Jan 23;284(4):2296-306
[
19047044.001
]
[Cites]
Biochim Biophys Acta. 2009 Mar;1794(3):375-97
[
19071235.001
]
[Cites]
Eur J Biochem. 1987 Aug 3;166(3):705-11
[
3111852.001
]
[Cites]
Methods Biochem Anal. 1991;35:127-205
[
2002770.001
]
[Cites]
Proc Natl Acad Sci U S A. 1991 Oct 15;88(20):9228-32
[
1924386.001
]
[Cites]
Arch Biochem Biophys. 1993 Nov 15;307(1):183-92
[
8239655.001
]
[Cites]
Pigment Cell Res. 2005 Oct;18(5):322-36
[
16162173.001
]
[Cites]
J Mol Biol. 2005 Oct 21;353(2):357-72
[
16171820.001
]
[Cites]
Biochemistry. 2006 Feb 28;45(8):2752-60
[
16489768.001
]
[Cites]
PLoS Biol. 2006 Jan;4(1):e6
[
16300414.001
]
[Cites]
Annu Rev Biochem. 2006;75:333-66
[
16756495.001
]
[Cites]
J Biol Chem. 2006 Jul 28;281(30):21198-208
[
16682408.001
]
[Cites]
Trends Biochem Sci. 2007 May;32(5):217-24
[
17412596.001
]
[Cites]
J Biol Chem. 2009 Feb 20;284(8):4749-53
[
18845536.001
]
[Cites]
Science. 2009 Jul 17;325(5938):328-32
[
19541956.001
]
[Cites]
Proc Natl Acad Sci U S A. 2009 Aug 18;106(33):13731-6
[
19666488.001
]
[Cites]
BMB Rep. 2009 Sep 30;42(9):541-51
[
19788854.001
]
[Cites]
J Biol Chem. 2009 Dec 18;284(51):35543-55
[
19840945.001
]
[Cites]
Arch Biochem Biophys. 2010 Feb 15;494(2):192-7
[
19995549.001
]
[Cites]
FASEB J. 2010 Mar;24(3):916-30
[
19884326.001
]
[Cites]
Nat Methods. 2010 Mar;7(3):237-42
[
20154676.001
]
[Cites]
FASEB J. 2010 May;24(5):1616-29
[
20056711.001
]
[Cites]
J Biol Chem. 2010 May 21;285(21):16166-83
[
20231267.001
]
[Cites]
J Invest Dermatol. 2000 Oct;115(4):607-13
[
10998131.001
]
[Cites]
Pigment Cell Res. 2001 Apr;14(2):86-93
[
11310796.001
]
[Cites]
Mol Biol Cell. 2001 Nov;12(11):3451-64
[
11694580.001
]
[Cites]
Annu Rev Biomed Eng. 2002;4:155-74
[
12117755.001
]
[Cites]
J Cell Biol. 2003 May 12;161(3):521-33
[
12732614.001
]
[Cites]
Proc Natl Acad Sci U S A. 1974 Dec;71(12):4864-8
[
4531026.001
]
[Cites]
Q Rev Biophys. 2006 Feb;39(1):1-55
[
16772049.001
]
(PMID = 21106765.001).
[ISSN]
1091-6490
[Journal-full-title]
Proceedings of the National Academy of Sciences of the United States of America
[ISO-abbreviation]
Proc. Natl. Acad. Sci. U.S.A.
[Language]
eng
[Grant]
United States / Intramural NIH HHS / / ZIA HL006034-01
[Publication-type]
Journal Article; Research Support, N.I.H., Intramural
[Publication-country]
United States
[Chemical-registry-number]
0 / Amyloid; 0 / PMEL protein, human; 0 / gp100 Melanoma Antigen; 8DUH1N11BX / Tryptophan
[Other-IDs]
NLM/ PMC3003087
63.
Minichsdorfer C, Hohenegger M:
Autocrine amplification loop in statin-induced apoptosis of human melanoma cells.
Br J Pharmacol
; 2009 Aug;157(7):1278-90
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Autocrine amplification loop in statin-induced apoptosis of human
melanoma
cells.
In particular,
melanoma
cells have been found to be susceptible to statin-induced apoptosis, although only after longer incubation times.
EXPERIMENTAL APPROACH: The human
melanoma
A375 and 518A2 cell lines were exposed to various statins in a time-dependent and dose-dependent manner, and indicators of apoptosis, caspase activity and individual apoptotic pathways were analysed for 3-hydroxy-3-methylglutaryl-coenzyme A reductase dependent and independent effects.
CONCLUSIONS AND IMPLICATIONS: Simvastatin and atorvastatin are capable of triggering an 'autocrine' suicide factor, which amplifies apoptosis via the extrinsic pathway in human
melanoma
cells.
This pro-apoptotic stimulus implies possible therapeutic potential and may guide feasibility for more potent statins in anti-
cancer
strategies.
[MeSH-minor]
Atorvastatin Calcium. Autocrine Communication. Caspase 3 / metabolism. Caspase 8 / metabolism. Caspase 9 / metabolism. Cell Line, Tumor. Enzyme Activation. Heptanoic Acids / pharmacology. Humans. Lovastatin / pharmacology.
Melanoma
. Pyridines / pharmacology. Pyrroles / pharmacology. Simvastatin / pharmacology. Time Factors
MedlinePlus Health Information.
consumer health - Statins
.
Hazardous Substances Data Bank.
LOVASTATIN
.
Hazardous Substances Data Bank.
SIMVASTATIN
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Clin Cancer Res. 1996 Mar;2(3):483-91
[
9816194.001
]
[Cites]
Cancer Res. 1994 Mar 1;54(5):1169-74
[
8118801.001
]
[Cites]
J Atheroscler Thromb. 2004;11(5):253-64
[
15557707.001
]
[Cites]
Melanoma Res. 2005 Apr;15(2):83-9
[
15846140.001
]
[Cites]
Cell. 2005 Jun 3;121(5):671-4
[
15935754.001
]
[Cites]
J Pharmacol Exp Ther. 2005 Sep;314(3):1032-41
[
15914674.001
]
[Cites]
Cancer Immunol Immunother. 2005 Nov;54(11):1127-36
[
15889255.001
]
[Cites]
Nat Rev Cancer. 2005 Dec;5(12):930-42
[
16341084.001
]
[Cites]
JAMA. 2006 Jan 4;295(1):74-80
[
16391219.001
]
[Cites]
Haematologica. 2006 Apr;91(4):542-5
[
16585018.001
]
[Cites]
Dev Cell. 2006 May;10(5):549-61
[
16678772.001
]
[Cites]
Cancer Res. 2006 Sep 1;66(17):8707-14
[
16951186.001
]
[Cites]
Mol Cancer Ther. 2006 Sep;5(9):2310-6
[
16985065.001
]
[Cites]
J Clin Oncol. 2006 Oct 20;24(30):4808-17
[
17001070.001
]
[Cites]
J Natl Cancer Inst. 2006 Nov 1;98(21):1538-46
[
17077356.001
]
[Cites]
Mol Cancer Ther. 2007 Jun;6(6):1886-97
[
17575117.001
]
[Cites]
Eur J Cancer. 2007 Nov;43(17):2580-9
[
17950596.001
]
[Cites]
Neoplasia. 2007 Dec;9(12):1078-90
[
18084615.001
]
[Cites]
J Natl Cancer Inst. 2008 Jan 16;100(2):134-9
[
18182618.001
]
[Cites]
BMC Cancer. 2008;8:9
[
18199328.001
]
[Cites]
Melanoma Res. 2008 Apr;18(2):85-94
[
18337644.001
]
[Cites]
Am J Med. 2008 Apr;121(4):302-9
[
18374689.001
]
[Cites]
Curr Opin Pharmacol. 2008 Jun;8(3):333-8
[
18243052.001
]
[Cites]
Clin Cancer Res. 2001 Jan;7(1):158-67
[
11205904.001
]
[Cites]
Int J Cancer. 2002 Jul 1;100(1):111-8
[
12115596.001
]
[Cites]
J Invest Dermatol. 2002 Nov;119(5):1172-6
[
12445208.001
]
[Cites]
Surg Clin North Am. 2003 Feb;83(1):109-56
[
12691453.001
]
[Cites]
Oncogene. 2003 May 19;22(20):3138-51
[
12789290.001
]
[Cites]
Exp Hematol. 2003 Sep;31(9):779-83
[
12962723.001
]
[Cites]
Circulation. 2004 Jun 15;109(23 Suppl 1):III39-43
[
15198965.001
]
[Cites]
Circulation. 2004 Jun 15;109(23 Suppl 1):III50-7
[
15198967.001
]
[Cites]
Anal Biochem. 1976 May 7;72:248-54
[
942051.001
]
[Cites]
Nature. 1990 Feb 1;343(6257):425-30
[
1967820.001
]
[Cites]
J Clin Pharmacol. 1990 Dec;30(12):1128-35
[
2125605.001
]
[Cites]
Cancer Res. 1991 Jul 1;51(13):3602-9
[
1711413.001
]
[Cites]
Br J Pharmacol. 2004 Nov;143(6):715-24
[
15289292.001
]
(PMID = 19563533.001).
[ISSN]
1476-5381
[Journal-full-title]
British journal of pharmacology
[ISO-abbreviation]
Br. J. Pharmacol.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Antineoplastic Agents; 0 / Biological Factors; 0 / Heptanoic Acids; 0 / Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0 / Pyridines; 0 / Pyrroles; 48A5M73Z4Q / Atorvastatin Calcium; 9LHU78OQFD / Lovastatin; AGG2FN16EV / Simvastatin; AM91H2KS67 / cerivastatin; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspase 8; EC 3.4.22.- / Caspase 9
[Other-IDs]
NLM/ PMC2743847
64.
Papagiannaros A, Upponi J, Hartner W, Mongayt D, Levchenko T, Torchilin V:
Quantum dot loaded immunomicelles for tumor imaging.
BMC Med Imaging
; 2010 Oct 18;10:22
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Here, we describe a tumor-targeted near infrared imaging agent composed
of cancer
-specific monoclonal anti-nucleosome antibody 2C5, coupled to quantum dot (QD)-containing polymeric micelles, prepared from a polyethylene glycol/phosphatidylethanolamine (PEG-PE) conjugate.
A lung pseudometastatic B16F10
melanoma
model was developed using tail vein injection.
Ex vivo results demonstrated that the agent detects
melanoma
nodes in a lung pseudometastatic model after a 24 hours wash-out period, while at one hour, only a uniform signal is detected.
MedlinePlus Health Information.
consumer health - Melanoma
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Nanomedicine. 2009 Jun;5(2):216-24
[
19223245.001
]
[Cites]
Int J Nanomedicine. 2009;4:123-31
[
19516891.001
]
[Cites]
Mol Pharm. 2009 Mar-Apr;6(2):468-79
[
19718800.001
]
[Cites]
Mol Cancer Ther. 2009 Oct;8(10):2861-71
[
19825804.001
]
[Cites]
Lasers Med Sci. 2010 Jul;25(4):479-84
[
19322625.001
]
[Cites]
Pharm Res. 2011 Feb;28(2):187-99
[
20549313.001
]
[Cites]
J Biomed Opt. 2007 Jul-Aug;12(4):044021
[
17867825.001
]
[Cites]
Eur J Nucl Med Mol Imaging. 2006 Oct;33(10):1196-205
[
16763815.001
]
[Cites]
Cancer Res. 2006 Oct 15;66(20):9929-36
[
17047055.001
]
[Cites]
Pharm Res. 2007 Jan;24(1):1-16
[
17109211.001
]
[Cites]
J Am Chem Soc. 2007 Jan 24;129(3):482-3
[
17226998.001
]
[Cites]
Methods Mol Biol. 2007;374:93-104
[
17237532.001
]
[Cites]
Curr Opin Biotechnol. 2007 Feb;18(1):17-25
[
17234399.001
]
[Cites]
Nat Med. 2007 Apr;13(4):504-9
[
17351626.001
]
[Cites]
Cancer Res. 2001 Jun 15;61(12):4750-5
[
11406547.001
]
[Cites]
Science. 2002 Nov 29;298(5599):1759-62
[
12459582.001
]
[Cites]
Nat Biotechnol. 2003 Jan;21(1):41-6
[
12459735.001
]
[Cites]
Proc Natl Acad Sci U S A. 2003 May 13;100(10):6039-44
[
12716967.001
]
[Cites]
Cancer Res. 2003 Nov 15;63(22):7870-5
[
14633715.001
]
[Cites]
Nat Biotechnol. 2004 Jan;22(1):93-7
[
14661026.001
]
[Cites]
Nat Med. 2004 Sep;10(9):993-8
[
15334072.001
]
[Cites]
Oncol Res. 1997;9(8):439-46
[
9436197.001
]
[Cites]
Cancer Res. 1998 Feb 1;58(3):485-90
[
9458094.001
]
[Cites]
Cancer Res. 1998 Jul 1;58(13):2825-31
[
9661897.001
]
[Cites]
Cancer Detect Prev. 1998;22(5):470-5
[
9727629.001
]
[Cites]
Trends Biotechnol. 2004 Dec;22(12):607-9
[
15542145.001
]
[Cites]
Curr Opin Biotechnol. 2005 Feb;16(1):63-72
[
15722017.001
]
[Cites]
Nat Med. 2005 Jun;11(6):678-82
[
15880117.001
]
[Cites]
Nat Methods. 2004 Oct;1(1):73-8
[
16138413.001
]
[Cites]
Curr Drug Deliv. 2005 Oct;2(4):319-27
[
16305435.001
]
[Cites]
Cancer Res. 2006 Jul 1;66(13):6732-40
[
16818648.001
]
[Cites]
Bioconjug Chem. 2006 Jul-Aug;17(4):865-8
[
16848390.001
]
[Cites]
Breast Cancer Res Treat. 2007 May;103(1):23-8
[
17028977.001
]
[Cites]
J Biomed Opt. 2007 Mar-Apr;12(2):024017
[
17477732.001
]
[Cites]
Nat Protoc. 2007;2(5):1152-65
[
17546006.001
]
[Cites]
AAPS J. 2007;9(2):E128-47
[
17614355.001
]
[Cites]
Br J Surg. 2007 Aug;94(8):996-1001
[
17380563.001
]
[Cites]
Int J Nanomedicine. 2006;1(4):473-81
[
17722280.001
]
[Cites]
J Invest Dermatol. 2007 Oct;127(10):2351-6
[
17522707.001
]
[Cites]
Bioconjug Chem. 2007 Sep-Oct;18(5):1391-6
[
17630789.001
]
[Cites]
Nat Protoc. 2007;2(10):2383-90
[
17947980.001
]
[Cites]
Radiology. 2008 Mar;246(3):734-41
[
18223125.001
]
[Cites]
Trends Pharmacol Sci. 2008 Feb;29(2):57-61
[
18179828.001
]
[Cites]
J Magn Reson Imaging. 2008 Mar;27(3):574-80
[
18219628.001
]
[Cites]
Nat Methods. 2008 May;5(5):397-9
[
18425138.001
]
[Cites]
Cancer Res. 2008 May 1;68(9):3334-41
[
18451160.001
]
[Cites]
Bioconjug Chem. 2008 Jun;19(6):1274-82
[
18505278.001
]
[Cites]
J Drug Target. 2008 Jul;16(6):486-93
[
18604661.001
]
[Cites]
Adv Drug Deliv Rev. 2008 Sep15;60(12):1421-34
[
18541331.001
]
[Cites]
Mol Cancer Ther. 2008 Jul;7(7):2233-40
[
18645032.001
]
[Cites]
Anal Bioanal Chem. 2008 Aug;391(7):2469-95
[
18548237.001
]
[Cites]
Biomaterials. 2008 Nov;29(31):4170-6
[
18691751.001
]
[Cites]
Int J Cancer. 2008 Nov 1;123(9):2138-47
[
18709639.001
]
[Cites]
Int J Cancer. 2008 Nov 1;123(9):1991-2006
[
18712708.001
]
[Cites]
Small. 2008 Sep;4(9):1406-15
[
18711753.001
]
[Cites]
Angew Chem Int Ed Engl. 2008;47(38):7284-8
[
18696519.001
]
[Cites]
Nano Lett. 2008 Sep;8(9):2599-606
[
18386933.001
]
[Cites]
Nano Lett. 2008 Sep;8(9):2851-7
[
18712930.001
]
[Cites]
Cancer Metastasis Rev. 2008 Dec;27(4):615-30
[
18506398.001
]
[Cites]
APMIS. 2008 Jul-Aug;116(7-8):754-70
[
18834417.001
]
[Cites]
Nano Lett. 2008 Nov;8(11):3834-8
[
18928324.001
]
[Cites]
Anal Chem. 2008 Nov 15;80(22):8649-55
[
18922019.001
]
[Cites]
J Biomed Opt. 2008 Jul-Aug;13(4):041312
[
19021320.001
]
[Cites]
Proc Natl Acad Sci U S A. 2008 Dec 9;105(49):19126-31
[
19015534.001
]
[Cites]
Anal Bioanal Chem. 2009 Jan;393(2):473-9
[
18982314.001
]
[Cites]
Opt Express. 2009 Jan 5;17(1):266-77
[
19129896.001
]
[Cites]
Mol Pharm. 2009 Jan-Feb;6(1):246-54
[
19049322.001
]
[Cites]
Eur J Pharm Biopharm. 2009 Mar;71(3):431-44
[
18977297.001
]
[Cites]
Clin Cancer Res. 2009 Mar 15;15(6):1973-80
[
19276264.001
]
[Cites]
Cancer Biol Ther. 2007 Jul;6(7):1136-42
[
17611407.001
]
[Cites]
Nano Lett. 2009 May;9(5):2073-6
[
19354297.001
]
(PMID = 20955559.001).
[ISSN]
1471-2342
[Journal-full-title]
BMC medical imaging
[ISO-abbreviation]
BMC Med Imaging
[Language]
ENG
[Grant]
United States / NIBIB NIH HHS / EB / R01 EB001961
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural
[Publication-country]
England
[Chemical-registry-number]
0 / Antibodies, Monoclonal; 0 / Antibodies, Neoplasm; 0 / Micelles
[Other-IDs]
NLM/ PMC2975645
65.
Bavaresco L, Bernardi A, Braganhol E, Wink MR, Battastini AM:
Dexamethasone inhibits proliferation and stimulates ecto-5'-nucleotidase/CD73 activity in C6 rat glioma cell line.
J Neurooncol
; 2007 Aug;84(1):1-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Malignant
gliomas are the most common and devastating primary tumors of the adult central nervous system.
MedlinePlus Health Information.
consumer health - Brain Tumors
.
Hazardous Substances Data Bank.
DEXAMETHASONE
.
Hazardous Substances Data Bank.
ADENOSINE 5'-PHOSPHATE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Anticancer Res. 1996 Mar-Apr;16(2):805-9
[
8687132.001
]
[Cites]
Anal Biochem. 1986 Sep;157(2):375-80
[
2946250.001
]
[Cites]
Am J Reprod Immunol. 2005 Mar;53(3):144-52
[
15727569.001
]
[Cites]
Vascul Pharmacol. 2005 Mar;42(4):153-62
[
15820441.001
]
[Cites]
J Cell Physiol. 2001 Jan;186(1):19-23
[
11147810.001
]
[Cites]
J Neurooncol. 2001 Jan;51(2):105-10
[
11386406.001
]
[Cites]
Science. 1968 Jul 26;161(3839):370-1
[
4873531.001
]
[Cites]
Drug Metab Dispos. 2006 Jun;34(6):1063-9
[
16531474.001
]
[Cites]
Pharmacol Rev. 1998 Sep;50(3):413-92
[
9755289.001
]
[Cites]
Pharmacol Ther. 2003 Oct;100(1):31-48
[
14550503.001
]
[Cites]
Neurology. 1997 Jun;48(6):1704-9
[
9191791.001
]
[Cites]
Purinergic Signal. 2006 Jun;2(2):409-30
[
18404480.001
]
[Cites]
Anticancer Res. 1994 Jul-Aug;14(4A):1585-8
[
7979189.001
]
[Cites]
J Steroid Biochem Mol Biol. 2004 Dec;92(5):375-82
[
15698542.001
]
[Cites]
Eur J Pharmacol. 1992 Oct 1;227(2):113-22
[
1426027.001
]
[Cites]
Br J Pharmacol. 1997 Jan;120(2):273-81
[
9117120.001
]
[Cites]
J Pharmacol Toxicol Methods. 2005 Sep-Oct;52(2):234-43
[
16125621.001
]
[Cites]
Genes Dev. 1995 Jul 1;9(13):1608-21
[
7628695.001
]
[Cites]
Neuroscience. 2000;96(2):417-25
[
10683582.001
]
[Cites]
Cell Tissue Res. 2002 Dec;310(3):257-70
[
12457224.001
]
[Cites]
Blood. 2003 Dec 15;102(13):4472-8
[
12947007.001
]
[Cites]
Am J Physiol Regul Integr Comp Physiol. 2001 Jan;280(1):R25-32
[
11124130.001
]
[Cites]
Oncogene. 1998 Sep 24;17(12):1567-75
[
9794234.001
]
[Cites]
Trends Pharmacol Sci. 2006 Mar;27(3):166-76
[
16487603.001
]
[Cites]
Apoptosis. 1999 Jun;4(3):197-211
[
14634282.001
]
[Cites]
Melanoma Res. 2006 Jun;16(3):213-22
[
16718268.001
]
[Cites]
BMC Cancer. 2006 Sep 23;6:226
[
16995949.001
]
[Cites]
Anal Biochem. 1976 May 7;72:248-54
[
942051.001
]
[Cites]
Trends Pharmacol Sci. 2006 Apr;27(4):211-7
[
16530853.001
]
[Cites]
Nucleic Acids Res. 1992 Feb 25;20(4):825-9
[
1531873.001
]
[Cites]
Cancer Lett. 2003 Aug 20;198(2):211-8
[